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Chapter 1
Introduction
1.1 Radiotherapy
Soon after the discovery of x-rays by Wilhelm Conrad Röntgen in 1895 [133] it was found
that ionizing radiation could be used for the treatment of malignant diseases [53]. Nowadays,
radiotherapy is with surgery and chemotherapy one of the three main modalities for treating
patients with cancer. The aim of curative radiation therapy is to deliver as high a dose to
diseased tissue as needed or as possible without causing unacceptable side effects to the patient.
Radiotherapy is applied as teletherapy and as brachytherapy. In brachytherapy dose delivery
is performed with radioactive sources that are put within diseased tissue. In teletherapy the
treatment usually consists of irradiation of the patient from different directions with high energy
photon and/or electron beams, generated with a linear accelerator. Beam directions are chosen
such that the radiation damage to critical organs and healthy tissues is minimized. In conformal
teletherapy the beams are shaped according to the geometrical projection of the target to further
improve conformity of the high dose volume to the tumor volume. To optimize the biological
effect of radiotherapy the total dose is usually given in several daily fractions. For very high
total doses more than 35 fractions may be delivered.
Research in the last decade has shown that dose distributions can often be significantly
improved by applying intensity modulated x-ray beams, calculated by means of inverse
treatment planning techniques [15, 19, 20, 75, 76, 138, 166–168]. Using customized beam
profiles, the high-dose region can often be conformed more closely to the target volume,
reducing dose delivery to healthy tissues. Moreover, for some tumor sites, a more homogeneous
dose distribution in the target volume can be obtained.
All (complex) procedures involved in the planning and execution of teletherapy treatments
contribute to the overall uncertainty in the dose distributions. Verification is therefore
mandatory. Treatment verification while the patient is irradiated can be split into geometrical
and dosimetrical verification.
1.2 Geometrical treatment verification
Radiotherapy requires a geometrical representation of the patient anatomy and localization
of the tumor, which may be obtained with a simulator, with computed tomography (CT) or
with magnetic resonance imaging (MRI). Usually, available CT data are used to design a 3D
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treatment plan with a computer treatment planning system (TPS) using individually customized
beams. Two separate factors may result in the tumor not being in the desired 3D high dose
volume produced by the treatment beams: setup errors and internal organ motion. The risk
of these geometrical inaccuracies is underdosage of a part of the tumor and/or overdosage of
surrounding tissues and organs.
Ideally, the position of the patient in the treatment beams is in agreement with the position
determined in the treatment planning process using the CT data and/or with the position found
at the simulator. Films or images acquired with an electronic portal imaging device (EPID,
see figure 1.1) may be used to visually check the position of the bony structures relative to the
field borders. To access and correct patient setup errors the bony structures visible in the film
or EPID image are aligned with the corresponding structures in a simulator image or digitally
reconstructed radiograph (DRR), calculated by the TPS using the planning CT data [8, 28–30].
Generally the strategy is to tolerate small random setup errors and to correct systematic setup
errors [8], although it is possible to correct for both errors using on-line correction [36, 156]. In
the last decade several EPIDs have been developed [34, 106, 151, 160, 164, 171]. Advantages
with respect to film are that the digital images are directly available (necessary for on-line
verification), that they can be processed to improve image quality and that they may be digitally
stored.
In several studies it has been found that organs can move relative to each other
significantly [4, 6, 7, 31, 87, 101, 102, 132, 152, 159, 163]. Melian et al. found prostate
movements of up to 3 cm [101]. Webb describes four solutions to this problem [169]: (i)
the use of implanted radio-opaque markers that can be imaged with an EPID using only a
single or a few monitor units; the patient position can be adjusted accordingly, (ii) adding
margins to the gros tumor volume (GTV) [73], (iii) regulating rectal and bladder filling and (iv)
correlating the irradiation with the breathing cycle. Recently, Kroonwijk et al. (chapter 5) have
demonstrated that for some patients internal prostate motion can be detected without the use of
markers by comparing predicted portal dose images (PDIs), i.e. the dose distribution behind the
patient in a plane normal to the beam axis, with PDIs measured with an EPID [84]. Off-axis
differences between measured and predicted PDIs were caused by frequently occurring gas
pockets inside the rectum of the patients during treatment or during acquisition of the planning
CT scan. The detected gas pockets did sometimes extend into the GTV area as outlined in the
planning CT scans, implying a shift of the anterior rectum wall and prostate in anterior direction.
Other approaches for on-line localization of the tumor are the use of an on-line megavoltage
CT acquired with an EPID [57, 67, 103, 107], tomotherapy [97] or ultrasound [153].
1.3 Dosimetric treatment verification
1.3.1 Accuracy required in radiotherapy dose delivery
In addition to geometrical precision, the treatment outcome also depends critically on the
dose delivered to the target volume and healthy tissues. The relation between the dose and
biological effect is described by dose-response curves for the tumor and the critical tissues.
A higher dose will result in better tumor control, but the limiting factor is the normal tissue,
that is also being irradiated. Often, dose-response curves are steep, therefore a small variation
in dose may have a large effect on the probability of complications and on the probability of
tumor control. Furthermore, a high dosimetrical accuracy is required to measure these curves
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Figure 1.1. The Philips SRI-100 EPID mounted on one of the gantries of the MM50
racetrack microtron at the Daniel den Hoed Cancer Center.
in clinical practice.
Accuracy requirements for the radiation dose delivered to patients in radiotherapy
treatments can, in principle, be determined from clinically measured dose response curves.
Based on the clinical information available in 1975, an accuracy requirement of 5% on the
delivery of dose to a target volume in a patient, was recommended in ICRU Report 24 [72].
Goitein proposed to consider the 5% dose accuracy as 1.5 standard deviations [54]. Dutreix
reports on two experiences at the Institute Gustave Roussy of clinical detection of systematic
dosimetric errors [41]. The author emphasizes the need for overall precision in the tumor dose
of 5%. Based on radiobiological models Brahme assessed the required accuracy in dose
delivery as a function of the parameter γ , the normalized dose gradient of the dose response
curve, γ D D dP=dD, with D the delivered dose and P the tumor control probability [17, 18].
He concluded that if γ is higher than 3, as is frequently the case in clinical practice, the
uncertainty in the mean dose in the target volume should be less than 3% (1 SD) to achieve an
absolute standard deviation in tumor control probability of less than 10%; the relative standard
deviation in the mean dose in the target volume should be less than 5% when γ is less than 3.
Mijnheer et al. proposed a requirement for the combined random and systematic uncertainty
in the absorbed dose delivery of 3.5% (1 SD) [104]. This requirement is based on the relative
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steepness of dose-effect curves for local tumor control and normal tissue damage.
1.3.2 In vivo dosimetry: clinical application and results
The overall accuracy in delivered dose in a radiotherapy treatment can only be assessed directly
by means of in vivo dosimetry: measurement during treatment. The dose can be measured at
the entrance and/or at the exit side of the patient.
Already in 1932 Sievert performed routinely patient dose measurements using small
ionization chambers. In the 1960s and 1970s thermoluminescence dosimetry (TLD) was
introduced for the determination of absorbed dose in routine therapy [23, 24, 134]. Rudén
evaluated the use of TLD for in vivo dosimetry at Radiumhemmet. He reports an average
deviation between measured entrance dose and prescribed dose of 0.6% for 619 measurements
during 1 year in an open 6 MV beam. The spread in the observed deviations was 4.8% (1
SD). Between 10 and 20% of the entrance dose measurements exceeded the action level at
Radiumhemmet (5% for the open 6 MV beam, 7% for beams with wedges). The precision
of an individual TLD reading was within 2% (1 SD). A systematic deviation of 4:45:0% (1
SD) was found for patients treated with irregularly shaped beams where lead blocks were placed
in the beam: too high a correction factor had been used for the attenuation of the radiation in
the perspex sheet on which the lead blocks were placed; a change had been made from a thicker
to a thinner sheet without giving notice to the planning department. Some severe errors in dose
delivery at Radiumhemmet, detected by means of in vivo dosimetry, were possible because of
the poor interlock system of one of the radiotherapy facilities.
In recent years, encouraged by the work of Rikner et al. [56, 128, 129], the use of
semiconductor detectors for in vivo dosimetry has been investigated [1, 26, 42, 45–48, 68, 70, 86,
90–92, 105, 109, 110, 130]. The main advantage of semiconductor detectors over TLD detectors
is the absence of a time delay between patient irradiation and availability of measurement
results, allowing an immediate check of all treatment parameters when an error in dose delivery
is detected. This eases identification of the sources of the error. Nilsson et al. report on entrance
dose measurements by means of semiconductor detectors in 1918 treatment fields with high
energy x-ray beams, involving 43 patients [109]. Frequency distributions of all measurements
of the ratio measured absorbed dose to prescribed absorbed dose show standard deviations of
4.3% (6 MV, open fields), 6.4% (6 MV, wedge fields), 4.6% (21 MV, open fields) and 6.7%
(21 MV, wedge fields). The increased standard deviation for wedge fields was attributed to the
relatively large influence on detector response of detector positioning errors in wedge fields.
The standard deviation for individual patients varied from 1% to almost 9%. Ciocca et al.
determined midline doses from entrance and exit doses, measured by means of semiconductor
detectors, for 38 treatment setups, involving 8 patients with breast cancer [26]. The mean
values (in per cent) of the ratios measured absorbed dose to prescribed dose were the following:
96:63:8% (N = 33; range: 90-104.2%) at the reference point, 96:84:3% (N=48; range: 89.6-
106%) at off-axis points in the central plane, 96:87:6% (N=18, range: 89.1-112%) in off-axis
planes. The systematic deviations between measured and prescribed dose were attributed to an
incorrect estimation of the scatter dose contribution by the treatment planning system. These
deviations have also been observed in phantom studies [82, 154]. Heukelom et al. performed
entrance and exit dose measurements, using semiconductor detectors, during irradiation of 14
patients with breast cancer [70]. Measurements were repeated on each patient at least during
4 fractions. The reproducibility of the in vivo dose measurements was better than 2% (1 SD).
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At the isocenter an average difference between measured and predicted dose of −2:0  1:3%
was found. For some points behind the lung an average discrepancy of 6:4  2:5% (1 SD)
was found between measured and predicted dose. Positioning of the diodes was checked by
means of an EPID. The performance of in vivo dosimetry added about 10 minutes to the regular
patient irradiation time per fraction. Leunens et al. performed entrance dose measurements
with semiconductor detectors on patients treated for head and neck and brain tumors [90]. A
total number of 554 treatment setups were measured. The mean value of the ratio measured
dose to expected dose was 97:8  2:8%. Deviations between measured and predicted dose,
larger than 5%, were detected in 3% of the investigated treatment setups. The measurements
on patients, treated with pancranial irradiation, proved the superiority with respect to precision
in dose delivery of an isocentric technique over a fixed SSD technique. Combined entrance
and exit dose measurements were performed with semiconductor detectors on 34 patients,
treated for neck and oral cavity malignancies [91]. In this study, results were obtained for 230
treatment setups divided over 83 treatment fields. The mean midline dose-to-prescribed dose
ratio was 97:2  3:0%. Underdosages of 5% or more at the midline were detected in 20.4%
(47/230) of the measurements. Three important causes, leading to erroneous dose delivery
were detected: (i) errors in patient contours, used for dose calculations, (ii) omittance of tissue
inhomogeneities in dose calculations, (iii) omittance of scatter defects in dose calculations.
Mitine et al. performed 261 entrance dose measurements in 34 treatment fields of 10 head
and neck cancer patients in order to assess the value of a single in vivo dose measurements
e.g. during the first treatment session [105]. For 8 of the 34 treatment fields the in vivo
dose measurements at the first session demonstrated a discrepancy larger than 4% between
measured and expected dose. All detected systematic errors (7) in dose delivery could already
be identified during the first in vivo measurement. Leunens et al. performed 920 entrance dose
measurements on 105 breast cancer patients [92]. They observed a striking difference in the
rate of occurrence of large dose delivery errors between an old and a modern treatment unit.
This difference was attributed to the availability at the new unit of a check-and-confirm system
and of beam accessory devices in a fixed position in the beam and to a team of radiographers
being responsible for the setups, instead of a single radiographer at the old unit. Noel et al.
derived the target dose using entrance and exit dose measurements [110]. During 5 years, the
target dose for 7519 patients was measured and 79 errors were detected, half of them could
have induced a variation of over 10% in the dose delivered. Except for one all errors were of
human origin.
The results of clinical studies demonstrate the value of in vivo dose measurements for
quality assurance of radiotherapy treatments. However, these studies have also demonstrated
weak points of presently applied equipment (TLD- and semiconductor-detectors) and methods:
i. TLD-detectors have the distinct drawback of an unavoidable time delay between
measurement and availability of the measurement result. Consequently, a direct check
of treatment parameters, when an error in dose delivery is detected, is not possible.
ii. Many correction factors have to be applied to convert semiconductor readings into dose
values [68, 91, 109]. Due to the different behavior of various diodes, even from the same
batch, it is necessary to determine the characteristics for each diode individually. Properties
of diodes may change with accumulated absorbed dose.
iii. The method, proposed by Rizzotti et al. [130], which is generally applied for determination
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of midline dose, using entrance and exit dose measurements [26, 70, 91, 130] has a limited
accuracy when inhomogeneities are in the treatment fields.
iv. Placing a semiconductor on the skin of a patient leads to an increase in temperature and
consequently in a change in sensitivity of the detector. A steady state is reached after 3-4
minutes with an increase in response of about 3% [56, 109].
v. Semiconductor-detectors as well as TLD-detectors act as build-up material and thus
increase the skin dose [109, 134]. Nilsson et al. observed a skin dose of more than 90%
of dose maximum for 60Co, 6 MV and 21 MV beams. Diodes, used for entrance dose
measurements, also attenuate the primary beam. This attenuation may still at 5 cm depth
give a dose reduction of 5% over an area of 1 cm2 [109]. Mitine et al. found a dose
reduction due to the diode of 4% at a depth of 10 cm [105]. For a 6 MV photon beam,
Sen et al. found an average dose reduction over a depth from dmax to 20 cm of 10% [136].
Both the increase in skin dose and the attenuation effect inhibit frequent performance of
in vivo dose measurements.
vi. Much care has to be taken for the correct positioning of semiconductor detectors, especially
when measurements are performed in wedge fields [90, 109]. Nilsson et al. observed larger
standard deviations for wedge fields than for open fields [109]. The reason for the increased
standard deviation is the difficulty in placing the diode in the proper position. The authors
demonstrated that a 1.5 cm displacement of the diode in a wedge field may give rise to
errors in measured dose of up to 14%, depending on wedge and beam energy.
vii. The treatment time increases due to the time needed to position the diode(s) on the patient.
The increase in treatment time per session is reported to be 1-2 minutes if only the
entrance dose is measured [88] and at most 10 minutes if both entrance and exit dose
are measured [69]. This may be a reason that there are only a few studies with large
numbers of patients [1, 86, 110].
viii. In order to determine midline doses, both entrance and exit dose measurements are
performed. For a proper interpretation of these measurements a portal image for each
treatment field may be needed to determine the actual positions of the detectors in the
treatment field and their relative positions [46, 70, 105].
ix. For practical reasons only very limited numbers of detectors are used for simultaneous
measurements in different spots of the treatment fields. Often only the entrance dose
is measured, with the consequence that the actual tumor dose cannot be verified and
that some errors due to the use of incorrect patient data, like patient contour errors, and
due to inadequate algorithms in the treatment planning system are not detected. Due to
the necessarily small number of detectors, full verification of treatments delivered with
dynamic multileaf collimation is not possible.
1.3.3 Dosimetric application of EPIDs
Above mentioned drawbacks and shortcomings of the presently available techniques for in vivo
dosimetry with TLDs and diodes can be avoided by using EPIDs:
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Figure 1.2. Schematic diagram of a fluoroscopic EPID. The detector screen is a stainless
steel plate coated with a layer of gadolinium oxysulfide. X-ray photons which hit the
detector screen generates visible light in the fluorescent layer, which is viewed by a CCD
camera using two mirrors.
i. Dosimetric information is simultaneously obtained over the whole beam area and not only
in a single or a few points.
ii. The same detector may be used for verification of patient positioning and of absolute dose
delivery. Hence, introduction of patient dose delivery verification does not result in an
increase in the regular treatment time per fraction.
iii. Detector positioning is not anymore an issue and dosimetric information can be directly
related to patient positioning information.
iv. Physical contact between detector and patient is not needed.
1.4 Objectives of this study
The aim of the study was to develop techniques for dosimetric treatment verification using a
fluoroscopic EPID. This type of EPID basically consists of a fluorescent screen, two mirrors
and a CCD camera (figure 1.2). The x-ray photons which are not absorbed in the patient and
hit the detector screen generate visible light in the fluorescent layer, that is monitored by the
CCD camera. The five main objectives were:
i. To investigate the dosimetric characteristics of a fluoroscopic EPID and to develop a
method to derive PDIs, from measured EPID images.
ii. To develop methods to predict PDIs, based on the planning CT data of the patient and the
irradiation geometry, as determined in the treatment planning process.
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Figure 1.3. Outline of the implemented method for dosimetric treatment verification with
an EPID with references to the corresponding chapters. Chapters 7 and 8 are not shown in
this flow diagram, in these chapters the use of the EPID for checks of intensity modulated
beams produced with compensators and DMLC before patient treatment is demonstrated.
iii. To develop a method for verification of the monitor unit calculation by deriving the on-axis
patient dose at a depth of 5 cm from the portal dose measured with the EPID, which is
compared with the intended dose derived from the relative dose distribution calculated by
the TPS and the isocenter dose prescribed by the radiation oncologist.
iv. To evaluate the developed techniques of comparing predicted and measured PDIs and
comparing prescribed and measured patient doses in clinical practice.
v. To develop techniques to verify intensity modulated beams produced with compensators
and with dynamic multileaf collimation (DMLC) before patient treatment.
Figure 1.3 shows a flow diagram with the implemented method of dosimetric treatment
verification with references to the corresponding chapters. In chapter 2 the physical
characteristics of the fluoroscopic EPID relevant for dosimetric applications in a 6 MV photon
beam are presented. The stability of the system and the response as function of size of the applied
x-ray beam and absorber thickness have been investigated. In chapter 3 a method is presented
to derive PDIs from measured EPID images. PDI measurements with the EPID are compared
with ionization chamber measurements for anthropomorphic phantoms irradiated with open,
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wedged and intensity modulated beams produced with dynamic multileaf collimation. In
chapter 4 a method for prediction of PDIs in open (non wedged) beams is presented, using the
planning CT data of the patient and the irradiation geometry, as determined in the treatment
planning process. The first clinical evaluation for 10 prostate cancer patients, of the verification
method based on comparing predicted and measured PDIs is presented in chapter 5. These
comparisons cannot reveal an error in the MU calculation, since the calculated number of
MU is both used for treatment (and thus affects the measured PDI) and for PDI prediction.
Therefore an extension to this method is presented in chapter 6 that enables a verification of
the MU calculation; the on-axis patient dose at a depth of 5 cm is derived from a portal dose
measurement and compared with the intended patient dose, calculated using the relative dose
distribution calculated by the TPS and the prescribed isocenter dose. The method was clinically
evaluated for a group of 115 prostate cancer patients.
The developed techniques can also be used for checks of intensity modulated beams
produced with compensators or dynamic multileaf collimation before patient treatment, as
discussed in chapters 7 and 8, respectively. In chapter 9 the developed method for dosimetric
treatment verification is evaluated and compared with other methods. Furthermore, the
dosimetric characteristics of the fluoroscopic EPID are compared with those of an EPID system
consisting of a matrix of liquid filled ionization chambers.

Chapter 2
Portal dose measurement in radiotherapy using an electronic
portal imaging device
B.J.M. Heijmen, K.L. Pasma, M. Kroonwijk, V.G.M. Althof, J.C.J. de Boer,
A.G. Visser and H. Huizenga
Phys. Med. Biol. 40(11): 1943-1955, 1995.
Physical characteristics of a commercially available electronic portal imaging device
(EPID), relevant to dosimetric applications in high energy photon beams, have been
investigated. The EPID basically consists of a fluorescent screen, mirrors and a CCD
camera. Image acquisition for portal dose measurement has been performed with a special
procedure, written in the command language that comes with the system. The observed
day-to-day variation in local EPID responses, i.e. measured grey scale value (EPID signal)
per unit of delivered portal dose, is 0.4% (1 SD); day-to-day variations in relative EPID
responses (e.g. normalised to the on-axis response) are within 0.2% (1 SD). Measured
grey scale values are linearly proportional to transmitted portal doses with a proportionality
constant which is independent of the thickness of a flat, waterequivalent absorber in the
beam, but which does significantly depend on the size of the applied x-ray beam. It is
shown that the observed increase in EPID response with increasing field size is mainly due
to contributions to the EPID signals from scattered light: Visible photons produced by the
x-ray beam in a point of the fluorescent screen do not only generate a grey scale value in the
corresponding point of the EPID image, but do also lead (due to scatter from components of
the EPID structure onto the CCD chip) to an increased grey scale value in all other points of
the image. A point spread function, derived from measured data and describing the increase
in EPID response at the beam axis due to off-axis irradiation of the fluorescent screen, has
been successfully applied to connect portal doses with grey scale values measured with the
EPID.
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2.1 Introduction
Several studies on dosimetric applications of EPIDs have been performed: Kirby and Williams
have evaluated the possibilities for the assessment of the field flatness of a treatment unit with
a Philips SRI-100 EPID [81]. Dirkx et al. have, during a long period, indeed used an SRI-
100 for daily quality control of the absolute output and field flatness of the 25 MV photon
beam of an MM50 racetrack microtron; daily measurements were performed for four different
gantry angles[39]. Evans et al. [51] and Yin et al. [174] have studied the use of an EPID for
measurement of patient transmissions for the design of tissue compensators for, respectively,
breast cancer patients and lung cancer patients. Hansen et al. [59], Heijmen et al. [63–66],
Kirby and Williams [80, 81], Leong [89], Stroom et al. [144], Swindell [149], Wong et al. [172]
andYing et al. [175] have performed studies related to the use of an EPID for on-line dosimetric
quality control of treatments (in vivo dosimetry).
Using an EPID for in vivo dosimetry has the following potential advantages in comparison
with the usually applied silicon diodes: (i) Dosimetric data are obtained for a full plane, i.e.
not only in a single or a few points. (ii) Dosimetric data are simultaneously obtained with
patient positioning data which facilitates the interpretation of the dosimetric data. (iii) In vivo
dosimetry with an EPID that is already in use for patient positioning verification does not lead
to increased treatment times of patients. (iv) There is no physical contact between the patient
and the detector.
Several approaches for in vivo dosimetry with an EPID have been investigated: Kirby
and Williams have developed a method for estimation of the on-axis patient exit-dose from
measured SRI-100-signals, using a set of calibration measurements for homogeneous, flat
waterequivalent absorbers [80, 81]. For patients treated for prostatic cancer, Stroom et al. have
calculated on-axis midplane doses from SRI-100-signals measured during treatment [144].
Leong [89] and Wong et al. [172] have proposed to compare predicted portal dose images
(PDIs) - i.e. dose distributions behind patients in a plane perpendicular to the beam axis - with
PDIs measured during treatment to verify the correct implementation of a treatment plan. For a
60Co beam, Wong et al. have assessed the accuracy of the Delta Volume method for prediction
of PDIs in a plane close behind the patient [172]. Hansen et al. have presented preliminary
data on the use of PDIs, measured with an EPID, for a 3D calculation of the dose distribution
that was actually delivered to the patient [59].
In our institute we have developed an algorithm for very accurate prediction (1-2%)
of transmissions of high energy photon beams through patients, based on CT-data [63, 64].
Calculations are performed in a plane at 160 cm from the focus, which is equal to the fixed
distance between the focus and the fluorescent screen of an SRI-100 EPID. In an on-going
project we will develop methods to use these calculated patient transmissions, together with
in vivo measured PDIs with an SRI-100, to estimate dose distributions that have actually been
delivered to the patients.
In this paper we report on characteristics of the Philips SRI-100 electronic portal imaging
device, relevant to accurate and reproducible portal dose measurement. The relation between
grey scale values measured with the EPID and portal doses, measured with an ionisation
chamber, has been investigated. The applied SRI-100 is the first prototype of this system,
which is in clinical use since April 1988.
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2.2 Materials and methods
The SRI-100 EPID basically consists of a fluorescent screen viewed by a CCD camera via two
mirrors. The fluorescent screen is a 1.65 mm thick stainless steel plate coated with a fluorescent
layer. The focus-to-fluorescent screen distance is 160 cm. At isocentre, the maximum optical
image (i.e. detectable radiation field) is 2721 cm2. Optical images are digitized using the
CCD camera (512256 pixels; pixel size at isocentre: 0:530:82 mm2). Charge integration
can be performed both on the CCD chip - as it operates in slow-scan mode - and by adding
multiple frames in a frame processor. In the final images the accumulated pixel signals are
presented using 256 grey scale values. Technical details of the EPID have been described by
Visser et al. [164].
Image acquisition for portal dose measurement was performed with a special procedure,
written in the macro command language that comes with the system. This procedure was
also used by Heijmen et al. [65, 66] and by Stroom et al. [144] and is similar to the procedure
described by Kirby and Williams [81]. Each image was acquired by accumulating 120 frames
in the frame processor and for each frame an integration time on the CCD chip of 240 ms was
used, resulting in a (fixed) acquisition time of about 38 seconds. Consequently, for the 6 MV
photon beam of the applied treatment unit (Philips SL 75-10) with a dose rate of 340 monitor
units min−1, EPID signals could be integrated for at maximum 220 monitor units (MU). The
camera gain, which was kept fixed for all measurements, was selected to yield grey scale values
of about 200 for an irradiation with an open, 3030 cm2 field with 200 MU. Each image was
corrected for ‘dark current’ in the CCD chip, which was measured in 30 frames prior to the
irradiation. To avoid that negative ‘dark current’ signals would be truncated, the camera offset
was chosen such that the average grey scale value in the ‘dark current’ image was about 20.
For noise reduction, grey scale values were always averaged over selected regions of interest
(ROIs) in the image.
In this paper, field sizes, coordinates in EPID images and PDIs, dimensions of ROIs in
images, as well as distances to the beam axis, are all defined in the plane through the isocentre,
perpendicular to the beam axis, i.e. at 100 cm from the focus.
2.2.1 Day-to-day variation in EPID response
A prerequisite for daily dosimetric quality control of linacs and in vivo dosimetry with an EPID
is an adequate time independence of the response of the device, i.e. day-to-day variations in
the response (measured grey scale value per unit of delivered portal dose) have to be small. To
assess the time dependence of the EPID response, on 14 days in a 38 days period, one EPID
image was measured in an open 3030 cm2 beam, followed by a characterisation of the beam
profile with a radiation beam analyser, consisting of a linear array of ionisation chambers.
Measurements with the analyser were performed along the two main axes of the EPID with a
focus-to-analyser distance of 100 cm. The distance between centres of neighbouring chambers
was 15 mm; the chamber dimensions were 9343 mm3. Irradiations were performed with
150 MU.
Position dependent, local responses of the EPID were determined as ratios of the average
grey scale value in a ROI of 934 mm2 in the EPID image defined by the projection of an
The applied procedure is available on request.
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ionisation chamber of the analyser onto the EPID screen, and the - for temperature and pressure
variations corrected - reading of the corresponding ionisation chamber.
In this way the day-to-day variation in the local EPID response was assessed for 14 points
along the x-axis (corresponding with 14 ionisation chambers) and 14 points along the y-axis.
2.2.2 The EPID response as a function of applied monitor units, absorber thickness and field
size
In the investigations regarding the dependence of the EPID response, G=Dp, on the applied
number of monitor units (MU), the absorber thickness (t) and the field size (w), G was the
average grey scale value in a ROI of 1 cm2 around the beam axis; the portal dose Dp was
measured at the beam axis at a depth of 1.0 cm in a polyethylene slab phantom (3535 cm2,
thickness 2.5 cm) using an NE-2571 ionisation chamber. The distance from the focus to
the surface of the polyethylene phantom was 160 cm which equals the focus-to-fluorescent
screen distance of the EPID. As EPID and portal dose measurements cannot be performed
simultaneously, the two types of measurements were always performed sequentially, keeping
the time interval as short as possible (less than 5 minutes).
2.2.2.1 Monitor units
The dependence of the EPID response on MU was studied with a flat waterequivalent absorber
(polystyrene) with a thickness of 20 cm in the beam. The source-to-surface distance was 90 cm
and the field size was 1010 cm2. The selected range of MU (> 80) is typical for most of our
treatments in the pelvic area.
2.2.2.2 Absorber thickness
As the fluorescent screen of the SRI-100 is composed of non-waterequivalent materials, the
EPID response might change with spectral changes in the photon beam, as introduced by
an absorber (patient) in the beam. To study the absorber thickness dependence of the EPID
response, G=Dp-ratios were determined for a water phantom absorber with thicknesses from
10 to 29 cm; the centre of the absorber was always located at the isocentre of the treatment
unit. Measurements were performed for fields of 66, 1010, 1515 and 20  20 cm2. All
irradiations were performed with 100 MU.
2.2.2.3 Field size
To assess the EPID response as a function of field size, G=Dp-ratios were determined for a set
of square fields from 33 to 2020 cm2, without any absorber in the beam. All irradiations
were performed with 100 MU.
The following two experiments, designated A and B, were performed to investigate the
cause of the observed increase in the on-axis G=Dp-ratio with increasing square field size. In
the first experiment (A) the fluorescent screen of the EPID was replaced by a, for visible light,
semi-transparant white PMMA plate which was irradiated with photons of the 2525 cm2
light field in the treatment head. CCD images were recorded for a range of square, optical
fields, defined by (black) cardboard collimators which were positioned on the PMMA plate. In
experiment B the CCD camera was directly viewing (i.e. without using optical elements like
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mirrors) a flat, diffuse light source; for this experiment the camera was outside the gantry and
the EPID box was not used. The set-up, consisting of the light source and the CCD camera,
was fully enclosed by a black curtain and positioned in a dark room. Again, CCD images were
recorded for a range of square, optical fields, defined by cardboard collimators.
A function K.r/, describing the increase in EPID response at the beam axis per cm2
irradiated surface of the fluorescent screen at a distance r from the beam axis, was derived from
on-axis measured G=Dp-ratios using the following method: First, the measured G=Dp-ratios
for all square fields wnwn .n D 1; : : : ; N/ were normalised to the ratio for the 1010 cm2
field. Next, these normalised G=Dp-ratios were used to derive normalised G=Dp-ratios for
circular fields, assuming that the normalised response, G=Dp.R/, for a circular field with a
radius R equals the normalised response for a square field of ww cm2 with w defined by
the relation w2 D 2R2. K1.r/, a first approximation of K.r/, was calculated by numerical
differentiation of the function G=Dp.R/. Modifications of K1.r/, performed to correct for
(small) errors related to the above assumed equivalence between square- and circular fields,
were calculated as follows: For all square fields wnwn .n D 1; : : : ; N/ in succession, starting
with the smallest field w1, the normalised G=Dp.wn/-ratio was estimated using the equation
G=Dp.wn/ D
∫
Kn.
√
.x0/2 C .y0/2/ dx0 dy0, with Kn.r/ the current approximation of K.r/;
next, KnC1.r/ was calculated by equally spreading the difference between the estimated and
the measured normalised G=Dp.wn/-ratio over rings with radii smaller than 12wn. Finally,
K.r/ was set equal to KNC1.r/.
In order to validate K.r/, measured on-axis G=Dp-ratios for rectangular fields ab
(including strongly elongated fields such as 620 and 206 cm2), centred around the beam-
axis, were compared with G=Dp-ratios calculated with
G D G
Dp
∣∣∣∣
1010
Dp
∫
.x0;y0/  .ab/
K.
√
.x0/2 C .y0/2/ dx0 dy0; (2.1)
with G=Dpj1010 the measured absolute response for the 1010 cm2 field and Dp the measured
absolute on-axis portal dose for the ab cm2 field.
2.2.3 Grey scale values and portal doses behind a thorax phantom
For a thorax phantom, experiments were performed to investigate the validity of the equation
G.x; y/ D
G
Dp
∣∣∣∣
1010
∫
.x0;y0/field
Dp.x
0; y0/ S.x0; y0/ K.
√
.x0 − x/2 C .y0 − y/2/ dx0 dy0; (2.2)
to connect grey scale values with portal doses, with G.x; y/ the measured grey scale value in
point .x; y/ of the EPID image, Dp.x; y/ the absolute portal dose in point .x; y/ of the PDI,
G=Dpj1010 the absolute, on-axis EPID response for the open 1010 cm2 field and S.x; y/
the local, relative EPID response in .x; y/. K.r/ has been described in the previous section.
As S.x; y/ should reflect the local EPID response in .x; y/, it was determined as the
measured G=Dp-ratio for a small field (33 cm2) centred around .x; y/, normalised at the beam
axis (S.0; 0/ D 1). G was the average grey scale value in a ROI of 1 cm2 around .x; y/ and Dp
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was the portal dose measured with an ionisation chamber in a set-up as described previously,
but with the chamber centre located at the ray-line through .x; y/. S.x; y/-measurements were
performed for points .x; y/ in a square grid with distances of 3 cm between neighbouring
points. Measurements were performed without any absorber in the beam.
In equation (2.2), K.r/ is used as the point spread function of the EPID, describing crosstalk
effects. The convolution integral expresses the idea that for non-flat portal dose distributions
Dp.x; y/, e.g. behind a patient or in case of application of intensity modulated beams, the
effect of the point spread function K.r/ has to be modulated with local beam intensities,
which are considered to be proportional to Dp.x; y/S.x; y/. Convolution integrals, defined in
equation (2.2), were solved using a Fast Fourier routine written in Fortran. The grid size was
2.5 mm. By performing a deconvolution, equation (2.2) could in principle be used to derive
PDIs from measured EPID images (this has not been done in this paper).
Grey scale value distributions G.x; 0/ along the x-axis, defined as average grey scale values
in ROIs of 3:23:7 mm2 around points .x; 0/, as derived from EPID images measured behind
the thorax phantom, were compared with values predicted with equation (2.2), using measured
absolute portal dose distributions as input. Relative portal dose distributions were measured
by scanning an ionisation chamber (0:15 cm3) at a depth of 1.0 cm through a water phantom
(Wellhöfer); for conversion to absolute portal doses, an absolute dose measurement at the beam
axis was performed. The source-to-surface distance was 160 cm. EPID measurements and
absolute portal dose measurements were performed with 150 MU irradiations.
The applied thorax phantom, made of PMMA and cork (lungs), had a constant cross
section in craniocaudal direction, i.e. in the y-direction. Portal dose measurements were
only performed along the x-axis; for G.x; 0/-predictions with equation (2.2) it was assumed
that Dp.x; y/ D Dp.x; 0/. Considering the symmetry of the phantom and the fact that portal
doses Dp.x; y/ only contribute in second order (i.e. via the tail of the point spread function
K.r/), to calculated grey scale values G.x; 0/, this is a reasonable assumption.
2.3 Results
2.3.1 Day-to-day variation in EPID response
In figures 2.1a and 2.1b, data are presented regarding day-to-day variations in the EPID
response. The 14 lines in figures 2.1a and 2.1b represent the observed time-behaviour of
measured local EPID responses in 14 points along, respectively, the x- and the y-axis of the
EPID. For all 214 EPID points separately, the day-to-day variation in the measured response
has been quantified as a standard deviation in the observed responses. The average of these
28 standard deviations is 0.55%. The estimated measurement uncertainty of local responses,
related to the uncertainty in the dose measurements with the radiation beam analyser and to the
unavoidable sequentiality of EPID and beam analyser measurements, equals 0.35%. Therefore,
the real average day-to-day response variation in the EPID points has been approximately 0.4%
(1 SD).
The curves in figures 2.1a and 2.1b are to a high degree parallel. As a consequence, the
day-to-day variations in relative EPID responses, e.g. normalised to the on-axis response, are
within 0.2% (1 SD).
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Figure 2.1. The observed day-to-day variation in a 38 days period in EPID response at
14 points along the x-axis of the EPID (a) and at 14 points along the y-axis (b). For
presentation purposes, a normalization has been performed such that, for each line (i.e.
each EPID point), the average observed response in the 38 days period is equal to unity.
2.3.2 The EPID response as a function of applied monitor units, absorber thickness and field
size
2.3.2.1 Monitor units
In figure 2.2, the measured on-axis EPID response is shown as a function of the applied
number of monitor units MU. Observed deviations from a linear response are within 0.5%. No
saturation effects have been observed. Kirby and Williams have also found a linear relationship
between measured grey scale values and applied dose for their SRI-100 EPID; they have also
investigated very small numbers of MU [80, 81]. Also Leong has reported this linearity for
a fluoroscopic system [89]. Both our system and Kirby’s system have a dynamic range that
allows resolving single monitor units.
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Figure 2.2. The observed EPID response at the beam axis as a function of the applied
number of monitor units. The presented G=Dp-values have been normalised to the average
measured value.
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Figure 2.3. Measured grey scale value/portal dose-ratios for the beam axis as a function
of absorber thickness t for a set of fields of ww cm2. For presentation purposes, for
each field size separately, the presented G=Dp- values have been normalised to the average
measured value. (figure 2.4 demonstrates that the G=Dp-ratio is rather strongly field size
dependent.) The thick, solid line shows the average t-dependence of the EPID response for
the four field sizes.
2.3.2.2 Absorber thickness
Figure 2.3 shows, for a set of field sizes, normalised, measured G=Dp-ratios as a function of
the absorber thickness t . The data in figure 2.3 indicate that, for a fixed field size, the EPID
response (G=Dp) does not significantly depend on the absorber thickness.
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Figure 2.4. Solid line + markers: the EPID response, measured at the beam axis, as a
function of the field size of the applied square irradiation fields. The presented on-axis
G=Dp-ratios have been normalised to the observed ratio for the 1010 cm2 field. There
was no absorber in the beam. The thick and thin dashed curves are results of experiments
A and B, described in section 2.3.2.3.
2.3.2.3 Field size
In figure 2.4, normalised, measured G=Dp-ratios are presented as a function of the field size of
the applied square irradiation fields, showing a rather strong field size dependence of the EPID
response. The thick- and thin dashed lines in figure 2.4 show for, respectively, experiments
A and B (both described in section 2.2.2.3) the measured grey scale values at the beam axis,
relative to the grey scale value for the 1010 cm2 field. The close agreement between the solid
line with markers and the thick, dashed curve proves that the G=Dp-dependence on radiation
field size is basically not a direct consequence of the interaction of the x-ray beam with the
fluorescent screen. The strongly reduced field size dependence observed in experiment B
proves that the increase of the EPID response with increasing x-ray field size is basically not
due to crosstalk effects in the CCD camera. From the results of the experiments A and B it may
be concluded that the increase in EPID response with increasing x-ray field size is mainly due
to contributions to the EPID signal from scattered light: Visible photons produced by the x-ray
beam in a point of the fluorescent screen do not only generate directly a grey scale value in the
corresponding point of the EPID image, but do also lead - due to light scatter from components
of the EPID structure, such as the walls and the mirrors, onto the CCD chip - to an increased
grey scale value in all other points of the image.
Using the method explained in section 2.2.2.3, the normalised, measured G=Dp-ratios
presented in figure 2.4 were used to derive the function K.r/. K.r/ is depicted in figure 2.5.
For all measured data points G=Dp.w/ in figure 2.4, K.r/ fulfills within 0.6% (maximum
deviation) the consistency relation G=Dp.w/ D
∫
K.
√
.x0/2 C .y0/2/ dx0 dy0.
In table 2.1, measured on-axis G=Dp-ratios for rectangular fields are compared with ratios,
calculated with equation (2.1). The agreement between measured and predicted ratios is within
0.3% (1 SD). The observed close agreement between measurements and predictions, also for
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Figure 2.5. The function K.r/, describing the increase in EPID response at the beam axis
per cm2 irradiated fluorescent screen at a distance r from the beam axis. K.r/ was derived
from the data (markers) presented in figure 2.4.
strongly elongated fields, supports the use of K.r/ and equation (2.1) for determination of the
on-axis portal dose Dp from measured grey scale values G in non-square irradiation fields.
2.3.3 Grey scale values and portal doses behind a thorax phantom
The experimental set-up for the investigations on the thorax phantom absorber is schematically
shown in figure 2.6a. In figure 2.6b, measured and predicted grey scale values are presented
for a 1510 cm2 x-ray field, showing close agreement (typically, deviations smaller than 1-2%
outside the penumbra regions) between G.x; 0/-measurement with the EPID and G.x; 0/-
prediction with equation (2.2). The same small deviations have been found for other field
sizes. The dotted line in figure 2.6b is the measured normalised EPID response - as defined in
section 2.2.3 - along the x-axis, i.e. S.x; 0/.
The dashed curve in figure 2.6b was derived using the following linear relation for grey
scale value prediction (instead of equation (2.2)): G.x; 0/ D C0Dp.x; 0/S.x; 0/ with C0 the
measured on-axis G=Dp-ratio for the open 1010 cm2 field, Dp.x; 0/ the portal dose in .x; 0/
behind the phantom, and S.x; 0/ the normalised EPID response in .x; 0/. Figure 2.6b shows,
around the beam axis, a reasonable agreement between this prediction and the measurements.
However, in the mediastinal region, deviations of up to 7% do occur; in the areas x < −8 cm
and x > 8 cm, deviations are as large as 50%. These observations do clearly demonstrate that
the magnitude of the crosstalk effects in the EPID is such that, grey scale value distributions
measured with the EPID, normalised to the on-axis value, can differ significantly in shape from
normalised portal dose distributions, also after correction for the non-uniform spatial EPID
response (S.x; y/). Furthermore, these results point at an inherently limited accuracy of the
method of Kirby et al. for the determination of on-axis patient exit-doses from measured SRI-
100-signals, using a set of calibration measurements for homogeneous, flat waterequivalent
absorbers, when applied in the thorax region of patients or in case of the use of (strongly)
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Table 2.1. Measured and predicted on-axis EPID responses G=Dp for rectangular fields.
The predictions were performed using equation (2.1).
Field size Grey Scale Value/Portal Dose
a [cm] b [cm] measured calculated diff. [%]
6 4 0.942
0.938 0.4
4 6 0.941 0.3
10 4 0.954
0.951
0.3
4 10 0.957 0.6
16 5 0.975
0.976 -0.1
5 16 0.980 0.4
12 8 0.995
0.993 0.1
8 12 0.993 -0.1
20 6 1.005
1.000
0.5
6 20 0.995 -0.6
14 10 1.017
1.019 -0.1
10 14 1.022 0.3
18 10 1.047
1.039 0.8
10 18 1.037 -0.2
20 15 1.099
1.095
0.3
15 20 1.099 0.3
intensity modulated beams [80, 81].
2.4 Summary and conclusions
Characteristics of the Philips SRI-100 electronic portal imaging device, relevant to portal dose
measurement in radiotherapy, have been investigated. Image acquisition has been performed
with a special procedure, written in the macro command language that comes with the system.
A day-to-day variation in EPID response of 0.4% (1 SD) has been observed; variations
in relative, local EPID responses (e.g. normalised to the on-axis response) are within 0.2%
(1 SD).
Measured grey scale values are linearly proportional to transmitted portal doses with
a proportionality constant which is independent of the thickness of a flat, waterequivalent
absorber in the beam, but which does significantly depend on the size of the applied x-ray
beam.
It has been shown that the observed increase in on-axis EPID response with increasing field
size is mainly due to contributions to the EPID signal from scattered light: Visible photons
produced by the x-ray beam in a point of the fluorescent screen do not only generate a grey
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Figure 2.6. (a) A schematic picture of the set-up used to generate the data presented in (b).
For the EPID measurements, the horizontal line at 160 cm from the focus represents the
fluorescent screen; for the portal dose measurements this line represents the water surface.
(b) Measured and predicted grey scale value distributions behind a thorax phantom. The
set-up is presented schematically in (a). The markers represent grey scale values measured
with the EPID. The solid line is the predicted grey scale value distribution according to
equation (2.2). The dashed curve is a prediction, based on an assumed linear relationship
between G.x; 0/ and Dp.x; 0/. The dotted line is the measured relative EPID response
along the x-axis.
scale value in the corresponding point of the EPID image, but do also lead - due to light scatter
from components of the EPID structure onto the CCD chip - to an increased grey scale value
in all other points of the image.
A function K.r/, describing the increase in EPID response at the beam axis per cm2
irradiated fluorescent screen at a distance r from the beam axis, has been derived from measured
on-axis G=Dp-ratios for square fields. For a set of rectangular fields, the measured on-axis
G=Dp-ratio has been compared with the predicted ratio, calculated with K.r/ and the known
on- axis portal dose. The observed close agreement between measurements and predictions,
also for strongly elongated fields, supports the proposed use of K.r/ for determination of the
portal dose Dp from measured grey scale values G in non-square irradiation fields. For a thorax
phantom, predicted on- and off-axis grey scale values, calculated with a convolution integral
with K.r/ as point spread function, are in close agreement (1-2%) with EPID measurements.
In conclusion: The observed small day-to-day variation in the response of the SRI-100 is
crucial for application of the EPID for accurate daily dosimetric quality control of treatment
units and for on-line dosimetric treatment verification (in vivo dosimetry). The, for each field
size observed, proportionality between measured grey scale values and transmitted portal doses,
independent of the absorber thickness in the beam, facilitates a straightforward application
of the SRI-100 for in vivo dosimetry and for the design of tissue compensators, based on
patient transmissions measured with the EPID. Methods have been developed that accurately
described the relation between grey scale values in EPID images and portal doses measured
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with an ionisation chamber. In an on-going project we are developing methods to use portal
doses, derived from ‘in vivo measured’ SRI-100 EPID images, to estimate dose distributions
that have actually been delivered to patients.
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Chapter 3
Accurate portal dose measurement with a fluoroscopic
electronic portal imaging device for open and wedged beams
and dynamic multileaf collimation
K.L. Pasma, M. Kroonwijk, J.C.J. de Boer, A.G. Visser and B.J.M. Heijmen
Phys. Med. Biol. 43(8): 2047-2060, 1998.
Measuring portal dose with an electronic portal imaging device (EPID) in external beam
radiotherapy can be used to perform routine dosimetric quality control checks on linear
accelerators and to verify treatments (in vivo dosimetry). An accurate method to measure
portal dose images (PDIs) with a commercially available fluoroscopic EPID has been
developed. The method accounts for (i) the optical “cross talk” within the EPID structure,
(ii) the spatially non-uniform EPID response and (iii) the non-linearity of the EPID response.
The method is based on a deconvolution algorithm. Measurement of the required input data
is straightforward. The observed non-linearity of the EPID response was largely due to the
somewhat outdated EPID electronics. Non-linearity corrections for more modern systems
are expected to be smaller. The accuracy of the method was assessed by comparing PDIs
measured with the EPID with PDIs measured with a scanning ionization chamber in a mini
phantom, located at the same position as the fluorescent screen. For irradiations in open,
wedged and intensity modulated 25 MV photon beams (produced with dynamic multileaf
collimation) EPID and ionization chamber measurements agreed to within 1% (1 SD).
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3.1 Introduction
The main application for electronic portal imaging devices (EPIDs) is patient set-up verification.
However, they can also be used for dosimetric treatment verification. Already in 1986, Leong
investigated the dosimetric properties of their video based EPID [89]. In 1991, Morton et al.
reported on the dosimetric characteristics of an EPID based on a linear array of scintillation
crystals [106]. In recent years, several other groups have also studied the properties of
their EPIDs for dosimetric measurements. Most studies were performed for two commercial
systems, the fluoroscopic, CCD camera based Philips SRI-100 EPID [61, 80, 81] and the Varian
PortalVision liquid-filled matrix ion chamber system [43, 44, 173, 176]. The SRI-100 was
developed in a collaboration between the former Philips Radiotherapy Systems, the former
Laboratory for Space Research in Leiden and the Daniel den Hoed Cancer Center [164]. The
PortalVision system was developed by van Herk and Meertens [160].
Several studies on dosimetric applications of EPIDs have been performed. Kirby and
Williams have evaluated possibilities for the use of the SRI-100 EPID for quality control
checks on the beam profile of a treatment unit [81]. In our institute, this EPID is in daily
use for quality control of the absolute output and field flatness of the 10 and 25 MV scanning
photon beams of a MM50 racetrack microtron [39].
A number of groups has performed studies with anthropomorphic phantoms and/or patients
to evaluate the use of EPIDs for dosimetric quality control of treatments (in vivo dosimetry)
[43, 44, 59–61, 80, 85, 98, 99, 125, 176]. Several approaches for in vivo dosimetry with an EPID
have been proposed. Kirby and Williams have presented a method for estimation of the on-axis
patient exit dose from measured SRI-100-signals, using a set of calibration measurements for
homogeneous, flat, water-equivalent absorbers [80, 81]. Leong [89] and Wong et al. [172]
have proposed to compare a portal dose image (PDI) - i.e. a dose distribution behind a patient
in a plane perpendicular to the beam axis, measured during treatment with an EPID - with a
corresponding predicted PDI. For a 60Co beam, Wong et al. have assessed the accuracy of the
delta volume method for prediction of PDIs in a plane close behind the patient [172]. McNutt
et al. have used the convolution/superposition method, based on precalculated Monte Carlo
data, to predict the dose distribution throughout an extended volume which includes the patient
and the EPID [98]. The calculated dose distribution in the EPID is then extracted, yielding a
predicted PDI.
In our institution, a method has been developed for prediction of PDIs in open and
wedged beams, using the planning CT-data of the patients [64, 115]. The calculations are
based on a set of input functions such as attenuation curves for primary radiation, and scatter
point spread functions describing the radiation scattered from the patient onto the EPID. The
input functions are derived from a limited set of measured beam transmissions through flat,
polystyrene absorbers. For anthropomorphic phantoms the predicted PDIs agree within 1-2%
with ionization chamber measurements. Both the method for PDI prediction and the method
for measuring PDIs with an EPID, as described in this paper, have been evaluated clinically
for prostate cancer patients [85]. It was shown that in some cases internal organ motion can be
detected by comparing PDIs measured during treatment with predicted PDIs.
A few back-projection methods for derivation of the patient dose distribution from a PDI
measured with an EPID have been proposed [59, 60, 99, 115, 175]. Accurate back-projection is
only possible if the patient position and anatomy during treatment closely resemble the situation
during acquisition of the planning CT-scan. In the method of Ying et al., a deviating patient
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anatomy at the time of treatment is accounted for with an iterative procedure that modifies the
planning CT-data [175].
Recently, we have published a paper on the dosimetric characteristics of our Philips SRI-
100 EPID for an open (non-wedged) 6 MV photon beam [61]. We found that the measured pixel
value Graw (EPID signals) is linearly proportional to the transmitted dose and that the system is
very stable: the observed day-to-day variation of the EPID response per unit of delivered dose
is 0.4% and the day-to-day variation in relative response (normalized to the on-axis response) is
within 0.2%. However, the EPID response does significantly depend on the size of the applied
x-ray beam. It was shown that this is mainly due to light scatter in the EPID structure: visible
photons produced by the x-ray beam in a point of the fluorescent screen do not only generate a
signal in the corresponding pixel of the EPID image, but also cause an increased signal at all
other pixels due to light scatter from components of the EPID structure onto the CCD chip. A
kernel describing the increase in on-axis EPID response per unit of area irradiated fluorescent
screen at a distance r from the beam axis was derived from the measured on-axis response as a
function of field size. It was shown that the derived kernel can be used in a convolution integral
to connect portal dose with pixel values Graw measured with the EPID.
In this paper we report on a method to derive absolute portal dose images from measured
EPID images in the 25 MV photon beam of a MM50 racetrack microtron using a deconvolution
algorithm to correct for the light scatter in the EPID structure as described by the kernel. The
non-uniform EPID response and the non-linearity of the EPID response are also taken into
account. Preliminary results have been presented at the XIIth ICCR [125].
3.2 Materials and methods
3.2.1 EPID hardware and software
The SRI-100 EPID basically consists of a fluorescent screen, two mirrors and a CCD camera.
The fluorescent screen is a 1.65 mm thick stainless steel plate coated with a 411 mg/cm2 thick
layer of Gd2O2S:Tb (gadolinium oxysulfide). To reduce the detection of high energy electrons
generated in the patient, we have mounted an additional 1 mm thick stainless steel slab on top
of the standard fluorescent screen. Image quality is hardly affected by this additional layer so
that acquired images can be used for patient set-up verification and portal dose verification at
the same time [85]. The water equivalent depth of the in total 2.65 mm thick stainless steel
layer is slightly smaller than the depth of maximum dose of the 25 MV photon beam (3.0 cm).
The added one millimeter thick stainless steel slab adds 1.3 kg to the weight of the EPID
structure. To prevent extra sagging of the structure, which originally weighted about 15 kg,
and to avoid loss of image quality we have chosen not to add a thicker slab. The EPID has a
fixed focus-to-fluorescent screen distance of 160 cm. In this paper, field sizes, coordinates and
distances to the beam axis are all defined in the plane through the isocenter (i.e. at 100 cm
from the focus). The maximum detectable radiation field in that plane is 25  19 cm2. The
CCD camera frames (512  256 pixels) are digitized to 8 bits and added in a 16 bit deep frame
store memory. Charge integration is performed both on the CCD chip and by adding multiple
frames in the frame store memory. Technical details of the EPID have been described by Visser
et al. [164] and Althof et al. [2]
Image acquisition for portal dose measurements is performed with a procedure written in
the macro command language that comes with the system. It is similar to the procedure used
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by Heijmen et al. [61] and Kirby and Williams [81]. However, several modifications have
been made to optimize the signal-to-noise ratio; (i) the integration time for each frame on the
CCD chip has been increased from 240 to 560 ms to reduce the read-out noise and (ii) the
16 bit deep images of the frame store memory are written directly to disk. In the original
procedure, the images that are stored on disk are only 8 bits deep. Especially for images with
low pixel values, the truncation error resulting from this procedure is significant. Since in
the new procedure no accuracy is lost due to truncation, the pixel values do not have to be
maximized and, consequently, the selection of the integration time on the CCD chip and the
number of frames that are accumulated in the frame store memory is less critical.
For dosimetric purposes, the total acquisition time has to exceed the irradiation time. In the
applied procedure a fixed number of 60 video frames is accumulated in the frame store memory
resulting in a fixed acquisition time of 38.4 s and a maximum irradiation time of 190 MU for a
doserate of 300 MU min−1. Each image is corrected for the ‘dark current’measured prior to the
irradiation. No image enhancement is performed on the images that are used to derive PDIs.
Image acquisition starts automatically when the measured pixel values in the center of the video
frame reach a threshold, i.e. when the beam is switched on. The last frames are accumulated
after the irradiation has ended. The measured pixel values (Graw) are an accumulation of the
pixel values in ‘filled’ (beam on) and ‘empty’ (beam off) frames divided by the total number
of frames (60). The camera gain is fixed to unity.
3.2.2 Dose measurements with an ionization chamber
Ionization chambers are considered the gold standard for dose measurements. In this study
a PTW ionization chamber (N31002) was used to derive the relationship between the EPID
images Graw and portal dose images (PDIs). The ionization chamber was positioned at a depth
of 2.5 cm in a polystyrene mini phantom with a transversal cross section of 7  7 cm2 and
a thickness of 5 cm. The center of the ionization chamber was positioned at a distance of
160 cm from the focus, which is equal to the fixed focus-to-fluorescent screen distance of our
EPID. For off-axis measurements, the mini phantom with the ionization chamber inserted, was
scanned in an empty RFA-300 water phantom.†
Empirically it was found that for a wide range of field sizes, a depth of 2.5 cm resulted
in minimal variations in the on-axis response of the system (pixel value/portal dose (G=Dp))
beneath flat phantoms with various thicknesses (t) and exit plane-to-detector-distances (L). In
these analyses, pixel values were corrected for the non-linear response of the EPID, described
in section 2.3.1.
3.2.3 The non-linear EPID response
In a recent study, EPID signals were found to be linearly proportional to transmitted portal
doses in a 6 MV photon beam [61]. For the 25 MV photon beam we found the ratio of Graw
and Dp to decrease with increasing portal dose Dp, mainly due to non-linear electronics in
the EPID [125]. These results are not contradictory. Due to the extra build-up layer in the
present study and the integration time that is a factor of 2 13 longer, EPID signals measured for
the 25 MV beam are at least a factor of 2 13 higher than those measured for the 6 MV beam.
The applied procedure is available on request.
†Scanditronix Medical AB
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Therefore, the 6 MV and 25 MV measurements are on different parts of the response curve of
the system.
3.2.3.1 A correction for the non-linear EPID response
A method has been developed to correct measured EPID signals for the non-linear response
of the EPID. This method not only corrects for non-linear electronics but also accounts for
(potential) differences in sensitivity of the EPID and the ionization chamber for spectral changes
in the beam due to the patient. The method is based on a conversion of measured pixel values
per filled frame, graw, into corrected values g. For each pixel, the value per filled frame graw is
derived from the measured pixel value Graw using
graw D γGraw; (3.1)
with γ the ratio of the total frames and filled frames which is equal to the ratio of the total
accumulation time and the irradiation time. graw-values are then converted into corrected values
g using a polynomial function:
g D a1 graw C a2 g2raw C a3 g3raw: (3.2)
Finally, g-values are divided by γ yielding corrected pixel values G.
To derive the parameters a1, a2 and a3 in this equation, on-axis Graw and Dp values are
measured beneath flat polystyrene absorbers of various thicknesses. The distance between
the exit plane of the absorbers and the detector (L) is fixed to 47.5 cm. Measurements are
performed for a set of square w  w fields. The parameters a1, a2 and a3 are determined by
minimization of
∑
w;t;L
(
g.w; t D 25; L D 47:5/
Dp.w; t D 25; L D 47:5/ −
g.w; t; L/
Dp.w; t; L/
)2
; (3.3)
g.w; t D 25; L D 47:5/ and g.w; t; L/ are derived from the measured on-axis pixel values
Graw using equations (3.1) and (3.2). The minimization of equation (3.3) is based on the
assumption that the optical “cross talk” in the EPID should be independent of the thickness t
of the absorber. An iterative algorithm with a Newton type search method is used to obtain a2
and a3. a1 is set to unity to prevent the non-physical a1 D a2 D a3=0 solution. The initial
values of a2 and a3 are zero.
3.2.3.2 Non-linearity of the EPID electronics
By varying the accumulation time on the CCD chip it is possible to determine which part of
the problem is only related to non-linear electronics. The ratio of the on-axis pixel values per
filled frame, corrected for the non-linear electronics, measured with integration times on the
CCD chip of Tint1 .g.w; t; L; Tint1)) and Tint2 (g.w; t; L; Tint2)) should be equal to the ratio of
the integration times. This should hold for each w; t; L-combination and can therefore be used
to derive a1, a2 and a3 of a third degree polynomial response curve of the EPID electronics by
minimizing:
∑
w;t;L
(
g.w; t; L; Tint1/
g.w; t; L; Tint2/
− Tint1
Tint2
)2
: (3.4)
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Since the spectrum of the beam is unchanged if only the integration time on the CCD chip is
altered, the derived g only corrects for non-linear electronics. Differences between the response
curve of the EPID electronics and the curve derived with the method described in the previous
section point at differences in spectral sensitivity of the EPID and the ionization chamber.
Using the same w; t; L-combinations as in section 3.2.3.1, we have performed EPID
measurements for two integration times on the CCD chip: Tint1=560 ms and Tint2=240 ms.
For the measurements with the integration time of 240 ms the number of frames was increased
from 60 to 120.
3.2.4 Deconvolution of EPID images to obtain portal dose images
3.2.4.1 Derivation of the sensitivity S.x; y; w/ of the EPID
In a previous paper we introduced the following relation between a corrected EPID image and
the corresponding PDI [61]
G D G
Dp
∣∣∣∣
ref
 DpS ⊗ K; (3.5)
with S an array describing the relative EPID sensitivity (S=1 at the beam axis), ⊗ refers
to a convolution, G=Dp
∣∣
ref is the absolute on-axis EPID response for a reference situation
(w  w=10  10 cm2, t=25 cm, L=47.5 cm, PD=300 MU min−1 and Tint=560 ms) and K
is a kernel describing the optical “cross talk” in the EPID. Pasma et al. observed that S in
equation (3.5) is slightly field size dependent [125]. This dependency is related to shortcomings
of the on-axis measured kernel K in describing optical “cross talk” in off-axis points.
S arrays are derived from corrected EPID images G and corresponding portal dose
distributions Dp for a set of square fields below a flat 25 cm thick polystyrene absorber
positioned at a distance L=47.5 cm from the detector plane. The set-up for the required
ionization chamber measurements is described in section 3.2.2. The function K.r/, describing
the increase in EPID response at the beam axis per square centimeter irradiated fluorescent
screen at distance r from the beam axis, is derived from on-axis measured G=Dp-values
(normalized to the reference situation) as a function of field size [61] and stored in a two
dimensional array K. For each field size, S is derived from equation (3.5) by deconvolving G
with K and dividing the resulting DpS array by Dp as measured with the scanning ionization
chamber. Straightforward deconvolving G with a fast fourier transform (FFT) routine yields
physically unrealistic solutions for S since G is derived from measured EPID images which
inevitably contain some noise [125]. Therefore, we use an iterative method based on successive
approximations [135]:
.DpS/iC1 D
(
G
Dp
∣∣∣∣
ref
)−1
G C .I − K/ ⊗ P.DpS/i ; (3.6)
with I the identity operator,  a constant parameter, P a constraint operator and i the ith iteration.
The initial approximation of the DpS-array (.DpS/0) is equal to Dp.w D 10; t D 25; L D 47:5/
inside the field and zero outside. Only physically realistic modifications are allowed; e.g.
negative elements of modified .DpS/i arrays are set to zero by operator P . Furthermore,
elements of S outside the field are set to zero. Within 10 iterations the procedure converges to
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a solution DpS. All calculations are performed with arrays of 64  64 elements, each element
represents a region of interest of 0:5  0:5 cm2.
3.2.4.2 Derivation of a PDI in clinical practice
In clinical practice, a measured EPID image Graw is corrected for the non-linear behavior of the
EPID using the method described in section 3.2.3.1 and the resulting image G is deconvolved
to account for the optical “cross talk” using the above described procedure. The resulting DpS
is then divided by the S-array of the smallest square field that includes the applied patient field
to derive Dp.
For dynamic multileaf collimation, the EPID measurements are performed with the
procedure described in section 3.2.1, with the difference that image acquisition was started
manually since the standard procedure uses pixels in the center of the image to detect whether
the beam has been switched on and these pixels are usually blocked by the leaves when the
irradiation starts. For dynamic multileaf collimation, the ratio of filled and empty frames γ ,
used for the non-linearity correction described in section 3.2.3.1, is not constant over the whole
image like for a static open or wedged field. We use the calculated number of MU for each
position divided by the total number of MU given during the irradiation to estimate γ for each
position.
3.3 Results
3.3.1.1 A correction for the non-linear EPID response
Measured on-axis ratios of Graw and Dp for square fields of 3  3, 5  5, 10  10, 15  15
and 18  18 cm2 and absorber thicknesses 0, 10, 15, 25 and 35 cm are depicted in figure 3.1
(dotted lines). Graw is the average EPID pixel value in a region of 1.5 cm2 around the beam
axis. From t=0 to t=35 cm the ratios increase by 6% and 10% for the smallest field and largest
field, respectively. For small thicknesses and large fields, i.e. for high portal doses and EPID
signals, the measured pixel values are relatively low; the response of the system is non-linear.
The measured pixel values per filled frame graw, for the same w; t-combinations as used
to derive the ratio Graw over Dp presented in figure 3.1 (dotted lines), have been plotted in
figure 3.2 (markers) against the fully corrected pixel values per filled frame g (corrected for
non-linear electronics and spectral sensitivity). The response curve (solid line) is defined by
equation (3.2) with a1-, a2- and a3-values of 1, -5.9  10−4 and 7.52  10−6, respectively.
The ratio of empty frames and filled frames, γ , was 1.28. The dashed line shows the response
of an EPID with a perfectly linear response.
Using the response function as depicted in figure 3.2 to correct measured ratios of Graw
and Dp presented in figure 3.1 (dotted lines) results in ratios of G and Dp (solid lines) that
show no systematic dependence on absorber thickness t ; the maximum standard deviation in
the derived ratios as a function of thickness is 0.7% for w=3 and the mean of the standard
deviations for all field sizes is 0.4%.
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Figure 3.1. Measured ratios of pixel value and portal dose (dotted lines) at the beam axis
as a function of the absorber thickness t for five square fields. For presentational purposes,
for each field separately, the presented ratios of G and Dp have been normalized to the
average measured value. The solid lines represent the ratios of G and Dp corrected for the
non-linear EPID response shown in figure 3.2. The results are discussed in section 3.3.1.1.
The dashed lines represent the ratio G and Dp corrected only for the non-linear EPID
electronics using the method described in section 2.3.2.
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Figure 3.2. The non-linear response of the EPID system; the measured on-axis pixel value
per filled frame graw as function of the corrected pixel value per filled frame g (markers).
The solid line represents the response curve of the system as defined by equation (3.2). For
comparison, the dashed line shows a perfect linear response. The deviation between the
two lines clearly indicates the non-linear response of the system for high portal doses.
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Figure 3.3. The profile along the y-axis of a corrected EPID image (solid line) and the
corresponding dose array (markers) for irradiation of a flat, 25 cm thick polystyrene phantom
with an 18  18 cm2 field. Both are normalized to the reference situation (w  w=10 
10 cm2, t=25 cm and L=47.5 cm). The inset shows the orientation of the x- and y-axes
relative to the EPID structure.
3.3.1.2 Non-linearity of the electronics
Using the method described in section 3.2.3.2 to correct solely for the non-linear electronics, a2
and a3 were found to be -0.00269 and 1:6910−5, respectively. The dashed lines in figure 3.1
show the ratios of Graw and Dp corrected only for the non-linear electronics. The (systematic)
absorber thickness dependencies of the dashed curves are less than those of the corresponding
raw data (dotted lines) but not negligible; the maximum standard deviation in the derived ratios
as function of thickness is 2.1% for w=3 and the mean of the standard deviations for all field
sizes is 1.5%. Hence, the non-linear EPID response is mainly due to non-linear electronics, but
a non negligible part is due to differences in spectral sensitivity of the EPID and the ionization
chamber.
3.3.2 Derivation of S-arrays
Portal dose measurements for derivation of S-arrays were performed at a square grid with
distances between neighboring points of 1 cm, except for the two largest fields (16  16 and
18  18 cm2) for which a 2 cm grid was used. As an example, cross sections through the
measured G and Dp-arrays for the 18  18 cm2 field are depicted in figure 3.3. The EPID
response increases in the -y direction, for which the distance between the fluorescent screen
and the mirror decreases.
Using the procedure described in section 3.2.4, S-arrays have been derived from the
measured G- and Dp-arrays. Cross sections through the S-arrays along the x- and y-axes
are depicted in figures 3.4a and 3.4b, respectively. Along the x-axis, the S-arrays are relatively
flat and they demonstrate no field size dependence. Along the y-axis however, S-values increase
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Figure 3.4. Cross sections along the x- (a) and y-axis (b) through the derived S-arrays for
fields 8  8, 10  10, 12  12, 14  14, 16  16 and 18  18 cm2.
with decreasing y. Moreover, the S-arrays show a field size dependence especially in the -y
direction. The kernel K.r/, derived from ratios of G and Dp measured at the beam axis, does
not exactly describe the “cross talk” in off-axis points. Especially for those points close to the
mirror, S does not only correct for changes in local EPID sensitivity but also for shortcomings
in the kernel.
3.4 Accuracy assessment of PDI measurement with the EPID
The accuracy of the described method for PDI measurement with the EPID has been assessed
by comparing PDIs derived from EPID measurements with PDIs measured with the ionization
chamber. Measurements were performed for a set of anthropomorphic phantoms irradiated
with the 25 MV photon beam of an MM50 racetrack microtron. Furthermore, a flat phantom
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was irradiated with an intensity modulated beam produced with dynamic multileaf collimation.
Leaf trajectory calculations were performed with an algorithm described by van Santvoort and
Heijmen [162] and Dirkx et al. [38]
3.4.1 Thorax phantom
The set-up with the thorax phantom is depicted in figure 3.5a. The phantom is made out of
cork and lucite and its cross section is constant in cranial-caudal direction. The phantom was
irradiated with a 14  12 cm2 field. The source to surface distance (SSD) was 100 cm and
the distance between the exit surface of the phantom and the detector plane was 37.5 cm. The
portal dose derived from EPID measurements (using the S-array of the 14  14 cm2 field)
show good agreement (0:4  0:7%) with ionization chamber measurements along the x-axis
(see figure 3.5b). Similar results were obtained with a 60o wedge in the beam (figure 3.5c); the
observed deviation between the ionization chamber and the EPID measurements is 0:10:6%.
3.4.2 Alderson phantom
The Alderson phantom was irradiated in the prostate region with a conformal field (figure 3.6a).
The on-axis distance between the exit plane of the phantom and the detector (L) was 48 cm.
The percentual differences between the portal dose derived from the EPID image, using the
S-array of the 1212 cm2 field, and portal dose measured with a scanning ionization chamber
at a 1 cm grid are depicted in figure 3.6b. The deviation is 0:5  0:8%.
The phantom was also irradiated in the thorax region with a 1014 cm2 field (figure 3.6c).
The PDI was derived using the S-array of the 1414 cm2 field. Percentual differences between
the ionization chamber measurements and the EPID measurements are shown in figure 3.6d.
The deviation is 0:0  0:8%.
3.4.3 Dynamic multileaf collimation
Figure 3.7 shows data for the irradiation of a flat 25 cm thick polystyrene absorber. The distance
L between the exit plane of the absorber and the detector was 47.5 cm. Ionization chamber
measurements were performed at a 1 cm interval along the y=+0.6 cm and y=-4.4 cm axis.
The axes where chosen such that they are not in the ‘overlap’ region between two adjacent leaf
pairs. The solid lines in figure 3.7 represent the EPID dose measurements along both axes,
derived using the S-array of the 16  16 cm2 field. The markers represent the corresponding
ionization chamber measurements. EPID and ionization chamber measurements agree well,
the deviation being -0:4  0:8%.
3.5 Discussion
Using the above described method it is possible to derive absolute portal dose images from EPID
images obtained with a Philips SRI-100 EPID in open, wedged and intensity modulated beams
(produced with dynamic multileaf collimation) that agree within 1% (1 SD) with ionization
chamber measurements. With more than a year’s experience with the current characterization
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Figure 3.5. Set-up with the thorax phantom (a) used to generate the data for the open (b)
and the wedged field (c). The solid lines in (b) and (c) represent portal doses measured
with the EPID and the dots are the corresponding ionization chamber measurements.
of our system we have found no evidence that the measurements to determine K and S have to
be repeated. This is in agreement with the observed high stability of the system [61].
The Varian PortalVision liquid-filled matrix ion chamber system is reported to be able to
measure the dose rate in open beams with an accuracy of 1% (1 SD) [11]. However, the fastest
PortalVision system developed so far has a scan time for acquisition of an image of about 1 s.
It is not yet clear how the system can perform dose measurements for dynamic treatments,
during which maximum leaf speeds are in the order of 2 cm/s.
A rather complicating feature of the system that was investigated is the non-linear behavior
of the complex and somewhat outdated electronics. It is expected that modern CCD camera
based systems will not suffer from this problem. At present, a newly developed CCD camera
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Figure 3.6. Digitally reconstructed radiographs (DRRs) of the Alderson phantom with
the contours of the applied fields for irradiation in the prostate region (a) and in the thorax
region (c). The crosses in the center of each DRR mark the isocenter. Percentual differences
between portal doses measured with the scanning ionization chamber at a 1 cm grid and
the portal dose measured with the EPID are depicted in (b) for the prostate irradiation and
in (d) for the irradiation in the thorax region. Numbers are centered around the measuring
point and negative values are in between brackets.
based EPID is being tested in our institute. The main improvements relevant for dosimetric
tasks compared to the present system are (i) the increased distance between the mirror and
the fluorescent screen, (ii) the use of a modern 10 bit frame grabber and (iii) the simplified
electronic coupling between the camera and the frame grabber. Experiments with the SRI-
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Figure 3.7. Absolute portal doses (cGy) measured in an intensity modulated field along
two lines (y=0.6 cm and y=-4.4 cm). A flat, 25 cm thick homogenous polystyrene absorber
was in the beam with an exit plane to detector distance L of 47.5 cm. The solid lines
represent the EPID measurements and the markers the corresponding doses measured with
an ionization chamber.
100 system showed that the higher response in the direction of the mirror decreases when the
distance between the mirror and the fluorescent screen is increased by shielding the top edge
of the mirror with black carbon paper. At present, the dosimetric characteristics of the new
system are being investigated.
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Chapter 4
Portal dose image prediction for dosimetric treatment
verification in radiotherapy I: an algorithm for open beams
K.L. Pasma, B.J.M. Heijmen, M. Kroonwijk and A.G. Visser
Med. Phys. 25(6): 830-840, 1998.
A method is presented for calculation of transmission functions for high energy photon
beams through patients. These functions are being used in our clinic for prediction of
portal dose images (PDIs) which are compared with PDIs measured with an electronic
portal imaging device (EPID). The calculations are based on the planning CT-scan of the
patient and on the irradiation geometry as determined in the treatment planning process.
For each beam quality, the required input data for the algorithm for transmission prediction
are derived from a limited number of measured beam data. The method has been tested for a
PDI-plane at 160 cm from the focus, in agreement with the fixed focus-to-detector distance
of our fluoroscopic EPIDs. For 6, 23 and 25 MV photon beams good agreement (1%)
has been found between calculated and measured transmissions through anthropomorphic
phantoms.
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4.1 Introduction
Three-dimensional (3D) planning systems and modern radiotherapy facilities allow the design
and delivery of complex treatment plans. Adequate verification of the correct implementation of
sophisticated plans is mandatory. Preferentially, treatment verification should not be restricted
to automatic checks with a record and verify system on prescribed treatment unit parameters
such as gantry angle and multi-leaf collimator (MLC) settings. Measurements during
treatments with thermoluminescent dosimeters (TLDs), diodes, film and electronic portal
imaging devices (EPIDs) can provide valuable information on delivered dose distributions
and patient set-up [8, 28–30, 43–45, 90, 92, 134].
Several groups have studied the application of EPIDs for dosimetric verification of
treatments (‘in vivo’ dosimetry) [44, 60, 61, 81, 98, 150, 173, 176]. Comparison of PDIs
derived from measured portal images with predicted PDIs can reveal problems like incorrect
(dosimetric) performance of the treatment unit, erroneous design, production or application
of compensators, and deviations between the actual patient anatomy during treatment and the
anatomy according to the planning CT-scan, e.g. due to tumor shrinkage or variations in rectum
filling [84, 85, 118].
A few groups have developed and tested algorithms for prediction of PDIs. For some
inhomogeneous phantoms and a patient, all irradiated with a 60Co beam, Wong et al. [172] and
Ying et al. [175] have compared predicted PDIs, calculated with the delta volume method, with
PDIs measured with film, TLD and a scanning ionization chamber. PDIs were predicted and
measured in the plane immediately behind the phantoms and the patient. In clinical practice it
is often quite unpractical, and for some EPIDs even impossible, to position the EPID detector
plane immediately behind the patient. The delta volume method is not suitable to predict PDIs
in case of a large air gap between the patient and the EPID [99]. McNutt et al. reported how
they used the convolution/superposition method, based on precalculated Monte Carlo data,
to predict the dose throughout an extended volume which includes a phantom and an EPID,
irradiated by a 6 MV photon beam [99]. The calculated dose distribution in the EPID was then
extracted and compared with a PDI measured with an EPID. They used distances between the
exit plane of the phantoms and the detector of 11 and 22 cm. In the central part of the fields
the calculated PDIs generally agreed within 4% with measurements.
In our institute Philips SRI-100 EPIDs are used for treatment verification. The fluorescent
screen is positioned at a fixed distance of 160 cm from the focus. In clinical practice the
distance between the exit plane of the patient and the fluorescent screen ranges from 30 to
50 cm. Photon beams of upto 25 MV are used. In the literature there are no methods for PDI
prediction available which have been tested for air gaps larger than 22 cm and energies above
6 MV. The aim of the work presented in this paper was to develop an accurate (2%) algorithm
for PDI prediction for these situations based on limited set of measured input data.
We use the following equation for prediction of PDIs
Dp.x; y/ D T .x; y/  Dp;0.x; y/; (4.1)
with Dp.x; y/ the portal dose in point .x; y/ of the PDI, T .x; y/ a transmission function and
Dp;0.x; y/ the portal dose that would have occurred in .x; y/ in the absence of the patient. In this
paper we focus on the algorithm that was developed for calculation of transmission functions
T .x; y/ (as defined by equation (4.1)) for open (non-wedged) beams. For the calculation of
the dose distributions Dp;0.x; y/ in the detector plane of the EPID, needed for prediction of
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PDIs with equation (4.1), we have slightly modified an algorithm that was developed in our
institute for dose calculations in water phantoms [141, 142].
The portal dose in each point .x; y/ of the PDI consists of a primary contribution, due
to photons that arrive in .x; y/ without interacting with the patient, and a scatter contribution
that stems from photons generated in interactions in the patient. In the presented method for
T .x; y/ prediction, primary and scatter contributions are dealt with separately as was proposed
by Cunningham for dose calculations inside patients [32]. The planning CT-data of the patient
and the treatment parameters such as the gantry angle and MLC-settings for all fields are used
as input for the calculations. The off-axis spectral shift in high energy photon beams and the
non-exponential attenuation of these beams in absorbers is taken into account. For each beam
quality, T .x; y/-predictions are based on a data set derived from measured on- and off-axis
transmissions through flat water equivalent absorbers and a dose profile measured in a large
field without an absorber in the beam. The method has been implemented and tested for a PDI-
plane at 160 cm from the focus. Predicted transmissions of 6, 23 and 25 MV photon beams
through anthropomorphic phantoms, with exit plane to detector distances of 37.5 to 50 cm have
been compared with measurements. Preliminary results of the algorithm for T .x; y/-prediction
have been reported by Heijmen et al. [64].
The presented work is part of a project to study the use of SRI-100 EPIDs for dosimetric
applications. We have investigated the characteristics of this EPID relevant for accurate and
reproducible dose measurements in a 6 MV photon beam [61] and we have developed a
method to derive PDIs from measured EPID images [116, 125]. Dirkx et al. have applied
this EPID for accurate daily dosimetric quality control of the 25 MV photon beam of a MM50
racetrack microtron [39]. The developed methods for prediction (as described in this paper)
and measurement of PDIs have been tested for a group of 10 prostate cancer patients. The
difference between the average on-axis measured portal dose and the predicted portal dose was
0:32:1% for the lateral field and 0:73:4% for the anterior field. For some patients localized
off-axis differences of upto 15% were found between predicted portal doses and portal doses
measured with the EPID during some of the treatment fractions. The observed large differences
pointed at variations in internal patient anatomy (‘internal organ motion’) due to variations in
rectum filling; for some patients the anatomy during the registration of the planning CT-scan
did not reflect the average anatomy during the daily treatments [84, 85].
In this paper, field sizes, coordinates and distances to the beam axis are all defined in the
plane through the isocenter (i.e. at 100 cm from the focus). The subscript ‘open’ refers to a
non-wedged beam.
4.2 The method of transmission prediction
As stated above the primary- and scatter components, T P .x; y/ and T S.x; y/, of the
transmission T .x; y/ are calculated separately and subsequently added, i.e.
T .x; y/ D T P .x; y/ C T S.x; y/: (4.2A)
T P .x; y/ and T S.x; y/ are defined by
T P .x; y/ D D
P
p .x; y/
Dp;0.x; y/
(4.2B)
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and
T S.x; y/ D D
S
p.x; y/
Dp;0.x; y/
; (4.2C)
with DPp .x; y/ the portal dose in point .x; y/ of the PDI due to primary photons, DSp.x; y/ the
portal dose in .x; y/ due to scattered radiation and Dp;0.x; y/ the portal dose that would have
occurred in .x; y/ in the absence of the patient.
The algorithms for the calculation of T P .x; y/ and T S.x; y/ for patients are based
on data derived from measured transmissions through flat, water equivalent (polystyrene)
phantoms (see section 4.3). To be able to use these data for the prediction of the transmission
through an (inhomogeneous) patient, the patient anatomy as described by the planning CT-
scan is substituted by an (imaginary) equivalent homogeneous phantom (EHP) consisting of
polystyrene. For each treatment beam, a separate EHP is calculated. For each ray line,
the patient and the EHP have equal (equivalent) polystyrene thicknesses and equal distances
between the center of mass and the detector plane. An EHP is thus defined by two two-
dimensional arrays, one with polystyrene thicknesses t.x;y/ and the other with distances L.x;y/
between the exit point of the EHP and the detector plane. In figure 4.1 an example is given for
an irradiation of a thorax phantom with an anterior field in a 6 MV beam (see section 4.4 for
details).
In the first step of the derivation of an EHP a ray tracing algorithm is used that derives
the water equivalent thicknesses (tH2O) of the patient along all ray lines in the treatment field.
Each CT-slice contains 256  256 pixels of typically 0:2  0:2 cm2 (the precise pixel size
depends on the size of the body contour of the patient), the inter slice thickness is 0.5 cm. For
each CT-voxel the algorithm uses nearest neighbor sampling to determine the corresponding
Hounsfield unit (HU) [137]. For HU-values below 1100 an electron density relative to water
of HU/1000 is assumed; higher values are converted using 0:54  HU=1000 C 0:51 (these
coefficients are for a Siemens somaton plus CT-unit). Finally, the derived water equivalent
thicknesses are converted to polystyrene (PS) thicknesses using tPS D tH2O H2O=PS, with
PS and H2O linear attenuation coefficients (m−1) for the effective beam energy [78], which
is assumed to be a third of the nominal beam energy.
4.2.1 Calculation of the primary component T P .x; y/
For an EHP, the primary component of the transmission in point .x; y/ of the PDI, positioned
at a distance r.x;y/ D
√
x2 C y2 from the beam axis, and corresponding to the thickness t.x;y/
of the EHP along the ray line through point .x; y/ (see also figure 4.1) is calculated using
T P .x; y/ D Copen.r.x;y/; t.x;y//  P.t.x;y//; (4.3)
with P.t.x;y// the on-axis primary transmission component for irradiation of a flat, polystyrene
phantom with thickness t.x;y/, and Copen.r.x;y/; t.x;y// a function to account for the difference in
penetrating beam quality between the beam axis and the off -axis point .x; y/. This difference is
due to the off-axis shift in beam spectrum. Since a clinical photon beam is not monoenergetic,
Copen does also depend on the phantom thickness. As T P .x; y/ is related to primary radiation
(i.e. photons that have not interacted in the patient), it does not depend on L.x;y/. The derivation
of functions P.t/ and Copen.r; t/ from measured input data is explained in sections 4.3.3.1 and
4.3.4.
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Figure 4.1. (a) Set-up for irradiation of a thorax phantom with an anterior field and (b) the
set-up for the corresponding equivalent homogeneous phantom (EHP), used for calculation
of the transmission through the thorax phantom. Both the thorax phantom and the EHP
have a constant cross section in cranial-caudal direction. s.r.x0−x;y0−y/,t.x0;y0/,L.x0;y0/)
and P.t.x;y/) in (b) are explained in sections 4.2.1 and 4.2.2.
4.2.2 Calculation of the scatter component T S.x; y/
The scatter component of the transmission through an EHP in point .x; y/ of the PDI, T S.x; y/,
is calculated using rotation symmetric scatter kernels s.r; t; L/. For a flat, polystyrene phantom
with a thickness t , positioned at a distance L from the PDI-plane, s.r; t; L/ is the contribution to
the on-axis transmission from photons scattered from an imaginary off -axis phantom column
defined by a ray line at a distance r from the beam axis, per unit of normalized incoming beam
fluence f .r/ and column cross section (see figure 4.2). The derivation of f .r/ and s.r; t; L/
from measured data is described in sections 4.3.2 and 4.3.3.2.
The following equation is used for the calculation of T S.x; y/ for an EHP:
T S.x; y/ D
∫
.x0; y0/  field
f .r.x0;y0//
f .r.x;y//
s.r.x0−x;y0−y/; t.x0;y0/; L.x0;y0// dx0 dy0; (4.4)
with s.r.x0−x;y0−y/; t.x0;y0/; L.x0;y0// the scatter contribution due to the imaginary EHP-column
connected to the ray line through .x0; y0/, with thickness t.x0;y0/ and absorber-to-detector-
distance L.x0;y0/, to the total transmission at point .x; y/, per unit of incoming beam fluence
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Figure 4.2. Set-up for measurement of beam data used to derive the required input data
for the algorithm for transmission prediction. The absorber is made of polystyrene. The
scatter kernels s.r; t; L/ and the primary contribution P.t/, defined in sections 4.2.1 and
4.2.2, are examples of derived input data.
at point .x0; y0/, f .r.x0;y0//, and EHP-column cross section .dx0 dy0/. See figure 4.1 for an
example.
Equation (4.4) has been derived from its definition (equation (4.2C)), assuming that (i) the
scatter kernels s.r; t; L/, describing scatter contributions to the beam axis, can also be used for
calculation of scatter contributions to off-axis points, (ii) the scatter kernels s.r; t; L/, derived
from measured transmissions through flat phantoms, can be used for curved EHPs and (iii)
beam penumbras in the PDI-plane, both with the patient in the beam and in the absence of the
patient are equal.
4.3 Derivation from measured input data of the functions f .r/, P.t/, s.r; t; L/ and
Copen.r; t/, used for transmission prediction
The functions f .r/, P.t/, s.r; t; L/ and Copen.r; t/ are derived from (i) a dose profile measured
along the diagonal of the largest square field without absorber in the beam and (ii) measured
on- and off-axis transmissions of the beam through flat, polystyrene phantoms. Examples are
given for the 6 MV photon beam of a Siemens KD-2 linac.
4.3.1 Experimental setup for measurement of input data
The experimental set-up for measurement of the required input data is depicted in figure 4.2.
Dose measurements are performed with a PTW ionization chamber (N31002), positioned in
a polystyrene mini phantom with a transversal cross section of 7  7 cm2 and a thickness of
5 cm. The short term reproducibility of the dose measurements is 0.2%. The center of the
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Figure 4.3. Normalized fluence profile f .r/ of a 6 MV beam.
ionization chamber is positioned at a distance of 160 cm from the focus, which is equal to the
fixed focus-to-fluorescent screen distance of our EPID. The depth of the ionization chamber in
the mini phantom is equal to the (effective) water equivalent depth of the fluorescent screen of
the EPID. This effective depth is defined as the depth of the ionization chamber for which the
variations in on-axis response of the EPID ((grey scale value measured with the EPID)/(portal
dose measured with the ionization chamber)) for various thicknesses and exit plane-to-detector
distances L of flat absorbers are minimal [116]. To reduce the detection of electrons generated
in the patient when irradiated with high energy photon beams, we have mounted an additional
1 mm thick stainless steel slab on top of the standard fluorescent screen of the EPID [125].
Image quality is hardly affected by this additional layer so that acquired images can be used for
patient setup verification and portal dose verification at the same time [84, 85]. The effective
water equivalent depth of the in total 2.65 mm thick stainless steel layer is 2.5 cm for the 25 MV
photon beam.
For off-axis measurements, the mini phantom with the ionization chamber inserted, is
scanned in an empty RFA-300 water phantom (Scanditronix Medical AB).
4.3.2 Derivation of the normalized incoming beam fluence profile f .r/
The dose profile, measured along the diagonal of the largest field without absorber in the beam,
is used to derive the normalized incoming beam fluence profile f .r/ with r the distance to the
beam axis. Assuming radial symmetry, f .r/ is constructed by replacing the penumbras of the
measured dose profile by a linear extrapolation of the remaining central part of the dose profile.
The extrapolation is performed upto 18 cm, which is the distance between the beam axis and
the corner of a 25  25 cm2 field. An example is given in figure 4.3.
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4.3.3 On-axis transmissions T .w; t; L/ through flat, polystyrene phantoms
On-axis primary contributions P.t/ and scatter kernels s.r; t; L/ defined in, respectively,
sections 4.2.1 and 4.2.2, are derived from measured on-axis transmissions through flat,
polystyrene absorbers. Transmissions are measured for a set of square ww fields, absorber
thicknesses t and distances L from the exit plane of the absorber to the detector plane (see also
figure 4.2). The absorbers consist of piled polystyrene slabs of 40401 cm3. The T .w; t; L/-
set that was measured for the 6 MV beam contains the transmissions for all combinations of
w = 3, 4, 5, 6, 8, 10, 12, 15, 20, 25 cm,
t = 5, 10, 15, 20, 25, 30 cm and
L = 40, 45, 50, 55 cm.
Note that also some clinically irrelevant w; t; L-combinations (e.g. t=5 cm, L=40 cm) are
included; they have been measured to get a better understanding of the behavior of the primary
and scatter contributions, also in extreme cases.
Irradiations were performed with 150 monitor units (MU). To reduce the effect of (small)
output fluctuations of the linac on the measured transmissions, for each w; L-combination the
time interval between the dose measurements with and without absorber was kept limited. For
L=50 cm, the measured transmissions are presented in figure 4.4a.
4.3.3.1 Derivation of on-axis primary contributions P.t/ from measured transmissions
T .w; t; L/
The contribution of scattered photons to the measured on-axis transmissions reduces to zero
for an infinitely small field. To estimate the on-axis primary contributions P.t/, for all t; L-
combinations, the curves T .w2; t; L/, as presented for L=50 cm in figure 4.4a, are linearly
extrapolated to w2=0, using a least square fit through the measured data points for w2 = 9, 16
and 25 cm2, yielding extrapolated transmissions T .w2 D 0; t; L/. Next, for each thickness t ,
the extrapolated transmissions T .w2 D 0; t; L/ for all L are averaged, yielding the primary
contribution P.t/. For all beam qualities and phantom thicknesses t , the observed standard
deviation in derived extrapolated transmissions T .w2 D 0; t; L/ for a range of distances L was
generally below 0.3% and no systematic L-dependence was observed. This is in agreement
with the behavior of primary radiation. For the 6 MV beam, data are presented in Table 4.1.
In figure 4.4b, the logarithm of P.t/ is presented as a solid line. The dashed line is the
extrapolation of the line through the data points for t=0 and t=5 cm. The deviation between
the solid and dashed lines for larger thicknesses is due to the non-exponential attenuation of
the non-monoenergetic beam.
Because extrapolated transmissions T .w2=0,t,L) do not depend on L, in clinical practice,
the measurement of transmissions for the 33 and 44 cm2 fields can be limited to L=50 cm,
yielding a reduction in the number of w; t; L-combinations mentioned above.
4.3.3.2 Derivation of scatter kernels s.r; t; L/
The total scatter contributions S.w; t; L/ to the measured on-axis transmissions T .w; t; L/ are
used to derive the scatter kernels s.r; t; L/, defined in section 4.2.2. The S.w; t; L/-functions
are obtained using S.w; t; L/ D T .w; t; L/ − P.t/. S.w; t; L D 50 cm/-functions derived
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Table 4.1. Extrapolated transmissions T .w2 D 0; t; L/. The last two columns show,
respectively, P.t/, as derived by averaging all T .w2 D 0; t; L/-data for each t , and the
standard deviation therein.
L [cm]
40 45 50 55
t [cm] T .w2 D 0; t; L/ P .t/ SD
5 0.7812 0.7800 0.7805 0.7801 0.7804 0.0005
10 0.6139 0.6141 0.6141 0.6139 0.6140 0.0001
15 0.4872 0.4867 0.4867 0.4863 0.4867 0.0003
20 0.3887 0.3880 0.3884 0.3883 0.3883 0.0003
25 0.3119 0.3115 0.3117 0.3114 0.3116 0.0002
30 0.2514 0.2512 0.2513 0.2512 0.2513 0.0001
from figures 4.4a and 4.4b are presented in figure 4.4c. Note that in this figure the scatter
contribution is maximum for t=15 cm. This observation is in agreement with the Monte Carlo
results published by Jaffray et al. [74].
For each t; L-combination, a corresponding scatter kernel s.r; t; L/ is derived such that it
obeys the following equation for each field ww:
S.w; t; L/ D
∫
.x0;y0/  ww
f .r.x0;y0// s.r.x0;y0/; t; L/ dx
0 dy0 (4.5)
The integral on the right hand side of equation (4.5) equals the expression of equation (4.4)
for the on-axis scatter contribution T S.0; 0/ for a flat polystyrene absorber with a thickness t ,
positioned at a distance L from the PDI-plane.
The algorithm that is applied for derivation of scatter kernels s.r; t; L/ that obey
equation (4.5) for each measured field ww is described in Appendix A. This algorithm is
similar to the method of Storchi and Woudstra to derive scatter kernels for dose calculations
inside water phantoms [142]. However, several improvements were made e.g. to avoid non-
physical, negative scatter contributions. The scatter kernels corresponding to the S.w; t; L D
50/ functions in figure 4.4c are depicted in figure 4.4d. The kink in the kernels around r=2.25 cm
is due to a twist in the S.w2; t; L/-curve at w=3 cm; for smaller fields there is no measured
data available and therefore the values are derived using a linear interpolation. No effort has
been made to smooth the kernels since the fluctuations average out in calculations of T S.x; y/
with equation (4.4).
4.3.4 Derivation of functions Copen.r; t/
The functions Copen.r; t/, used in equation (4.3) for calculation of primary contributions to the
transmission through an EHP, describing the off-axis change in penetrating quality of the beam
are calculated using Copen.r; t/ D P.r; t/=P .t/ with P.t/ and P.r; t/ primary contributions to,
respectively, on- and off-axis transmissions through flat, polystyrene phantoms of thicknesses
t . Derivation of the required function P.t/ is described in section 4.3.3.1. Off-axis primary
contributions P.r; t/, needed for calculation of Copen.r; t/, are determined using P.r; t/ D
T .r; ab; t; L/ − T S.r; ab; t; L/ with T .r; ab; t; L/ a measured off-axis transmission in
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Figure 4.4. Measured on-axis transmissions T .w2; t; L=50 cm) of a 6 MV beam through
flat, polystyrene absorbers and derived primary and scatter contributions. Extrapolation of
the measured transmission functions depicted in (a) to w2=0 yields the primary contribution
P.t/ in (b) (continuous line). The deviation between P.t/ and the dashed line demonstrates
the non-exponential attenuation of the beam. The scatter functions S.w2; t; L=50 cm) in
(c) have been derived with S.w2; t; L D 50 cm/ D T .w2; t; L D 50 cm/ − P.t/. The
derivation of the scatter kernels s(r,t,L=50 cm) in (d) from the S.w; t; L D 50 cm)-data in
(c) is explained in section 4.3.3.2
a rectangular field ab and T S.r; ab; t; L/ the corresponding scatter contribution calculated
with equation (4.4).
As primary contributions do not depend on L (see sections 4.2.1 and 4.3.3.1), Copen.r; t/-
functions are derived from transmissions measured for only one L. Furthermore, the derivation
of the Copen.r; t/-functions can be performed with measured off-axis transmissions of only one
large field. However, for noise reduction we have combined data measured for three fields:
20  8, 20  14 and 20  20 cm2. For those fields, measurements were performed at off-axis
points x=2, 4 and 8 cm, for absorber thicknesses 5, 10, 20 en 30 cm and a fixed exit plane
to detector distance of 50 cm. Derived Copen.r; t/-functions are depicted in figure 4.5. The
observed decrease in penetrating quality of the beam with increasing off-axis distance is due
to the shape of the flattening filter and the off-axis spectral shift. For all r; t-combinations, the
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Figure 4.5. Functions Copen.r; t/ (lines) describing the off-axis decrease in penetrating
quality of the 6 MV beam. The dots represent the derived value of Copen.r; t/ for each field
size.
Table 4.2. P.r; t/-values obtained by extrapolation to field size zero of measured
transmissions for square fields w2 D 3  3, 4  4 and 5  5 cm2 centered around off-
axis points r=5 and r=10 cm, and P.r; t/-values calculated using P.r; t/=T .r; ab; t; L/-
T S.r; ab; t; L/. All data are for a 23 MV beam.
r=5 cm r=10 cm
t P .r; t/ P .r; t/ Diff. P.r; t/ P .r; t/ Diff.
[cm] extrapolated calculated [%] extrapolated calculated [%]
10 0.7373 0.7373 0.0 0.7263 0.7278 -0.2
15 0.6359 0.6361 -0.0 0.6238 0.6244 -0.1
20 0.5505 0.5500 0.1 0.5372 0.5369 0.1
standard deviation in the Copen.r; t/-values derived from measured data from different fields
ab was generally less than 0.1%.
For the 23 MV beam of a Siemens KD-2 linac, the above described method for generation of
off-axis primary contributions, P.r; t/, used for derivation of the functions Copen.r; t/, has been
compared with an alternative method which is similar to that used for generation of the on-axis
function P.t/ (see section 4.3.3.1). Each alternative P.r; t/-value is obtained by extrapolation
to field size zero of measured transmissions for square fields w2 D 3  3, 4  4 and 5  5 cm2
centered around the off-axis point r . Data are presented in Table 4.2. For points up to 10 cm
from the beam axis, the maximum deviation between these alternative primary contributions
and those derived with the method described above was only 0.2%.
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4.4 Comparison of predicted and measured transmissions for anthropomorphic
phantoms
The accuracy of the method for transmission prediction (described in section 4.2) has been
assessed by comparing predictions with ionization chamber measurements for a large set of
anthropomorphic phantoms. The setup for the measurements is described in section 4.3.1.
The ionization chamber was used since it is the gold standard for dose measurements. A
method for accurate dose measurement with our EPID has been presented elsewhere [116,
125]. Predictions were performed at a 0.25 cm grid using equation (4.3) for the primary
component and equation (4.4) for the scatter component. In this section, representative data
are presented for irradiations with the 6 and 23 MV photon beams of a Siemens KD-2 linac. The
anthropomorphic phantoms consist of polystyrene, lucite and cork. Therefore the calculation
of EHPs is somewhat different from the applied procedure for patients that is described in
section 4.2. The geometrical thicknesses of these materials along the ray lines are derived
from CT-data and then converted to water equivalent thicknesses, using =H2O ratios for the
effective beam energy (2 MeV and 7.6 MeV for the 6 and 23 MV photon beam respectively).
As for patients the water equivalent thicknesses are then converted to polystyrene thicknesses,
yielding the EHP. The /H2O ratios for lucite and polystyrene are respectively 1.137 and
1.018 for the 6 MV photon beam and 1.117 and 0.987 for the 23 MV photon beam [79]. Since
no accurate data for cork was available, 0.3 was used for both energies, in agreement with the
electron density relative to water according to the CT-scanner. The reported percent differences
between predicted and measured PDIs are defined by (calculation-measurement)/measurement
 100.
The thorax phantom depicted in figure 4.6a, made out of cork and lucite, is symmetric in
cranial-caudal direction. This phantom was irradiated by a 14  12 cm2 field with the 6 and
23 MV photon beams. The source to surface distance (SSD) was 100 cm and the distance
between the exit surface of the phantom and the detector plane was 37.5 cm. The EHP for
transmission prediction for a 6 MV beam is shown in figure 4.1. Measured and predicted
transmissions with the primary and scatter components are depicted in figure 4.6b. The solid
lines represent the predicted transmissions and the squares the measurements. The percent
differences are depicted in figure 4.6c. The observed agreement, except for the point on the
steep gradient (x=3.7 cm), is 0:4  0:4% for the 6 MV beam and 0:3  0:7% for the 23 MV
beam.
A second thorax phantom, made out of polystyrene and cork and symmetric in cranial-
caudal direction, was irradiated with a lateral 2020 cm2 field of the 6 MV photon beam. The
setup is depicted in figure 4.7a. The distance between the exit surface of the phantom and the
detector plane was 45 cm. Measurements and predictions are depicted in figure 4.7b. Excluding
the points on the steep gradients (x=-6.9, -6.3, -5.6, -2.5 and -1.9 cm), the observed agreement
between measured and predicted transmissions is 0:2  1:0%. Note that in figure 4.7b the
predicted and measured transmissions for −10 < x < −7 are slightly higher than 1. The
incoming (primary) photon beam reaching this part of the detector plane has not passed any
phantom material. Therefore, the primary component of the transmission is 1; side scatter from
the phantom yields a total transmission higher than 1.
The head and neck phantom depicted in figure 4.8, made of polystyrene with an air gap of
4  4 cm2, has a constant cross section in the lateral direction. This phantom was irradiated
with an anterior, 16  10 cm2 field of the 6 MV photon beam. The SSD was 100 cm and the
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Figure 4.6. (a) Schematic picture of the setup for irradiation of a thorax phantom with
the 14  12 cm2 field of the 6 and 23 MV beams. (b) The markers represent measured
transmissions. Continuous lines show the calculated transmissions. The percent difference
between the measurements and calculations are depicted in (c).
on-axis distance between the exit surface of the phantom and the detector plane was 44 cm. The
squares and the solid line in figure 4.8 are, respectively, measured and predicted transmissions.
The upper dashed curve is the calculated primary component and the lower dashed curve the
calculated scatter component. Outside the points in areas with steep gradients (x D −1:3, 1.9
and 5.7 cm) measured and predicted transmissions agree within 0:3  0:8%.
The calculated on-axis scatter contribution T S(0,0) depicted in figures 4.6b, 4.7b and
4.8 often significantly differ from off-axis scatter contributions. Assuming off-axis scatter
contributions to be equal to the on-axis scatter contribution may lead to systematic errors in
predicted off-axis transmissions of up to 3%. Hansen et al. have applied a simple model for the
on-axis scatter contribution to estimate off-axis scatter contributions. They claim an acceptable
accuracy of this approach which is attributed to the large (2 m) distance between the focus and
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Figure 4.7. (a) Schematic picture of a thorax phantom irradiated with a lateral 2020 cm2
field of the 6 MV beam. (b) The predicted transmission is represented by a solid line and
the measured transmission with markers. The upper and lower dashed lines represent the
primary and scatter component of the calculated transmission.
the EPID [60].
4.5 Discussion
In clinical practice it is convenient to have a large clearance between the treatment head of the
accelerator and the EPID. EPIDs are generally positioned at a distance between 150 and 200 cm
from the focus [44, 60]. Our SRI-100 EPIDs are positioned at 160 cm from the focus. Due to
the resulting relatively large air gap between irradiated patients and the fluorescent screen of the
EPID, our treatment planning system cannot be used for the accurate prediction of PDIs, needed
for dosimetric treatment verification. This was the main motivation to implement a separate
algorithm for PDI-prediction. Our preference to have a dosimetric treatment verification that
is independent from our commercial treatment planning system was an additional reason for
starting up the project. In the literature there are no methods for PDI prediction available which
have been tested for air gaps larger than 22 cm and energies above 6 MV. The work presented
in this paper covers these situations.
For each photon beam, the input for the algorithm for PDI prediction is completely derived
from a set of measured beam data. Our treatment planning system is also fully based on basic
measured input data such as dept dose curves and beam profiles [141, 142]; precalculation
of input data using Monte Carlo codes is not required. This was a reason why we preferred
to develop a method for PDI prediction that did not force us to start working with Monte
Carlo codes for generation of input data for these dose calculation algorithms, as would be
required by the method of McNutt et al. [99]. A disadvantage of our approach could be the
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Figure 4.8. The depicted polystyrene head and neck phantom with a constant cross section
in lateral direction was irradiated with a 1610 cm2 field of the 6 MV beam. The predicted
(solid line) and measured (markers) transmission are shown. The upper and lower dashed
line represent the primary and scatter component of the calculated transmission.
required effort for the measurement of the beam data. As mentioned in section 4.3.3, the set
of w; t; L-combinations for which transmission measurements were performed for the 6 MV
beam contains some clinically irrelevant combinations. Furthermore, the fields 3  3 and
4  4 cm2, used to derive the primary component, only have to be measured for one L (see
section 4.3.3.1). Skipping these w; t; L-combinations and the one’s for which the isocenter is
outside or at the edge the phantom the set reduces from 240 w; t; L-combinations, as listed
in section 4.3.3, to 140. For dosimetric verification of the open (non-wedged) fields used for
treatment of prostate cancer patients with the 25 MV beam of the MM50 racetrack microtron,
the relevant beam data set could be measured in only 4 hours.
The substitution of patients by equivalent homogeneous phantoms makes this algorithm
easy to implement and fast. Using a Hewlett Packard 712-80 workstation (32 MB, HP-UX
10.20, 92.0 million instructions per second (MIPS)) calculation of the EHP for one field takes 4
minutes, of T .x; y/ 25 seconds and of Dp;0.x; y/ 20 seconds. These calculations are performed
off-line in batch mode and only have to be done once for each patient. The accuracy of calculated
transmissions is very high (1%, see section 4.4). No systematic deviations between measured
and predicted transmissions have been found.
Following equation (4.1), Dp;0.x; y/, i.e. the PDI that would have been measured in the
absence of the patient, can be derived from
Dp;0.x; y/ D Dp.x; y/=T .x; y/
with Dp.x; y/, the measured PDI with the patient in the treatment beam and T .x; y/ the
predicted transmission. Dp;0.x; y/, which is proportional to the beam fluence entering the
patient, could then be used for a check on the beam flatness and symmetry or for a forward
calculation of the actually delivered dose distribution in the patient. A potential problem with
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the above described scenario for derivation of Dp;0.x; y/ is that the calculated transmission
T .x; y/, used in this scenario for the derivation of Dp;0.x; y/ does, in turn, also depend
on the incoming beam fluence (f .r/ in equation (4.4)) and therefore on Dp;0(x,y). To
study the dependence of transmissions T .x; y/ on the beam fluence profile f .r/, we have
compared transmission predictions with the nominal beam fluence profile in equation (4.4)
with predictions performed with two alternative profiles substituted in equation (4.4). By
definition, both alternative profiles were normalized to 1 at the beam axis. The first was a highly
non-flat, linear profile with a value of 1.30 at r=18 cm. The other, consisting of two straight
lines defined by, respectively, f .x; −18/=0.7 and f .x; 18/=1.30 was highly asymmetric in
the y-direction. The transmissions calculated with the nominal beam fluence and the two
alternative profiles differ less then 1% for all points .x; y/. Hence, also for strongly deviating
fluence profiles Dp;0.x; y/ can be derived from a measured PDI using the transmission function
T .x; y/ calculated with the expected nominal profile.
For several prostate cancer patients we have observed large local differences between PDIs
measured with the SRI-100 during some of the treatment fractions and PDIs predicted with
the methods described in this paper. The observed large differences point at variations in
internal patient anatomy (‘internal organ motion’) due to variations in rectum filling; for some
patients the anatomy during the registration of the planning CT-scan did not reflect the average
anatomy during the daily treatments [84, 85]. Therefore, a forward calculation of the dose
distribution delivered to the patient, based on a measured PDI and the planning CT-scan, can
lead to erroneous conclusions. This problem could be overcome by using on-line measured
CT-data generated with a tomotherapy unit [97].
The presented method for transmission prediction is only suitable for non-wedged photon
beams. An extension for transmission prediction in wedged beams, based on only very few
extra measured input data, is under investigation. The first results are promising [117]. PDI-
prediction for intensity modulated beams generated either by dedicated tissue compensators or
by dynamic multileaf collimation is a subject of future research.
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Appendix: Derivation of scatter kernels s.r; t; L/
For each t; L-combination separately, the corresponding kernel s.r; t; L/ is calculated with the
following algorithm.
Step 1 Definition of s0.r; t; L/
A new function is introduced
s0.r; t; L/ D f .r/  s.r; t; L/: (A1)
According to equation (4.5) s0.r; t; L/ should obey
S.w; t; L/ D
∫
.x;y/  ww
s0.r D
√
x2 C y2; t; L/ dx dy (A2)
for all fields ww.
Step 2 Calculation of a first approximation of s0.r; t; L/
First, on-axis scatter contributions S.R; t; L/ for circular fields are estimated from the measured
scatter contributions for rectangular fields using S.R; t; L/ D S.w; t; L/, with R D w=p
the radius of the circular field. Assuming the validity of this procedure for calculation of
S.R; t; L/, the following equation for s0.r; t; L/ can be derived from equation (A1)
S.R; t; L/ D
R∫
rD0
2  r s0.r; t; L/ dr (A3)
and a first approximation for s0.r; t; L/ at points r D n (=0.25 cm) can be calculated by
numerical differentiating S.R; t; L/:
s0.n  ; t; L/ D S.n  ; t; L/ − S..n − 1/  ; t; L/
2n2
n D 1; : : : ; N; (A4)
N is the index of the largest circular field involved.
The applied conversion of measured scatter contributions for square fields into scatter
contributions S.R; t; L/ for circular fields introduces (small) errors in the function s0.r; t; L/.
Therefore, the following iterative algorithm is applied to calculate s0.r; t; L/ from its first
approximation.
Step 3 Calculation of s0.r; t; L/ in an iterative procedure
First, scatter contributions S.wj; t; L/ for all square fields wj D 0:5  j are determined by
interpolation in the measured S.w; t; L/-data. Then, starting with the largest field, these
scatter contributions are also calculated using
T S.wj ; t; L/ D
∫
.x;y/  wj wj
s0.r D
√
x2 C y2; t; L/ dx dy: (A5)
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and the difference between S.wj; t; L/ and T S.wj; t; L/ is spread over all elements of s0.r; t; L/
that contribute to the calculated scatter:
nj D
√
1
2w
2
j

1 D S.wj ; t; L/ − T
S.wj ; t; L/
nj
(A6)
s0.n  ; t; L/  s0.n  ; t; L/ C 1
2n2
n D 1; : : : ; nj
with nj the number of elements contributing to the on-axis scatter in a wj  wj-field and where
 means an update of the value for s0.n  ; t; L/. The procedure of calculating the scatter
contribution with equation (A5) and correcting s0.r; t; L/ with (A6) is subsequently repeated
for the next field .j − 1/ and so forth up to the smallest field .j D 1/. This whole iterative
procedure for correcting s0.r; t; L/ is repeated five times after which s0.r; t; L/ has converged
to a stable solution. The differences between the measured and calculated transmissions are
then smaller than 0.2%.
Step 4 Calculation of the scatter kernel s.r; t; L/
The scatter kernel s.r; t; L/ can be calculated from the derived s0.r; t; L/ using equation (A1).
However, the maximum radius r for which s0.r; t; L/ can be obtained with the above described
procedure is equal to the radius of the largest equivalent circular field. To be able to account
for the scatter contribution from one corner to the opposite corner of a large field, the tail of
the kernel is logarithmically extrapolated to r D √2w2max, with wmax the size of the largest
square field.
Chapter 5
In vivo dosimetry for prostate cancer patients using an
electronic portal imaging device; demonstration of internal
organ motion
Marco Kroonwijk, Kasper L. Pasma, Sandra Quint, Peter C.M. Koper,
Andries G. Visser and Ben J.M. Heijmen
Radiother. Oncol. 49(2): 125-132, 1998.
Purpose: To investigate the use of a commercially available video-based EPID for in vivo
dosimetry during treatment of prostate cancer patients.
Methods: For ten prostate cancer patients, the inter-fraction variation within measured portal
dose images (PDIs) was assessed and measured PDIs were compared with corresponding
predicted PDIs, based on the planning CT scan of the patient.
Results: For the lateral fields, the average standard deviation in the measured on-axis
portal doses during the course of a treatment was 0.9%; for the anterior fields this standard
deviation was 2.2%. The difference between the average on-axis measured portal dose and
the predicted portal dose was 0.3  2.1% (1 SD) for the lateral fields and 0.7  3.4% (1
SD) for the anterior fields. Off-axis differences between measured and predicted portal
doses were regularly much larger (up to 15%) and were caused by frequently occurring
gas pockets inside the rectum of the patients during treatment or during acquisition of the
planning CT scan. The detected gas pockets did sometimes extend into the gross tumour
volume (GTV) area as outlined in the planning CT scans, implying a shift of the anterior
rectum wall and prostate in anterior direction (internal organ motion).
Conclusions: The developed procedures for measurement and prediction of PDIs allow
accurate dosimetric quality control of the treatment of prostate cancer patients. Comparing
measured PDIs with predicted PDIs can reveal internal organ motion.
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5.1 Introduction
EPIDs have become a useful tool for the verification and correction of daily patient set-up
during radiotherapy treatment [8, 28]. For this purpose, the position of bony structures in a
portal image, relative to the treatment field, is compared with their position in a corresponding
simulator image or digitally reconstructed radiograph (DRR).
Portal images also contain dosimetric information; the pixel signals (grey scale values)
in portal images are related to the portion of radiation transmitted through the patient and
hence also related to the dose absorbed by the patient. Several years ago investigations started
to find out whether the video-based SRI-100 EPID (Philips Medical Systems, Crawley, UK)
can be used for dosimetric treatment verification. The linearity and stability of this system
make it very suitable for dosimetric applications [39, 61, 81]. Since 1994, two of these EPIDs
are in daily use for dosimetric quality control of the scanning photon beams of our MM50
Racetrack microtron (Scanditronix Medical, Uppsala, Sweden) [39]. Recently, an algorithm
has been developed to convert a measured EPID image into an absolute portal dose image
(PDI), defined as the (transmitted) dose distribution in the plane of the fluorescent screen of the
EPID, located at 160 cm from the focus [61, 116, 125]. Also, a method has been developed for
prediction of PDIs, based on the planning CT scan of the patient [64, 115]. Comparing PDIs
obtained with the EPID during treatment with predicted PDIs can reveal problems like incorrect
(dosimetric) performance of the treatment unit, erroneous design, production or application of
compensators and deviations of the patient anatomy during the daily treatment fractions from
the anatomy during acquisition of the planning CT scan [172].
This paper reports on our first clinical experience with in-vivo dosimetry using an EPID.
For the ten prostate cancer patients in this study, EPID images were acquired for all treatment
fields on every treatment day. The inter-fraction (i.e. day-to-day) variation in measured PDIs
was assessed and measured PDIs were compared with a corresponding predicted PDI which
was calculated using the planning CT scan of the patient. The obtained data point at internal
organ motion due to observed gas pockets in the rectum of the patients.
5.2 Material and Methods
5.2.1 Patients
Six out of ten prostate cancer patients in this study participated in a randomized trial, comparing
conventional treatment using rectangular fields with conformal treatment using multi-leaf
collimator (MLC) defined fields [83]. One of the patients was treated after a prostatectomy.
For all ten patients a planning CT scan was acquired with a slice distance of 5 mm. The
patients were asked to retain full bladder at the time of acquisition of the planning CT scan
and during the daily treatments. No attempts were made to control the rectal contents of the
patients. For each patient the visible prostate and the seminal vesicles were outlined manually
on all applicable CT slices by the radiation oncologist. The obtained gross tumour volume
(GTV) [73] was then extended automatically in 3-dimensions (3D) [145, 147] with a margin
of 15 mm, yielding the planning target volume (PTV) [73]. The treatment plans were designed
with the CadPlan 3D treatment planning system (TPS) (Varian-Dosetek, Espoo, Finland). All
patients were treated in supine position with a three field, isocentric technique, consisting of one
anterior and two lateral oblique fields that were partially delivered with a 60o wedge inserted.
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Figure 5.1. Schematic overview of the implemented dosimetric treatment verification
method (in vivo dosimetry) for comparison of measured and predicted PDIs.
The treatments were performed with the 25 MV photon beam of a MM50 racetrack microtron.
The doserate was 300 monitor units (MU) min−1. A total dose of 66 Gray was prescribed to
the isocenter and delivered in 33 fractions. Apart from some minor underdosages (<2%) in
small parts of the superior and inferior ends of the PTV of some patients, the treatment plans
fulfilled the ICRU-50 recommendations on dose homogeneity in the PTV [73]. (At present,
these underdosages are avoided by using intensity modulated beams) [37].
During treatment, patient set-up was verified and corrected using an off-line correction
protocol, based on analysis of the position of bony structures in EPID images, acquired in the
non-wedged portion of each treatment field [8]. Using this protocol the standard deviation of
systematic and average random 3D set-up errors are as low as 1.5 and 2.0 mm, respectively.
Prior to the analyses of measured PDIs, the position of the bony structures in all daily measured
images was registered with the bony anatomy visible in a corresponding DRR that was derived
from the planning CT scan of the patient.
5.2.2 In vivo dosimetry
For the patients in this study, EPID images were acquired for all treatment fields on every
treatment day and the inter-fraction variation in measured PDIs was assessed. Moreover,
measured PDIs were compared with a corresponding predicted PDI calculated using the
planning CT scan of the patient; this procedure is schematically shown in figure 5.1. Details
on the prediction and measurement of PDIs are discussed in sections 5.2.2.1 and 5.2.2.2.
5.2.2.1 PDI prediction
The fixed focus-to-fluorescent screen distance of the applied EPID is 160 cm. Due to the
resulting large air gap between the patient and the EPID detector (35-55 cm) the CadPlan TPS
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cannot be used for accurate prediction of PDIs for this EPID. Therefore, we have developed our
own algorithms to predict PDIs, using planning CT data of the patient as input [64, 85, 115].
Primary photon contributions and contributions from photons scattered from the patient onto
the EPID are calculated separately and are added to obtain the PDI.
For calculation of the primary component, beam-hardening effects, e.g. due to a flattening
filter, a wedge or a compensator, are taken into account. Scatter contribution calculations are
basically convolutions of the two-dimensional beam fluence profile entering the patient with
scatter kernels, describing the scatter from the patient onto the EPID. Basic input data for the
calculations are obtained from a set of transmission measurements through flat, polystyrene
absorbers for relevant absorber thicknesses, field sizes and distances to the EPID detector [115].
For a wide range of inhomogeneous anthropomorphic phantoms and treatment energies,
predicted portal dose values and doses measured with an ionisation-chamber agree within
1% (1 SD) [64, 85, 115].
5.2.2.2 PDI measurement
Portal images were acquired with a commercially available video-based SRI-100 EPID. This
EPID basically consists of a fluorescent screen, two mirrors and a charge coupled device
(CCD) camera [2, 164]. In order to reduce detection of high energy electrons generated inside
the patient, an extra one millimeter thick stainless steel plate was mounted on top of the
standard fluorescent screen, which consists of a 1.65 mm thick stainless steel plate coated with
a fluorescent layer. The total water equivalent depth of the EPID detector is only slightly smaller
than the depth of maximum dose of the applied 25 MV photon beam [116]. The extra build-up
layer resulted in a minor decrease in resolution but at the same time led to an increase of the
signal-to-noise ratio in portal images. Modifications to the software of the SRI-100 system
were performed at the level of the macro command language that comes with the system: (i)
the standard image acquisition time was adjusted to fully enclose the irradiation time in order to
measure the total delivered dose for each treatment field (58 MU: 12.8 s, 59-69 MU: 15.36 s,
70-86 MU: 19.2 s, 87-115 MU: 25.6 s, 116-173 MU: 38.4 s and 174-384 MU: 76.8 s) and
(ii) for dosimetric purposes, an additional “raw” 16-bit image was saved to avoid digitization
noise in low grey scale value images [85, 116, 125]. Image enhancement procedures, used
to obtain adequate image quality for patient set-up verification, continued automatically after
the raw image was saved. With these modifications, acquisition of portal images, suitable for
in vivo dosimetry, could be fully integrated into existing imaging routines for patient set-up
verification without introducing an increase in the overall treatment time.
Visible photons produced by the x-ray beam in a point of the fluorescent screen not only
generate a signal in the corresponding pixel of the EPID image, but also generate a (much
lower) signal in all other pixels. Heijmen et al. have shown that this is due to light scatter from
components within the EPID structure onto the CCD chip [61]. PDIs are derived from measured
EPID images by removing the contributions from scattered light to the pixel signals in an EPID
image using a deconvolution algorithm, as described by Pasma et al. [116, 125]. Using this
method, derived PDIs generally agree within 1% (1 SD) with ionisation-chamber measurements
in open, wedged and intensity modulated beams for various anatomical phantoms.
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5.2.3 EPID stability
During the study, the stability of the EPID response was verified on a two-weekly basis by
comparing the pixel signals in acquired EPID images with measurements performed with an
ionisation chamber array, positioned at 100 cm from the focus. Details on the applied set-up and
equipment are given in [39]. During the four month period of this study, the variation in absolute
on-axis EPID response was 0.7% (1 SD). The variation in the EPID response, relative to the
on-axis measured grey scale value was less than 0.2% (1 SD). Both the observed variations
in absolute on-axis response and in the relative off-axis response are in agreement with the
observations of Heijmen et al. [61] and Dirkx et al. [39]. In the analyses of the inter-fraction
variation in the portal doses measured during patient treatment, the reported standard deviations
were obtained by subtracting 0.72 from the square of each measured standard deviation; this
corrected standard deviation is more directly correlated with patient thickness variations.
5.3 Results and discussion
For each patient, acquisition of EPID images was planned for all of the 33 treatment fractions.
However, some portal image acquisitions failed, e.g. because of accelerator interlocks or
starting image acquisition too late, leaving about 30 successful acquisitions per treatment field,
per patient.
5.3.1 On-axis portal doses
For each patient and for the lateral and anterior fields separately, the on-axis inter-fraction
variation in measured PDIs and the average on-axis differences found between the measured
PDIs and the predicted PDI are presented in table 5.1. For the lateral fields, the average standard
deviation in the on-axis measured portal doses was 0.9%. For the anterior fields the standard
deviation was 2.2%. For the ten patients, the average difference between the on-axis measured
portal dose and the predicted portal dose was 0.3  2.1% (1 SD) for the lateral fields and 0.7
 3.4% (1 SD) for the anterior fields.
From the measured set of transmissions through flat water-equivalent absorbers, as used
for the PDI prediction algorithm, relationships between radiological thicknesses and portal
doses were derived for typical lateral and anterior treatment fields. A variation in radiological
thickness of 1 cm, e.g. due to a variation in rectum and/or bladder filling, results in a variation
in the transmitted dose of approximately 1.9% for a lateral field and 3.1% for an anterior field.
This difference between lateral and anterior fields is an explanation for the observed larger
standard deviations for the anterior fields. Variations in on-axis portal dose could also be
slightly higher for the anterior fields because for these fields the central ray-line passes both the
rectum and the bladder, whereas the central ray-line of the lateral fields does not pass organs
with a variable filling.
5.3.2 Off-axis portal doses
For the six patients with the largest inter-fraction variation in measured PDIs, the observed
variations for the right lateral field are presented in figure 5.2, together with beam’s-eye-view
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Table 5.1. On-axis inter-fraction variation in measured PDIs and average on-axis difference
between measured and predicted PDIs for lateral and anterior fields separately, for ten
prostate cancer patients.
Lateral field Anterior field
patient Difference Inter-fraction Difference Inter-fraction
number between variation between variation
measured and (1 SD) [%] measured and (1 SD) [%]
predicted PDI predicted PDI
[%] [%]
1 -0.1 1.2 -4.2 3.5
2 2.7 0.5 2.0 1.6
3 1.2 0.3 -0.3 0.2
4 0.5 1.1 1.5 1.7
5 1.9 0.6 3.6 2.6
6 -4.6 1.0 3.7 1.3
7 2.2 1.1 4.2 4.2
8 1.6 0.2 -5.6 2.8
9 -0.8 1.5 1.3 2.2
10 -1.3 1.1 0.8 0.7
(BEV) contours of the GTV (prostate + seminal vesicles), the rectum and the bladder, as
derived from the planning CT scan. For patient 8, the inter-fraction variation is also presented
in colour in figure 5.3a. For the lateral fields, areas with large variations (SD > 3%) are mainly
found for pixels corresponding to rays passing through the planned position of the rectum, the
superior/posterior portion of the prostate, and the posterior part of the seminal vesicles. For
rays passing only through the bladder, the observed variations in measured portal doses are
generally much smaller. For the anterior fields, the areas with large variations are also strongly
correlating with the BEV contour of the rectum, as depicted in figure 5.3b for patient 8.
For those treatment fractions that show large differences between measured and predicted
PDIs, the deviations do mostly occur in the areas of the PDI for which also large inter-fraction
variations are observed. For patient 8, differences between the PDI measured during fraction
13 and the corresponding predicted PDI are presented in figures 5.3c and 5.3d for the right
lateral field and the anterior field, respectively. The maximum difference between measured
and predicted portal dose is 15%, pointing at a difference in lateral radiological pathlength
Figure 5.2. Observed inter-fraction variations in measured PDIs for the right lateral
treatment field of patients 1 and 5-9. Each pixel represents the standard deviation in
the observed portal doses during the course of the treatment. The dashed BEV contours
represent, from left to right, the rectum, the GTV including prostate and seminal vesicles
(not available for patient 1 because of prostatectomy) and the bladder. The presented iso-
standard deviation contours connect pixels with standard deviations of 2 and 3% for patients
1, 5 and 6. For patients 7, 8 and 9 only the 3% contour is displayed, because maximum
standard deviations in these images are larger than 4%.
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with the planning CT scan of about 6 cm. Also for patient 8, figures 5.3e and 5.3f show the
difference between the average measured PDI (average of 27 fractions) and the predicted PDI
for the right lateral field and the anterior field, respectively.
5.3.3 Gas pockets and organ motion
Observed variations in both lateral and anterior measured PDIs were often due to localized
areas of increased portal dose inside the rectum contour and the posterior part of the GTV
contour, pointing at the presence of gas pockets inside the rectum of the patients of variable
size and shape. In the presence of both faeces and a gas pocket, the gas is generally floating
on top of the faeces. In figures 5.3c and 5.3d, the red spots inside the GTV contour are due
to the presence of a large gas pocket inside the rectum of patient 8 during treatment. During
acquisition of the planning CT scan, the rectum of patient 8 also contained a (smaller) gas
pocket, see figure 5.4. Due to this gas pocket, the differences between measured and predicted
portal doses inside the BEV contour of the rectum in the lateral view (figure 5.3c) and on-axis
differences in the anterior view (figure 5.3d) are relatively small.
The presence of a large gas pocket within the BEV contour of the GTV, as observed in the
lateral field (figure 5.3c), points at internal organ motion. During fraction 13, the positions of
the prostate and seminal vesicles were in disagreement with the planning CT scan. The gas
pocket in the rectum of the patient pushed both the anterior part of the rectal wall and the GTV
in anterior direction, yielding a risk for an unintended irradiation of a large part of the rectum
and for underdosing the anterior part of the GTV. Similar observations were made for other
fractions of patient 8 and also for other patients.
Figures 5.3e and 5.3f show, for patient 8, for each pixel the difference between the average
measured portal dose (average of 27 fractions) and the predicted portal dose for the right lateral
field and the anterior field, respectively. The blue spots are due to the presence of the gas pocket
during acquisition of the planning CT scan (figure 5.4). The deviations inside the upper part
of the GTV contour as presented in figure 5.3e, point at the presence of gas pockets during
treatment that resulted in movement of the GTV in anterior direction.
Figure 5.3. The blue, red and yellow contours represent the BEV contours of, respectively,
the rectum, the gross tumour volume and the bladder; point (0,0) corresponds to the
isocenter.
a. Observed inter-fraction variations (1 SD) in the measured portal doses for the right lateral
field of patient 8.
b. As figure 5.3a but now for the anterior field.
c. Differences between the portal doses measured during fraction 13 of patient 8 for the
right lateral field and the corresponding predicted portal doses.
d. As figure 5.3c, but now for the anterior field.
e. Differences between the average measured PDI (average of 27 fractions) and the predicted
PDI for the right lateral field of patient 8.
f. As figure 5.3e, but now for the anterior field.
The applied scale in figure 5.3c is different from the scale in figures 5.3d, 5.3e and 5.3f,
due to the large deviations in portal dose as measured in fraction 13 in the lateral beam of
patient 8.
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Figure 5.4. The planning CT scan of patient 8, used for PDI prediction. The transversal
slice shown contains the isocenter. The closed white contour indicates the GTV volume
and the dashed lines show the applied beams. Notice the gas pocket inside the rectum.
In recent years, several groups have studied internal organ motion in prostate cancer
patients [4, 6, 7, 31, 87, 102, 132, 152, 159, 163]. The observed prevalence in this study of gas
pockets occurring in the upper part of the rectum close to the superior portion of the prostate
and the seminal vesicles (figures 5.2 and 5.3) is in agreement with the presence of internal
organ motion in these areas reported in the literature, see e.g. Beard et al. [7] and van Herk et
al. [159]
For back-projection methods aiming at calculation of the 3D patient dose distribution from
measured portal images (see e.g. Hansen et al. [60] and McNutt et al. [98]), an accurate 3D
representation of the patient is required. In this study, we have observed that large deviations
between measured and predicted portal doses were always due to differences in patient anatomy
during acquisition of the planning CT scan and during the treatment fractions, due to gas pockets
in the rectum of the patients. In case of large deviations between predicted and measured PDIs,
calculation of the patient dose distribution based on the planning CT scan would therefore have
resulted in non-meaningful dose distributions in the corresponding volumes in the patients. In
on-going studies we are investigating the applicability of gas pockets visible in EPID images
for on-line geometrical verification and correction of the position of the prostate of the patient
in the treatment beams. The data presented in this paper do not allow to decide whether EPID
images can be used for detection of internal organ motion due to variation in the amount of
faeces present in the rectum.
5.4 Conclusions
The small average on-axis differences between measured and predicted PDIs and the variation
therein indicate that the developed methods and procedures allow accurate dosimetric quality
control of the treatment of prostate cancer patients in clinical practice. Large off-axis differences
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between measured and predicted PDIs have been found to correspond with frequently occurring
gas pockets inside the rectum of the patient during treatment or during acquisition of the
planning CT scan. In case a detected gas pocket extends into the GTV area, as outlined in the
planning CT scan, organ motion is evident.
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Purpose Comparison of predicted portal dose images (PDIs) with PDIs measured with an
electronic portal imaging device (EPID) may be used to detect errors in the dose delivery
to patients. However, these comparisons can not reveal errors in the MU calculation of a
beam, since the calculated number of MU is both used for treatment (and thus affects the
PDI measurement) and for PDI prediction. In this paper a method is presented that enables
‘in vivo’ verification of the MU calculation of the treatment beams. The method is based
on comparison of the intended on-axis patient dose at 5 cm depth for each treatment beam,
D5, with D5 as derived from the portal dose Dp measured with an EPID. The developed
method has been evaluated clinically for a group of 115 prostate cancer patients.
Methods and Materials The patient dose D5 was derived from the portal dose measured
with a fluoroscopic EPID using (i) the predicted beam transmission (i.e. the ratio of the
portal dose with and without the patient in the beam) calculated with the planning CT data
of the patient and (ii) an empirical relation between portal doses Dp and patient doses D5.
For each beam separately, the derived patient dose D5 was compared with the intended dose
as determined from the relative dose distribution as calculated by the treatment planning
system and the prescribed isocenter dose (2 Gy). For interpretation of observed deviating
patient doses D5, the corresponding on-axis measured portal doses Dp were also compared
with predicted portal doses.
Results For three beams, in total 7828 images were analyzed. The mean difference between
the predicted patient dose and the patient dose derived from the average measured portal
dose was: 0:43:4% (1 SD) for the anterior-posterior (AP) beam and −1:52:4% (1 SD)
for the lateral beams. For 7 patients the difference between the predicted portal dose and
the average measured portal dose for the AP beam and the corresponding difference in
patient dose were both greater than 5%. All these patients had relatively large gas pockets
(3-3.5 cm in AP direction) in the rectum during acquisition of the planning CT, which were
not present during (most) treatments.
Conclusions An accurate method for verification of the MU calculation of an x-ray beam
using EPID measurements has been developed. The method allows the discrimination of
errors that are due to changes in patient anatomy related to appearance or disappearance of
gas pockets in the rectum and errors due to a deviating cGy/MU-value.
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6.1 Introduction
So far, electronic portal imaging devices (EPIDs) have been mainly used for patient set-up
verification. For this purpose the position of the bony anatomy in a portal image is compared
with the position in a corresponding simulator image or digitally reconstructed radiograph
(DRR). An EPID can also be used to measure portal dose images (PDIs), i.e. a dose distribution
behind the patient in a plane perpendicular to the beam axis [116, 172]. Several methods to
use EPIDs for dosimetric treatment verification have been proposed [14, 60, 84, 98, 115, 118,
172, 175]. Only a few, small studies have been performed to evaluate proposed procedures in
clinical practice [14, 60, 84, 118].
Boellaard et al. derived midplane dose distributions (2D) from measured PDIs [14]. Their
method did not require CT data; the radiological thickness of the patient is determined from the
ratio of a PDI acquired with and without the patient in the beam. Besides requiring an extra EPID
measurement for each field this method has the drawback that it assumes inhomogeneities to be
symmetrically positioned with respect to the patient midplane. This approach did sometimes
result in an erroneous dose distribution, e.g. for the anterior beam of a prostate cancer patient
with a large gas pocket in the rectum. Hansen et al. derived the primary fluence from a measured
PDI and back projected that fluence through the patient to yield the primary fluence distribution
in the patient. This distribution was then convolved with dose deposition kernels to derive the
3D dose distribution in the patient [60]. Results were presented for a humanoid phantom and
a pelvic patient. McNutt et al. developed an iterative convolution/superposition algorithm to
reconstruct the dose distribution in a patient from a measured PDI and showed results for three
phantoms [98]. The last two methods require that the patient representation during treatment
is known. In the method of Ying et al., a deviating patient anatomy at the time of treatment is
accounted for with an iterative procedure that modifies the planning CT data [175].
In our institution, PDIs are measured with a fluoroscopic EPID [61, 84, 116]. Pasma
et al. have developed a deconvolution method to derive these PDIs from measured EPID
images [116]. For anthropomorphic phantoms, the PDIs measured with the EPID agree
within 1% with absolute portal dose measurements performed with an ionization chamber.
Kroonwijk et al. have used this EPID for the daily measurement of PDIs for 10 prostate cancer
patients [84]. In the lateral beams they observed large day-to-day variations in the areas of the
PDIs corresponding with the rectum, situated adjacent to the upper part of the prostatic gland
and the vesiculae seminalis. These variations were due to frequently occurring gas pockets
with variable dimensions. Measured PDIs for these patients were also compared with predicted
PDIs. These predictions were based on the planning CT scan of the patients [115]. Again,
for the lateral beams large deviations between predictions and measurements occurred in areas
close to the posterior/superior border of the prostate and the posterior part of the vesiculae
seminalis. These deviations were due to the presence of large gas pockets during acquisition of
the planning CT scan or during treatment. Gas pockets in the measured images did sometimes
extend into the beam’s-eye-view projection of the gross tumor volume (GTV) as derived from
the planning CT scan, implying a shift of the anterior rectum wall and the prostate in ventral
direction (internal organ motion).
Comparison of predicted PDIs with measured PDIs can reveal problems like a deviating
cGy/MU-value, a deviating beam profile, erroneous data transfer from the treatment planning
system (TPS) to the treatment unit, and deviations between the actual patient anatomy and the
anatomy according to the planning CT scan. The calculated number of monitor units (MU)
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for a beam is both used for treatment and for PDI prediction. Therefore, an error in the MU
calculation of a treatment beam cannot be detected by comparison of measured and predicted
PDIs.
In this paper we present a new and simple method to verify the calculated number of monitor
units for a treatment beam. For each beam, the measured portal dose (Dp) is used to derive
the corresponding on-axis patient dose at 5 cm depth (D5), which is then compared with the
predicted dose as determined with the relative dose distribution calculated by the TPS and the
prescribed isocenter dose (2 Gy). The method has been clinically evaluated for 115 prostate
cancer patients. For interpretation of observed differences, the on-axis measured portal doses
were also compared with the portal dose calculated with the algorithm described in [115].
6.2 Methods and Materials
6.2.1 Patients
The 115 prostate cancer patients in this study were treated in the period February 1996 until
March 1998 with the 25 MV photon beam of a Scanditronix MM50 racetrack microtron. 100
patients were treated in supine position and 15 in prone position. An isocentric technique was
used for all patients, consisting of an anterior-posterior field (AP) and left lateral (LL) and
right lateral (RL) oblique fields, which were partially delivered with a 60o wedge inserted.
Individually customized field shapes were created by a multileaf collimator. During each
fraction a dose of 2 Gy was planned to be delivered to the isocenter. The treatment plans were
designed with the Cadplan 3D treatment planning system (V2.7.9, Varian Dosetek, Espoo,
Finland). The slice distance of the planning CT scans was 5 mm.
During treatment, the patient setup was verified and corrected using an off-line correction
protocol, based on an analysis of the position of bony structures in EPID images, acquired in
the non-wedged portion of each treatment field [8]. Using this protocol the systematic and
random 3D setup errors were as low as 1.5 and 2.0 mm (1 SD), respectively. The time to
setup the EPID software for image acquisition is about equal to the time required to rotate
the gantry and to setup the next (non-wedged) field. The time to setup a wedged field (using
a motorized wedge) after delivery of an open field for the same gantry angle is less than the
setup time of the EPID. To prevent an increase in treatment time, EPID measurements in this
study were therefore limited to the non-wedged fields. For the first 104 patients in the study the
intention was to acquire images on a daily basis. For the last group of 11 patients, images were
only acquired when required for the setup verification protocol (for these patients on average
9 images were acquired for each beam).
6.2.2 Portal dose measurements and predictions
Portal images were acquired with a commercially available fluoroscopic EPID (SRI-100,
Philips Medical Systems, Crawley, UK). This EPID basically consists of a fluorescent screen,
two mirrors and a CCD camera [2, 164]. The fluorescent screen is a 1.65 mm thick stainless steel
plate coated with a layer of gadolinium oxysulphide. The focus to fluorescent screen distance of
this EPID was fixed at 160 cm. To reduce the detection of high energy electrons generated in the
patient, an additional 1 mm thick stainless steel slab was mounted on the standard fluorescent
screen. Image quality is hardly affected by this additional layer; acquired images can be used
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both for geometrical and for dosimetrical treatment verification [85]. Charge integration was
performed both on the CCD chip and by adding multiple frames in the frame store memory.
Each image was corrected for ‘dark current’ in the CCD chip, which was measured in 10 frames
prior to the irradiation. These 8 bit deep ‘dark current’ frames were first multiplied by the ratio
-120/10 and then added in a 16 bit frame store memory. Storing camera frames was then halted
until the center pixel values of the camera frames reached a threshold, i.e. when the beam was
switched on. Acquisition of the preset number of camera frames was then automatically started.
Each frame was multiplied by the ratio of 120 and the preset number of frames and added in
the frame store memory. Subsequently, the data in the frame store memory was divided by
120 and the 16 bit deep images were written to disk. The resulting pixel values are the mean
of the pixel values in the acquired frames corrected for the dark current on the CCD chip. The
accumulation time on the CCD chip was set to 560 ms. All irradiations were performed with
a doserate of 300 MU min−1. The machine was calibrated such that 1 MU delivers 1 cGy of
dose at 100 cm from the focus at a depth of dose maximum in water for a 10  10 cm2 field.
To ensure that the whole treatment could be monitored, the acquisition time was automatically
adjusted according to the preset number of MU by adapting the number of frames that were
accumulated (58 MU: 12.8 s, 59-69 MU: 15.36 s, 70-86 MU: 19.2 s, 87-115 MU: 25.6 s,
116-173 MU: 38.4 s and 174-384 MU: 76.8 s).
To be able to verify whether frame accumulation did fully enclose the beam-on time,
two extra frames were acquired, one immediately after the acquisition of the frames used to
determine the dark current and one just after acquisition of the preset number of frames used
to acquire an image for geometrical and dosimetrical treatment verification. For both extra
frames, the mean pixel value around the central axis was stored in a log file. In case one
of these pixel values exceeded a threshold value it was concluded that image acquisition had
started too late or too early and the image was not used in the analyses.
Conversion of measured EPID images into PDIs was performed in three steps. Acquired
images were first corrected for the non-linear response of the system [116]. Subsequently, the
image was corrected for the optical ‘cross talk’by deconvolving it with a point spread function.
This function describes the on-axis EPID response increase due to an off-axis irradiation of
the fluorescent screen. The point spread function is derived from on-axis EPID response
measurements (portal dose/pixel value) as function of field size [61, 116]. Finally, the resulting
array is divided by a sensitivity array to correct for the spatially non-uniform EPID response.
This array is slightly field size dependent, related to shortcomings of the on-axis measured
point spread function in describing optical ‘cross talk’ in off-axis points [116]. The applied
procedure allows accurate conversion of pixel values into portal doses for all field sizes. For
anthropomorphic phantoms, derived PDIs generally agreed within 1% with the dose measured
with an ionization chamber chamber [116]. The on-axis portal doses used for the derivation
of patient doses at 5 cm depth were defined as mean portal doses in a region of 1:5  1:5 cm2
(defined at 100 cm from the focus), centered around the beam axis.
During the study period, the EPID response gradually decreased due to radiation damage
to the CCD chip (3%/year). This decrease was carefully monitored and corrected for using
the daily acquired images for the quality control of the absolute output and field flatness of the
scanning photon beams of the MM50 [39] and the two-weekly output checks with an ionization
chamber.
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Figure 6.1. Overview of the method used to derive the patient dose D5 from the measured
portal dose Dp . The process is described in section 6.2.3.
PDI prediction was performed using the following equation
Dp.x; y/ D T .x; y/  Dp;0.x; y/; (6.1)
with Dp.x; y/ the portal dose in point .x; y) of the PDI, T .x; y/ a transmission function and
Dp;0 the portal dose that would have occurred in .x; y/ in absence of the patient. The calculation
of T .x; y/ was based on the planning CT scan of the patient and the irradiation geometry as
determined in the treatment planning process. Separate calculations were performed to assess
the contributions from primary (non-scattered) photons and from photons that scattered from the
patient onto the PDI-plane, which were then added. The applied algorithm is described in detail
elsewhere [115]. For anthropomorphic phantoms irradiated with 6 MV, 23 MV and 25 MV
photon beams, predicted and measured transmissions agreed within 1%. For the calculation
of Dp;0.x; y/ (used in equation (6.1)) we used an algorithm developed for dose calculations in
water phantoms and the calculated number of MU [115, 141, 142].
6.2.3 Derivation of the patient dose D5 from the measured portal dose Dp
Derivation of the on-axis patient dose at a depth of 5 cm was performed in a two step process
(see figure 6.1). First, the on-axis portal dose that would have been measured with the EPID
without the patient in the beam (Dp;0) was derived using the inverse of equation (6.1). Dp;0
was then multiplied with a conversion factor yielding D5, the on-axis patient dose at a depth
of 5 cm:
D5 D Dp;0  C.w; SSD/; (6.2)
with w the equivalent square field size of the applied field and SSD the on-axis source-to-
surface distance. C.w; SSD/ was experimentally determined for a set of relevant SSDs and
square fields (SSD=75, 80, 85, 90 and 95 cm and w=6, 8, 10, 12 and 14 cm) using a 25 cm
thick water equivalent slab phantom and taking equation (6.2) as the definition of C.w; SSD/.
The on-axis portal dose without an absorber in the beam, Dp;0, and the dose D5 in the slab
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Figure 6.2. C.w; SSD/; the measured dose in a water equivalent slab phantom at 5 cm
depth, divided by the corresponding portal dose measured in absence of the phantom.
phantom were both measured with an ionization chamber using 150 MU. Dp;0 was measured
as a function of field size, D5 also as a function of SSD. Data are presented in figure 6.2.
6.2.4 Derivation of the patient dose D5 from the prescribed isocenter dose
The relative contribution of each individual beam to the combined dose distribution of all
the beams (normalized to 100% in the isocenter) was calculated by the treatment planning
system. For each beam separately, the relative on-axis dose at 5 cm depth was determined,
which was converted to the absolute patient dose D5 using the prescribed isocenter dose per
fraction of 2 Gy. For the (retrospective) verification of the MU-calculation of each treatment
beam of an individual patient, this predicted D5 was compared with the D5 derived from the
average on-axis portal dose measured during the treatment sessions for which EPID-images
were acquired.
6.3 Results
For the 115 patients in the study, in total 8038 images were acquired for the three treatment
beams. Acquisition of the images did sometimes fail, due to a too early or too late start of
image acquisition resulting in an incomplete accumulation of signal (the method to detect these
errors is described in section 6.2.2), or due to an incomplete signal accumulation because of a
treatment interrupt. The MM50 log file was used to identify these acquisition errors. In total
210 images had acquisition failures and were therefore excluded from the analyses.
For the two lateral beams and the AP beam distributions of the observed standard deviations
in the measured on-axis portal doses for individual patients are depicted in figure 6.3. The mean
standard deviation for the AP beam was 1.8% which is higher than the 1.2% for the lateral
beams; this was also found in a previous study with 10 prostate cancer patients [84]. In
the anterior-posterior direction variations in radiological thickness have relatively more effect
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Figure 6.3. Distributions of observed standard deviations in the daily measured on-axis
portal dose for the 115 patients in this study.
on the transmitted dose than in a lateral-direction. Furthermore, variations in radiological
thicknesses for the AP fields are larger and more frequent since the central ray-line passes
both the rectum and the bladder, whereas the central ray-line of the lateral fields does not pass
through organs with a variable filling. Remarkable is the inter-patient variation of the observed
standard deviations; which ranges from 0.5% upto 5%.
The distributions of per cent differences between the predicted and the average measured
portal dose and the predicted and average measured D5 for the LR beam, the RL beam and the
AP beam are depicted in figure 6.4. As expected the standard deviations of the differences in
D5 are slightly higher than those in Dp, since the standard deviation of D5 is a combination
of the uncertainty in Dp and the uncertainty in the method to derive D5 from Dp (this method
is described in section 6.2.3). For the AP beam (figure 6.4c) there are 7 patients for which the
difference between the predicted and average measured portal dose and the difference in patient
dose D5 are both greater than 5% (arbitrary value). A variation in radiological thickness of
1 cm results in a variation in transmitted dose of approximately 3% for the anterior field [84].
According to the planning CT-data, all these patients had a gas pocket in the rectum of 3-3.5 cm
in AP direction. Apparently these gas pockets where absent during (most of) the treatments.
For the LR and RL beams the observed differences in portal dose are maximally 5%.
Figure 6.5 shows the correlation of differences between predicted and measured portal
doses and the corresponding differences between predicted and back projected patient doses.
A deviation between the actual patient anatomy and the anatomy according to the planning
CT scan equally affects both the difference between the predicted and measured portal dose
and the difference between the predicted and back projected patient dose. This is also true in
case of a deviating cGy/MU-value of the treatment beam. The latter deviation would result in
a constant difference over the entire radiation field between the measured and predicted PDIs.
The data points in the upper right corner of figure 6.5 belong to the 7 patients with a large gas
pocket in the rectum during acquisition of the planning CT scan (see also figure 6.4c). In this
study the differences between predicted and measured PDIs were always limited to an area
around the beam axis; constant differences over the entire irradiation field did not occur, i.e.
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Figure 6.4. Histograms showing frequencies of observed per cent differences between the
predicted and average measured portal doses Dp and between the predicted and average
measured patient doses D5 for (a) the left lateral beam, (b) the right lateral beam and (c)
the anterior-posterior beam
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Figure 6.5. Correlation between the differences in predicted portal dose and the measured
portal dose and the differences in predicted patient dose and the back projected patient
dose. Each marker resembles one treatment beam for one patient. The solid straight line
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Figure 6.6. The per cent difference between the predicted portal dose and the measured
portal dose, averaged over all patients and all beams, as a function of the fraction number.
The error bars show the 1 SD variations.
deviating cGy/MU-values were not encountered.
In figure 6.5, an error in the calculated number of monitor units would result in a point far
above (MU too high) or below (MU too low) the 1-to-1 line, since such an error only affects the
difference in patient dose (parallel to the y-axis) and not the difference in portal dose (parallel
to the x-axis), since both the measured and the predicted portal dose are based on the same
(incorrect) number of MU. No errors of this type were found in this patient group.
In figure 6.6 the per cent difference between the predicted and measured portal dose as
function of the fraction number has been plotted. The data shows that there is no time trend in
the measured portal dose due to a systematic change in radiological thickness of the patients
during the cause of treatment.
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6.4 Discussion
So far most dosimetric verification studies have been performed using diodes for point
measurements. However, diodes have several drawbacks: i. The increase in treatment time
due to the time needed to position the diode on the patient. ii. Diodes act as a buildup material
and thus increase the skin dose [109]. iii. If used for entrance dose measurements, diodes
attenuate the primary beam [109]. iv. For practical reasons only very limited numbers of
diodes are used for simultaneous measurements. v. In order to determine the midplane dose
both entrance and exit dose measurements have to be performed. For a proper interpretation of
these measurements a portal image for each treatment field is needed to determine the actual
position of the detectors in the treatment field and their relative positions [70]. (The detector for
the exit dose measurements is in the shadow of the detector for the entrance dose measurement
if both detectors are placed on the beam axis.) Due to these drawbacks there are only a
few studies with large numbers of patients, like that of Noel et al. with 7519 patients [110]
and of Lathinen et al. who performed 1912 diode measurements at the first treatment and
every time a treatment parameter was changed [86]. Both groups analyzed treatments for
which discrepancies between the planned and measured dose occurred and found causes like:
incorrect SSD, forgotten wedge filter, erroneously placed compensators, calculation errors and
incorrect MU settings.
Using an EPID for dosimetric treatment verification has several advantages: there is no
increase in treatment time (acquired images can be used both for setup verification and transit
dosimetry), the portal dose can be acquired not in one or a few points, but for all points in the
treatment field (also allowing a check of the validity of the planning CT-scan by comparison
of predicted and measured PDIs [84]) and there is no physical contact of the detector with the
patient. A potential problem of transit dosimetry with an EPID is that measured portal doses
are rather insensitive to variations in the applied source-to-surface distances. However, this
problem does not occur when transit dosimetry is combined with patient setup verification, as
performed in this study [8].
For 7 out of the 115 patients the planning CT data was not representative for the treatment;
bowel gas in the planning CT scan may have pushed the prostate in anterior direction [84]
compared to its average position during treatments. However, we did not quantify this shift.
Currently a study is performed based on multiple CT data [146]. For each patient, changes in
anatomy as indicated by the planning CT scans will be correlated with changes in the calculated,
i.e. simulated, PDIs that would have been measured with the EPID during treatment.
In principle the back projection method described in this paper can be expanded to derive
the 3D dose distribution in the patient. Equation (6.1) can be used to derive the dose distribution
that would have been measured in absence of the patient. This dose distribution is proportional
to the beam fluence entering the patient [115]. The measured beam fluence can be used for a
forward calculation of the dose distribution in the patient using the standard or an independent
TPS. This dose distribution can then be compared with the planned dose distribution. A major
difficulty is that the reconstructed dose distribution will be incorrect along the ray lines that
pass through parts of the patient anatomy that have deviated compared to the situation during
acquisition of the planning CT scan.
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6.5 Conclusions
In this paper a method is presented that enables a verification of the MU calculation of treatment
beams using EPID portal dose measurements. For each beam separately, the on-axis patient
dose at a depth of 5 cm, D5, is derived from the portal dose measured with an EPID and
compared with the intended patient dose as determined from the relative dose distribution
calculated by the TPS and the prescribed isocenter dose of 2 Gy. Comparison of an observed
difference between measured and the predicted portal dose with the corresponding difference
between the back projected and intended patient dose allows the discrimination of errors in
the MU calculation and errors caused by a deviating patient anatomy due to appearance or
disappearance of gas pockets in the rectum. All observed deviations larger than 5% (arbitrary
value) could be attributed to variations in patient anatomies.
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Chapter 7
Verification of compensator thicknesses using a fluoroscopic
electronic portal imaging device
Kasper L. Pasma, Marco Kroonwijk, Erik B. van Dieren, Andries G. Visser
and Ben J.M. Heijmen
Med. Phys. in press
A method is presented for verification of compensator thicknesses using a fluoroscopic
electronic portal imaging device (EPID). The method is based on the measured transmission
through the compensator, defined by the ratio of the portal dose with the compensator in
the beam and the portal dose without the compensator in the beam. The transmission is
determined with the EPID by dividing two images, acquired with and without compensator
inserted, which are only corrected for the non-linear response of the fluoroscopic system.
The transmission has a primary and a scatter component. The primary component is
derived from the measured transmission by subtracting the predicted scatter component.
The primary component for each point is only related to the radiological thickness of the
compensator along the ray line between the focus and that point. Compensator thicknesses
are derived from the primary components taking into account off-axis variations in beam
quality. The developed method has been tested for various compensators made of a granulate
of stainless steel. The compensator thicknesses could be determined with an accuracy of
0.5 mm (1 SD), corresponding to a change in the transmitted dose of about 1% for a 10 MV
beam. The method is fast, accurate and insensitive to long-term output and beam profile
fluctuations of the linear accelerator.
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7.1 Introduction
Compensators can be used in radiotherapy for beam intensity modulation. In our institute, a
group of head and neck cancer patients is treated with a conformal technique based on intensity
modulation to improve sparing of the salivary glands [157].
There have been several publications on how to perform quality assurance for compensators.
Chu et al. used film for a 2D verification of the dose distribution at the exit plane of a
phantom [25]. An advantage of using film is that the required equipment is commonly available
in a radiotherapy department. Obvious disadvantages are the time needed for processing the
films and the need of a sensitometric curve to convert optical densities into absorbed doses.
Mejaddem et al. compared the intended profile of the mold of a compensator with the profile
measured with a laser interferometric transducer [100]. They found an average difference
of 0.04 mm (1 SD) between the intended profile and the laser measurements. The high
accuracy of this technique was needed since a deviation of 0.1 mm in thickness of the applied
Cerrobend filling corresponded to 0.5% change in transmission dose for a 6 MV beam. The
described technique is suited for commissioning of a milling device (especially for high-density
compensators), but is impractical for routine checks of the produced molds.
Low et al. developed a method for verification of compensators by comparing the fluence
measured with an electronic portal imaging device (EPID) with the fluence calculated using
the intended filter shape [95]. They investigated the use of a liquid-filled matrix ionization
chamber system (PortalVision, Varian). An advantage of using an EPID is that it can perform
quick two-dimensional measurements. They limited their tests to relatively simple compensator
geometries since they had no independent way to verify more complex geometries. The
predicted and measured fluence for a 6 MV beam agreed within 3%, which was considered
acceptable. For one test situation the measured fluence was asymmetric due to asymmetric
accelerator output. Roback et al. used this type of liquid-filled matrix ionization chamber to
verify the uniformity of the exit dose beneath a wedge and a step phantom for beams with
missing tissue compensators [131].
In this paper we describe a method to determine the 2D thickness profile of a compensator,
prior to clinical application, with an accuracy of 0.5 mm (1 SD). An error of 0.5 mm in
thickness corresponds to a change in transmitted dose of 1% for a 10 MV beam. The method
is based on the transmission through the compensator measured with a fluoroscopic, CCD
camera based EPID (Philips SRI-100). This transmission array is used to derive the equivalent
polystyrene thicknesses of the compensator along each rayline. The polystyrene thicknesses
are then converted into the thicknesses of the compensator material. An advantage of using the
transmission is that the method is not sensitive to long-term output and beam profile fluctuations
of the linear accelerator.
7.2 Materials and Methods
7.2.1 Design and production of compensators
The compensators that are used in our institute consist of a Styrofoam mold filled with a
granulate of stainless steel [161]. The filled mold is mounted between two lucite plates, which
are screwed together. The mold and the lucite plates are attached to a tray which fits only in one
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Figure 7.1. Setup to verify the depth of a Styrofoam mold.
way in the accessory tray of an MM50 racetrack microtron. The applied beam energy is 10 MV
(quality index 0.704; the percent depth dose curve is similar to a 7 MV photon beam [21]). The
distance between the focus and the entrance plane of the compensator is 71 cm. The maximum
allowed thickness of the steel granulate is 3 cm. Required thicknesses of compensators are
calculated using an in house developed inverse treatment planning algorithm. Outside the field
the compensator thickness along each line parallel to the x-axis is set equal to the thickness at the
corresponding field edge. The calculated thicknesses are transferred to a computer controlled
milling device (PAR Scientific ACD−5) which mills out a cavity in the Styrofoam block. The
vertical cutting inaccuracy of this device is specified to be 0:1 mm. The inaccuracy in the
positioning of the Styrofoam block is estimated to be 0:5 mm. To prevent the drill from
moving outside the Styrofoam block due to this positioning inaccuracy the minimal thickness
of the steel granulate is set to 0.3 cm.
For this paper we used a simple setup (depicted in figure 7.1) for an independent verification
of the depths of the milled out molds. In this way depths could be measured with an accuracy
of 0:1 mm. The setup could only be used to measure mold depths in areas without a gradient.
It was used to verify whether there was a systematic offset in the milled out profile.
7.2.2 Transmission measurements with the EPID
The transmission through a compensator is defined by
T .x; y/ D Dp.x; y; with compensator/
Dp.x; y; without compensator/
; (7.1)
with Dp.x; y/ the portal dose in point .x; y/ of the fluorescent screen. In our institute we use
Philips SRI-100 EPIDs, which basically consist of a fluorescent screen, two mirrors and a CCD
camera [164]. The focus to fluorescent screen distance of these EPIDs is fixed to 160 cm. The
maximum detectable field size in the plane through the isocenter is 1925 cm2 [116], which
is sufficient for our compensators used in the head and neck region. To reduce the detection
of high energy electrons generated in the patient, we have mounted an additional 1 mm thick
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stainless steel slab on the standard fluorescent screen. Image quality is hardly affected by this
additional layer [85].
The raw EPID signals (Graw) are not linearly related to the incident dose [116]. This is due
to non-linear electronics of the EPID and due to differences in spectral sensitivity between an
ionization chamber and the EPID. A third-order polynomial function derived from the on-axis
measured response (Graw=Dp) of the system is used to convert the raw EPID signals (Graw)
into corrected EPID signals (G).
We have previously described the characteristics of this EPID relevant for accurate and
reproducible dose measurements in a 6 MV photon beam [61] and we have developed a method
to derive portal dose images (Dp) from corrected EPID images (G), using a deconvolution
method that corrects the measured EPID images for optical ‘cross-talk’ and (small) variations
in local EPID sensitivity [116]. For transmission measurements, the field size for the EPID
image with and without the compensators inserted is equal and therefore the correction for
variations in EPID sensitivity is identical for both images. Furthermore, the effect of ‘cross-
talk’ was expected to be similar. Therefore we have tested whether equation (7.1) can be
approximated by
T .x; y/ D G.x; y; with compensator/
G.x; y; without compensator/
; (7.2)
with G.x; y/ the measured pixel value at point .x; y/, corrected for the non-linearity in the
EPID response.
The validity of this equation was tested by comparing on-axis ionization chamber
transmission measurements with EPID transmission measurements for flat, polystyrene
absorbers. Transmissions were measured for a set of square fields (ww), absorber thicknesses
(t) and distances from the exit plane of the absorber to the detector (L). The ionization chamber
(PTW, N31002) was inserted in a mini phantom with a transverse cross section of 7  7 cm2
and a thickness of 5 cm; this phantom was also used in other studies [115, 116]. The center of
the ionization chamber was positioned at a depth of 2.0 cm. The mini phantom was positioned
at the beam axis in the plane of the fluorescent screen, the distance between the surface and the
focus was 158 cm. The data were acquired using the 10 MV photon beam of an MM50 racetrack
microtron. The dose rate was set to 200 MU min−1 and measurements were performed with
150 MU. For the EPID measurements the camera gain was set to unity, the accumulation time
on the CCD chip was set to 560 ms and the number of camera frames that where accumulated
was set to 120. For noise reductions, each image was acquired twice and averaged. The
parameters of the third-order polynomial function used to correct for the non-linear response
of the EPID for 10 MV were 1, -0.0124, and 6.8710−6, respectively. Results are presented
in section 7.3.1.
7.2.3 Derivation of the compensator thicknesses
The transmission T .x; y/ consists of a primary component T P .x; y/, related to photons that
have not interacted with the compensator, and a scatter component T S.x; y/, originating from
photons that are generated in interactions in the compensator. The primary componentT P .x; y/
is derived from the measured transmission T .x; y/ using
T P .x; y/ D T .x; y/ − T S.x; y/; (7.3)
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with T S.x; y/ the calculated scatter component of the transmission, using the intended
compensator thicknesses as input. T P .x; y/ is only related to the radiological thickness of
the compensator along the corresponding ray line. Using a measured relationship between
the radiological compensator thickness and the primary component of the transmission the
thickness of the compensator along each ray line is derived. Off-axis variations in beam
quality are taken into account.
7.2.3.1 Calculation of T S.x; y/.
T S.x; y/ is calculated using an algorithm developed to predict the transmission through patients
for in vivo dosimetry [115]. The intended compensator is substituted by an (imaginary)
equivalent homogeneous phantom (EHP) consisting of polystyrene (PS). Along each ray line,
the thickness of the EHP (tPS) is equal to the corresponding radiological thickness of the
compensator. The relation for this thickness is
tPS D steel
PS
tsteel C lucite
PS
tlucite; (7.4)
with tsteel the thickness of the granulate of stainless steel, tlucite the thickness of the two
lucite plates of the tray and steel, PS and lucite the linear attenuation coefficients of the
primary component of the transmission for steel, polystyrene and lucite, respectively. The
ratio lucite/PS is 1.12 [115]. The ratio steel/PS has been derived from measurements
described in section 7.2.3.3. The radiological thickness of the Styrofoam mold is neglected.
The distance between the exit plane of the compensator and the fluorescent screen of the
EPID ( 87 cm) is larger than the distance between a patient and this screen. To be able to
calculate T S.x; y/ with the input data that are also used for transmission predictions through
patients, the EHP of the compensator is shifted such that the distance between the exit plane
and the screen is 60 cm. The resulting overestimation of the scatter component is corrected
using the inverse square law. The database used for transmission predictions through patients
contains input data for L ranging from 40 to 60 cm, for prediction of T S.x; y/ for compensators
only a sub-set (L=60 cm) of this database is required.
7.2.3.2 Derivation of tsteel.x; y/ from T P .x; y/
The thickness of the granulate of stainless steel, tsteel.x; y/, is derived in a step process. In the
first step, T P .x; y/ is used to determine the equivalent polystyrene thickness tPS.x; y/ of the
compensator. In the second step this thickness is converted into a stainless steel thickness.
To determine the equivalent polystyrene thickness tPS.x; y/ corresponding to the derived
primary component T P .x; y/, T P .x; y/ is first converted into the on-axis primary component
corresponding to the equivalent polystyrene thickness of the compensator at point .x; y/,
P.tPS.x; y//. The relation between these two components is [115]
P.tPS.x; y// D T
P .x; y/
Copen.r.x; y/; t
i
PS.x; y//
; (7.5)
with t iPS.x; y/ the intended equivalent polystyrene thickness (calculated with equation (7.4))
and tPS.x; y/ the measured equivalent polystyrene thickness. Copen.r.x; y/; t iPS.x; y// is a
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Figure 7.2. The on-axis primary component of the transmission as a function of the
polystyrene absorber thickness for the 10 MV beam of an MM50 racetrack microtron
function to account for the difference in beam quality between the beam axis and the off-axis
point .x; y/ at a distance r.x; y/ D √x2 C y2 from the beam axis. Derivation of this function
from measured data is explained in another paper [115].
For each point the thickness tPS.x; y/ is calculated from the derived on-axis primary
component, P.tPS.x; y//, using a measured relationship between the thickness of a polystyrene
absorber and the on-axis primary transmission, P.tPS/, derived from the input database. P.tPS/
for the applied 10 MV beam is depicted in figure 7.2. Finally, the thickness of the granulate of
stainless steel, tsteel.x; y/, is derived from tPS.x; y/, using equation (7.4).
The derived thicknesses could be used to repeat the above described process iteratively, but
this would only affect the scatter component, which contributes less than 4% to the transmission,
and the function Copen.r.x; y/; tPS.x; y//, which depends only slightly on thickness (for the
10 MV beam of the MM50 a difference of 1 cm stainless steel corresponds to a change of
Copen of less than 0.5%). As described in section 7.3.2 one iteration is sufficient to derive
compensator thicknesses to within 0.5 mm (1 SD).
7.2.3.3 Derivation of the ratio steel/PS
The ratio steel/PS is used for the conversion of stainless steel thicknesses into the
equivalent polystyrene thicknesses (see section 7.2.3.1). It was derived from on-axis measured
transmissions through flat compensators of 2:00 cm and 3:02 cm thickness (the thicknesses
were measured with the setup depicted in figure 7.1), irradiated with fields of 8  18 and
1818 cm2. To achieve maximum accuracy, these transmission measurements were performed
with an ionization chamber using the setup described in section 7.2.2. Measurements were
performed with 150 MU and dose rate was set to 200 MU min−1. The thickness of the two lucite
tray holders .tlucite/ was 0.91 cm, which corresponds to an equivalent polystyrene thickness
(using equation (7.4)) of 1.02 cm.
The radiological thickness of the compensator was derived from the measured transmissions
using the method described in the previous sections. For calculation of the EHP of the
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Table 7.1. Derivation of the ratio steel/PS from on-axis measured transmissions through
two flat compensators.
tsteel field size T T S T P < T P > tPS steelPS
[cm] [cm2] [−] [−] [−] [−] [cm] [−]
3.02 8  18 0.5219 0.0064 0.5155 0.5162 14.90 4.600
18  18 0.5320 0.0152 0.5169
2.00 8  18 0.6377 0.0063 0.6314 0.6319 10.23 4.606
18  18 0.6463 0.0139 0.6324
mean: 4.603
compensators a first approximation of the ratio steel/PS of 4.5 was used, based on the density
of the filling material [161]. With equation (7.4) the ratio steel/PS was derived from the
measured radiological thicknesses. Results are presented in table 7.1.
7.3 Results
7.3.1 EPID transmission measurements
To verify the accuracy of the EPID transmission measurements they have been compared with
on-axis transmission measurements with an ionization chamber using the setup described in
section 7.2.2. The EPID signals were corrected for the non-linear response of the system. The
T .w; t; L/ set that was measured contains all possible combinations of
w = 3, 10, 18 cm,
t = 10, 20, 30 cm, and
L = 40, 50, 60 cm.
The EPID and ionization chamber transmission measurements for all these situations agreed
within −0:2  0:5% (1 SD). The short term reproducibility of the ionization chamber
transmission measurements was 0:3% (1 SD), hence the short term reproducibility of the EPID
transmission measurements was 0:4% (1 SD). Using raw EPID signals (Graw) resulted in a
deviation between EPID and ionization chamber transmission measurements of −1:0  1:3%
(1 SD).
7.3.2 Compensator thicknesses measured with the EPID
To verify the accuracy of the developed method for compensator thickness verification, the
compensator thicknesses derived from EPID measurements were compared with intended
thicknesses, for molds containing areas without a gradient the intended depth was verified
using the method described in section 7.2.1. Data are presented for four compensators: (i)
a flat 1 cm thick compensator, (ii) a spherical compensator (figure 7.3), (iii) a wedge-shaped
compensator and (iv) a clinical compensator (figure 7.7). All compensators were irradiated with
a square 16  16 cm2 field. Image aquisition was performed with the EPID settings described
in section 7.2.2. Field sizes, coordinates and distances to the beam axis are all defined in the
plane through the isocenter (i.e. at 100 cm from the focus). EPID images were corrected for the
88 Verification of compensator thickness
Figure 7.3. Spherical compensator.
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Figure 7.4. Measured (markers) and realized (lines) thicknesses of the spherical
compensator depicted in figure 7.3, along the y=0 and y=6 cm axes.
non-linear response of the system and resampled to arrays of 64  64 elements; each element
represents a region of interest of 0:5  0:5 cm2.
Using the setup described in section 7.2.1 it was found that the thickness of the flat
compensator was 1.04 cm instead of the intended 1.00 cm. In the central 14  14 cm2 part of
the beam, the mean deviation between the thickness measured with the EPID and the realized
thickness of 1.04 cm was 0:2  0:2 mm (1 SD).
The realized on-axis thickness of the spherical compensator (depicted in figure 7.3) was
3.08 cm, which decreased to 1.08 cm at r=10 cm, for r  10 cm the thickness was 1.08 cm.
These thicknesses have been measured using the setup described in section 7.2.1. The mold was
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Figure 7.5. (a) Compensator thicknesses measured with the EPID (markers) compared with
the intended thicknesses (lines) (a) along the x-axis and (b) along the y-axis for x D −5,
0 and 5 cm for a wedge-shaped compensator.
0:08 cm deeper than intended. Cross sections along the y=0 and y=6 cm axis of the measured
and realized thickness of the spherical compensator are depicted in figure 7.4. Within the
central 14  14 cm2 part of the beam, the mean deviation between the measured and realized
thickness was 0:4  0:3 mm (1 SD).
The wedge-shaped compensator had an intended thickness of 3 cm at x D −10 cm which
decreased to 1 cm at x D10 cm and was symmetrical in the y-direction. Due to the gradient
in the mold, the actual depths could not be verified independently. Results are presented in
figures 7.5a and 7.5b. The mean deviation between the measured and intended thicknesses
within the radiation field, but outside the penumbra region, was 0:1  0:3 mm (1 SD).
The clinical compensator designed for elective treatment of the neck is depicted in figure 7.6.
The minimal thickness was 1 cm. To verify the realized thickness it was irradiated with the
16  16 cm2 field. For patient treatment a smaller, assymetrical conformal field is used.
Measured and intended thicknesses agreed within 0:0  0:4 mm (1 SD). Results are depicted
in figure 7.7; points outside the patient field were excluded.
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Figure 7.6. Clinical compensator.
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Figure 7.7. Measured (markers) and intended thicknesses (lines) of the clinical compensator
depicted in figure 7.6, along the lines through points x D 0 cm and x D −6 cm parallel to
the y-axis.
7.4 Discussion and conclusions
An accurate method has been developed for measuring the thickness of compensators with
an EPID. Using a fluoroscopic EPID, the mean deviation between the intended and measured
thicknesses for the four compensators was 0:2  0:3 mm (1 SD). The accuracy of determined
thicknesses of the steel granulate is estimated to be at least 0.5 mm (1 SD). The accuracy is
limited by the accuracy of the EPID transmission measurements of 0.4% (1 SD), corresponding
to an error in the derived thicknesses of 0.2 mm (1 SD). A difference in thickness of 0.5 mm
7.4 Discussion and conclusions 91
corresponds to a change in the transmitted dose of about 1% for a 10 MV beam, the accuracy
of the method is thus sufficient.
In clinical practice the developed method can be used to verify the thicknesses of a
compensator before the patient is treated. If a square radiation field is applied that encompasses
the fields used for patient treatment, inaccurate transmission measurements in the beam
penumbra can be avoided. In this way accurate thickness verification of the whole compensator
is achieved, including areas close to the clinical field borders. An image of the field without
compensator inserted only has to be acquired once and then all compensators that need to
be verified can be irradiated. Systematic deviations between the intended and measured
thicknesses can be corrected by adjusting the number of monitor units. Non-systematic
deviations point at the use of the wrong compensator (designed for an other field or patient) or
a manufactering error.
The applied procedure for the prediction of the scatter component was originally developed
for patients for which the distance between the exit plane and the detector can be as small as
40 cm [115]. The distance between the exit plane of the compensator and the detector is about
87 cm, which results in a scatter component that contributes less than 4% to the transmission.
Hansen et al. [60] have developed a simpler method to estimate the scatter component for these
large exit plane to detector distances, based on the work of Swindell and Evans [150]. We have
not used this method, since we already had an accurate method.
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Dose distributions can often be significantly improved by modulating the two-dimensional
intensity profile of the individual x-ray beams. One technique for delivering intensity
modulated beams is dynamic multileaf collimation (DMLC). However, DMLC is complex
and requires extensive quality assurance. In this paper a new method is presented for a
pretreatment dosimetric verification of these intensity modulated beams utilizing a charge-
coupled device (CCD) camera based fluoroscopic electronic portal imaging device (EPID).
In the absence of the patient, EPID images are acquired for all beams produced with DMLC.
These images are then converted into two-dimensional dose distributions and compared
with the calculated dose distributions. The calculations are performed with a pencil beam
algorithm as implemented in a commercially available treatment planning system using the
same absolute beam fluence profiles as used for calculation of the patient dose distribution.
The method allows an overall verification of (i) the leaf trajectory calculation (including the
models to incorporate collimator scatter and leaf transmission), (ii) the correct transfer of
the leaf sequencing file to the treatment machine and (iii) the mechanical and dosimetrical
performance of the treatment unit. The method was tested for intensity modulated 10 and
25 MV photon beams; both model cases and real clinical cases were studied. Dose profiles
measured with the EPID were also compared with ionization chamber measurements. In
all cases both predictions and EPID measurements and EPID and ionization chamber
measurements agreed within 2% (1  ). The study has demonstrated that the proposed
method allows fast and accurate pretreatment verification of DMLC.
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8.1 Introduction
Dose distributions delivered by multiple field irradiation techniques can often be significantly
improved by modulating the two-dimensional intensity profile of the individual x-ray
beams [15, 19, 20, 75, 76, 138, 166–168]. Intensity modulated (IM) beam profiles, calculated
by means of inverse treatment planning, can be realized in several ways. One technique is
the use of dynamic multileaf collimation (DMLC). So far, the ‘sliding window’ technique in
combination with DMLC has received most attention in the literature. This technique is based
on moving each leaf pair of a multileaf collimator (MLC) independently but unidirectionally
across the treatment field while the beam is on, effectively sweeping apertures of variable widths
across the treatment field. The width of the aperture varies between leaf pairs. Moreover, for
each leaf pair the width is also a function of time. Convery and Rosenbloom have described
the basic algorithm to calculate the required leaf trajectories; the algorithm has the form of
an optimization problem in which the beam on time is minimized [27]. Three groups have
independently developed analytical equations to calculate the leaf trajectories [139, 140, 148],
which were further developed by others [38, 162, 170]. Compared to the algorithm of Convery
and Rosenbloom computation times of the analytical approaches are much shorter. The first
group of patients were irradiated using DMLC in 1995 at Memorial Sloan-Kettering Cancer
Center, NY [93]. Recently, treatment of head and neck cancer patients with DMLC has started
in our clinic.
A disadvantage of the dynamic technique is that it is difficult to verify due to its
complexity. Bortfeld et al. have therefore proposed to produce intensity modulated beams by
superpositioning a number of partially overlapping, static, irregularly shaped fields produced
with the MLC [16]. Controlling the delivery of a sequence of small doses and static
leaf settings was considered to be a straightforward extension of existing linear accelerator
control. However, in contrast with DMLC [38, 162, 170], a method to avoid tongue-and-groove
underdosage has not yet been described for the static technique.
For verification of segmented beam delivery Curtin-Savard and Podgorsak proposed the
use of the scanning liquid ionization chamber EPID [33]. Without a patient in the beam,
portal images were acquired for each subfield of the leaf sequence and converted into a dose
rate distribution. Subsequently, the images were converted into absolute dose distributions
by multiplication with the corresponding monitor unit setting. Finally, the individual dose
distributions were summed to produce a dose distribution at the measurement depth. These
distributions were then compared with dose distributions predicted by a treatment planning
system. Because of the use of the monitor unit setting, the comparison with the dose distribution
of the planning system is basically a verification of the relative dose distribution. The applied
EPID is relatively slow in returning to the initial state. Therefore, they had to apply a 60 s
rest interval between measurement of subsequent segments, yielding long overall measurement
times of typically one hour. Due to the scanned signal readout and the measurement of dose
rate instead of dose, the applied EPID is not suitable for high precision dosimetric verification
of DMLC.
To test the reproducibility and accuracy of DMLC, the use of film has been reported [22,
94, 165]. At Memorial Sloan-Kettering Cancer Center film dosimetry is performed in a flat
homogeneous phantom for each field prior to the first treatment. Measured dose distributions
are compared with corresponding calculated dose distributions [94]. A disadvantage of film
dosimetry is that it is time consuming since it requires developing and scanning of the film,
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furthermore a sensitometric curve is needed to convert optical densities into doses.
CCD camera based EPIDs are a promising tool for verification of DMLC due to their high
data acquisition rate and capability to measure simultaneously in all points of the treatment
field [5, 96, 112, 116]. Balter et al. showed preliminary results of a method to derive leaf
positions in each camera frame acquired during treatment and to compare them with a table
of prescribed leaf positions [5]. Leaf positions could be determined with an accuracy of
0.6 mm and a duty cycle of less than 1 s. A similar approach was implemented by Partridge et
al. [112] They used a custom made EPID with image acquisition synchronized to the accelerator
magnetron current pulse production, with one CCD camera frame acquired per accelerator
pulse. Data were presented for a 6 MV beam. The accuracy of the leaf position measurements
was 2 mm. Due to a limitation of the camera triggering hardware the pulse rate of the linac had
to be reduced. Ma et al. calculated normalized reference images from MLC leaf sequencing
files and compared these with normalized images measured with a fluoroscopic beam imaging
system (BIS, Wellhöfer Dosimetrie, Schwarzenbruck, Germany) for a 6 MV photon beam [96].
This imaging system can be fastened to the blocking tray holder of a linear accelerator. It was
especially designed for quality control tasks. For the calculation of the reference images a
measured portal image of a large open field was used. The reference images were therefore not
only related to the prescribed fluence, but also contained optical distortions in the EPID system.
A global correlation coefficient was used to compare the calculated reference image with the
image measured with the BIS system. This method can be used to verify whether the leaf
sequencing files have been transferred correctly to the linac control computer and whether the
treatment can be correctly executed without machine faults. Transmission through the leaves
(both intraleaf and interleaf) was not taken into account and a simple empirical method was
used to model extrafocal scatter. Despite these limitations, they concluded that it was possible
to detect uncertainties of less than 0.5 mm in leaf position during DMLC.
The above described methods to verify leaf motion cannot be used to check whether
the calculated leaf trajectories do indeed generate the absolute beam fluence profiles used
in treatment planning. In this paper a new method is presented for a pretreatment verification
of these absolute beam fluence profiles utilizing a commercially available CCD camera based
fluoroscopic EPID. In the absence of the patient EPID images are acquired for all beams
produced with DMLC. These images are then converted into two-dimensional dose distributions
and compared with calculated dose distributions. The calculations are performed with a pencil
beam algorithm as implemented in a commercially available treatment planning system (TPS)
using the same absolute beam fluence profiles as used in the TPS for calculation of the patient
dose distributions. In this paper results are presented for intensity modulated 10 and 25
MV photon beams; both model cases and real clinical cases were studied. Absolute dose
profiles measured with the EPID were also compared with ionization chamber measurements.
Preliminary results on measurements of absolute dose distributions in IM fields produced with
DMLC have been reported [116].
8.2 Materials and Methods
8.2.1 EPID and ionization chamber dose measurements
The applied EPID was a Philips SRI-100 (Philips Medical Systems, Crawley, UK), which
basically consists of a fluorescent screen, two mirrors and a CCD camera. The fluorescent
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screen is a 1.65 mm thick stainless steel plate coated with a layer of gadolinium oxysulphide.
To reduce the detection of high-energy electrons generated in patients, an extra 1 mm thick
stainless steel slab has been mounted on the standard fluorescent screen [116]. The added
slab hardly affects the image quality [85]. The acquired images may be used both for set-up
verification and for in vivo dosimetry [84]. The EPID has a fixed focus to fluorescent screen
distance of 160 cm. Technical details of the EPID have been described by Visser et al. and
Althof et al. [2, 164]
Image acquisition is performed with a procedure written in the macro command language
that comes with the system. The integration time on the CCD chip was set to 240 ms and 120
camera frames were accumulated in the frame store memory. The read out time needed to
transmit a frame from the CCD to the frame grabber (during which no signal is accumulated)
is 80 ms. The final image is the mean of the integrated camera frames, corrected for the dark
current measured prior to the irradiation. In the original procedure image acquisition starts
automatically when the measured pixel values in the center of the camera frame exceed a
threshold, i.e. when the beam is switched on. For the DMLC measurements described in this
paper image acquisition was started manually, since with the sliding window technique the
pixels in the center of the image are blocked by the leaves when the irradiation starts. The
procedure is discussed in detail in another paper [116].
Due to sagging of the EPID structure the field center can shift slightly. To correct the image
for this shift the position of the field center was derived using the position of the field borders in
an EPID image of a (static) square field, which is stored in a lookup table. The raw EPID images
of 512256 pixels were then resampled to arrays of 6464 elements; each element represents
a region of interest with an area of 0:5  0:5 cm2 projected at isocenter. Conversion of these
arrays into absolute dose distributions was performed in three steps. Acquired images were
first corrected for the non-linear response of the system [116, 125]. Subsequently, the image
was corrected for the optical ‘cross talk’ by deconvolving it with a point spread function [61,
116]. Finally, the resulting array was divided by an array that accounts for relative EPID
sensitivity [116]. The system was calibrated once. The observed day-to-day variation of the
EPID response per unit of delivered dose is 0.4% (1  ) [61]. Due to radiation damage to
the CCD chip the EPID response gradually decreases ( 3%/year) [122]. This decrease was
carefully monitored and corrected for using the daily acquired images for the quality control
of the absolute output and field flatness of the scanning photon beams of the MM50 [39] and
the two weekly output checks with an ionization chamber.
Dose measurements were also performed with a N31002 ionization chamber (PTW,
Freiburg, Germany). The ionization chamber was inserted in a polystyrene mini phantom [115]
at a depth of 2.0 cm for the 10 MV beam and at 2.5 cm for the 25 MV beam. For those depths it
was experimentally found that the variations in the on-axis response of the EPID (EPID pixel
value/portal dose measured with the ionization chamber (G=Dp)) were minimal for field sizes
ranging from 33 up to 1818 cm2 and polystyrene absorber thicknesses ranging from zero up
to 35 cm. For a 25 MV photon beam the mean of the standard deviations of the EPID response
for all field sizes was 0.4% [116]. The mini phantom was scanned in an empty RFA-300
water phantom (Scanditronix Medical AB, Uppsala, Sweden) with the center of the ionization
chamber positioned at a distance of 160 cm from the focus, which is equal to the fixed focus
to fluorescent screen distance of the EPID.
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8.2.2 Calculation of the dose distribution at the detector
Starting point for the calculation of the dose distribution at the fluorescent screen of the detector
is the optimized beam fluence Fopt.x; y/ (in MU) to be delivered at position .x; y/, which is the
result of a computer optimization or inverse treatment planning. A fluence of 1 MU corresponds
to the fluence due to an irradiation that results in a dose delivery of 1 cGy at a depth of dose
maximum in water with a source surface distance (SSD) of 100 cm in a static 10  10 cm2
field. Using an iterative algorithm described by Dirkx et al. leaf trajectories are then calculated
taking into account collimator scatter and the effective leaf transmission, which is the sum of the
transmission through the leaves and the extra focal radiation under the moving leaves [38]. The
algorithm fully avoids tongue-and-groove underdosage effects [162]. Generally less than 10
iterations are necessary to minimize the difference between optimized (Fopt.x; y/) and realized
fluence profiles (F.x; y/), which are used for calculation of the final dose distribution in the
patient with the CadPlan 3D TPS (Varian-Dosetek, Espoo, Finland).
The expected absolute dose distribution in the plane of the fluorescent screen of the EPID,
Dp;0.x; y/, is calculated from the realized fluence profile using the pencil beam algorithm as
implemented in the CadPlan TPS [142, 143]. In the current implementation (CadPlan v2.7.9)
the penumbra width is a linear function of the SSD. As a result the predicted dose distributions
would become inaccurate for the SSD of the detector (160 cm), which is much larger than the
SSDs clinically used. Therefore, the dose distribution is calculated at 100 cm from the focus by
enlarging the field with a factor of 1.6 (160/100). The dose distribution is then normalized using
the calculated on axis dose in a static 16  16 cm2 field for 150 MU. Finally, the absolute dose
distribution is calculated using the measured cGy/MU value at the detector for a 10  10 cm2
field. Dose calculations and the calibration measurement are performed at a water depth of
2 cm for the 10 MV photon beam and at a depth of 2.5 cm for the 25 MV beam, equal to the
effective measuring depths of the EPID, as discussed in the previous section.
8.2.3 Realization and verification of fluence profiles
Measured and predicted dose distributions Dp;0.x; y/ were compared for the 10 and 25 MV
photon beams of the MM50 racetrack microtron (Scanditronix MedicalAB, Uppsala, Sweden).
The dose rate was 200 MU min−1 for the 10 MV beam and 300 MU min−1 for the 25 MV
beam. The microtron produces 200 radiation pulses per second (pps). The unit is equipped
with a double-focused multileaf collimator with 32 leaf pairs. Projected at isocenter the leaf
width is 1.25 cm. The maximum leaf speed is 1 cm s−1. For all measurements the leaves
moved from left to right parallel to the x-axis. During DMLC, every 50 ms the accelerator
control system compares the actual leaf positions, measured with potentiometers, with the
prescribed positions. If the deviation between a prescribed and a measured position is more
than 0.2 cm during three subsequent checks, the irradiation is interrupted. Realization of IM
fluence profiles with this unit is discussed in detail elsewhere [38].
The developed method was tested for a range of fluence profiles, both model cases and
real clinical cases were studied. Calculated absolute dose distributions (section 8.2.2) were
compared with dose distributions derived from EPID images and with dose profiles measured
with an ionization chamber (section 8.2.1). The axes for comparisons in the leaf direction
were chosen at the center of each leaf pair (y D 0:6; 1:9; 3:1; ::). Throughout the paper
positions and distances are defined at the plane normal to the beam axis at 100 cm from
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Figure 8.1. Predicted (line) and measured absolute dose (n EPID, + ionization chamber)
along the y D 0:6 cm axis for a wedge profile produced with DMLC using the 10 MV
photon beam.
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Figure 8.2. Predicted (line) and measured absolute dose (n EPID, + ionization chamber)
along the y D 0:6 cm axis for an IM 10 MV beam.
the focus. The reported differences are the mean deviation in percent and the corresponding
standard deviation in percent (mean  1  T%U).
8.3 Results
In figures 8.1 and 8.2 data are presented for intensity modulated 10 MV beams. Within the
treatment field the leaf trajectories were identical for all leaf pairs; the presented data are
for y D 0:6 cm. Outside the penumbra, there is an excellent agreement between EPID and
ionization chamber measurements ((EPID-ionization chamber)/ionization chamber) for both
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Figure 8.3. Predicted (line) and measured absolute dose (n EPID, + ionization chamber)
along the y D 0:6 cm axis for an IM 25 MV beam.
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Figure 8.4. Predicted (line) and measured absolute dose (n EPID, + ionization chamber)
along the y D 0:6 cm line for an IM 25 MV beam.
beams: 0:30:6% (figure 8.1) and 0:10:8% (figure 8.2). The actual agreement may even be
slightly better, since each ionization chamber measurement required the complete irradiation
to be repeated. The short term reproducibility of the absolute dose delivery with DMLC at the
MM50 racetrack microtron is 0.2% [40]. The deviations between the calculated dose profile
and the profile measured with the EPID are −2:1  1:2% and 0:9  0:8%, respectively.
The data presented in figure 8.3 are for a beam fluence profile that was also used to generate
the data in figure 8.2, but now realized with the 25 MV beam. Again deviations between EPID
and ionization chamber measurements are small: −0:2  1:3%. The deviation between the
predicted dose profile and the profile measured with the EPID is −1:0  0:7%. Similar results
were found for the profile presented in figure 8.4: 0:2  1:0% and −1:0  1:4%, respectively.
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(d)
Figure 8.5. Raw EPID images of IM 25 MV photon beams are shown in (a) and (b). In (c)
and (d) the corresponding measured (n EPID, + ionization chamber) and predicted (line)
absolute dose profiles along the y-axis (normal to the axis along which the leaves move)
are shown.
In figures 8.5a and b acquired EPID images (512  256 pixels) for two non-square IM
25 MV beams are shown. The fluence decreases in the y-direction; the dose at the top of the
image is a factor of 2.2 lower than at the bottom. Due to the synchronization of leaf trajectories
of adjacent leaves, underdosage (lower pixel values) do not occur in the overlap regions [162].
The small overdosage (higher pixel values) in the overlap regions of adjacent leaves are due
to the interleaf leakage of about 2% [38]. These overdosages can be avoided using partial
synchronization [170]. Figures 8.5c and d show cross sections along the y-axis (normal to
the axis along which the leaves move) of the two-dimensional dose profile derived from the
EPID images shown in figures 8.5a and b. Corresponding predicted dose profiles and dose
profiles measured with an ionization chamber are included. For the first field (figure 8.5a) the
deviation between EPID and ionization chamber measurements was 0:2  1:1% and for the
second field (figure 8.5b) 0:4  2:0%. The deviations between the predicted profile and the
EPID measurements were −0:91:7% and −1:41:7%, respectively. Standard deviations are
slightly increased due to the interleaf leakage that was measured but not taken into account in the
calculations. Under the center of the leaves the deviations are −0:7  1:2% and −0:4  1:6%,
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Figure 8.6. Predicted (line) and with the EPID measured (n) absolute dose profile along
the y=-1.9 cm axis of a lateral IM 25 MV photon beam for a prostate cancer patient.
respectively.
In figure 8.6 results are presented for a two-dimensional IM profile designed for treatment of
a prostate cancer patient. The deviation between the predicted profile and the profile measured
with the EPID is 0:5  1:1%.
8.4 Discussion and conclusions
A procedure for pretreatment verification of absolute beam fluence profiles realized with DMLC
was developed and tested. The time required to verify an IM beam is about 2 minutes, which is
much shorter than any other dosimetric technique. The EPID system only has to be calibrated
once. The agreement between calculations and EPID measurements and between EPID and
ionization chamber measurements was within 2% (1  ). The procedure allows an overall
verification of (i) the leaf trajectory calculation (including the models to incorporate collimator
scatter and leaf transmission), (ii) the correct transfer of the leaf sequencing file to the treatment
machine and (iii) the mechanical and dosimetrical performance of the treatment unit. It is
not always possible to distinguish between these types of errors using only portal images.
Previously published DMLC verification methods with EPIDs only verified leaf motion [5, 112]
or relative dose profiles [96]. The excellent agreement between EPID and ionization chamber
measurements in all cases, shows that the read out time of 80 ms (during which no signal is
collected) has no detectable effect; the data acquisition rate is sufficiently high [96].
In the near future the developed method will be extended to enable verification of DMLC
during patient treatment. Acquisition of portal images suitable for dosimetric verification of
DMLC can be fully integrated into existing imaging routines for patient set-up verification,
without introducing an increase in the overall treatment time [84]. Preliminary results on
measurements of portal dose images (PDI), i.e. the dose distribution behind a patient in a plane
normal to the beam axis, in an IM beam have been reported [116]. The calculation of a PDI for
a patient irradiated with an IM beam is a relatively simple extension of existing methods [115].
The relation is Dp.x; y/ D Dp;0.x; y/ T .x; y/, with Dp.x; y/ the predicted portal dose at
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position .x; y/ beneath the patient, Dp;0.x; y/ the predicted portal dose in absence of the
patient (as described in section 8.2.2), and T .x; y/ the predicted transmission through the
patient using the planning CT-data. The method for calculation of these transmission functions
has been described elsewhere. A potential problem is to distinguish between deviations in
predicted and measured PDIs due to machine faults and differences due to deviations between
the patient anatomy during acquisition of the planning CT scan and during treatment. For
prostate cancer patients we have observed that deviations in patient anatomy introduce large
local differences between predicted and measured PDIs [84]. Machine faults are likely to
produce a constant difference over the whole irradiation field. In case of malfunctioning of a
single leaf, the difference will be limited to the beam’s eye view of that leaf.
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Chapter 9
Discussion
9.1 Introduction
The main objective of this study was to develop techniques for dosimetric treatment verification
using a fluoroscopic electronic portal imaging device (EPID). Therefore we determined the
dosimetric characteristics of the EPID (Chapter 2 [61]) and developed a method to derive portal
dose images (PDIs) from measured EPID images (Chapter 3 [116]). A separate algorithm was
developed for accurate prediction of these PDIs, based on the planning CT data of the patient,
the irradiation geometry and the calculated number of monitor units, as determined in the
treatment planning process (Chapter 4 [115]). In a pilot study with ten prostate cancer patients,
good on-axis agreement agreement between measured and predicted portal doses was found
(Chapter 5 [84]). However, off-axis comparisons revealed large deviations for the lateral field,
due to variations in rectal filling that resulted in variations in the actual position of the prostate
in the treatment beams (‘internal organ motion’). Comparison of a measured PDI with a
corresponding predicted PDI cannot reveal an error in the monitor unit (MU) calculation of
the beam. Therefore we also developed a method to derive the on-axis patient dose at 5 cm
depth from the portal dose measured with the EPID. For 115 prostate cancer patients this
patient dose was compared with the intended dose, derived from the relative dose distribution
calculated by the TPS and the prescribed isocenter dose (Chapter 6 [122]). Finally, we also
developed methods for pretreatment verification of intensity modulated beams generated with
compensators (Chapter 7 [124]) or dynamic multileaf collimation (DMLC) (Chapter 8 [113]).
9.2 Dosimetric characteristics of EPIDs
Already in 1986, Leong investigated the dosimetric properties of his video based EPID [89].
In 1991, Morton et al. reported on the dosimetric characteristics of an EPID based on a linear
array of 128 scintillation crystals [106]. In recent years, several other groups have also studied
the properties of their EPIDs for dosimetric measurements. Most studies were performed for
two commercial systems, the fluoroscopic, CCD camera based Philips SRI-100 [61, 80, 81,
116, 125] and the Varian PortalVision liquid-filled matrix ion chamber system [9, 11, 43, 44,
173, 176].
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9.2.1 The liquid-filled EPID
The liquid-filled EPID was developed at the Antoni van Leeuwenhoek Hospital in Amsterdam
by van Herk and Meertens [160] and is commercially available as the PortalVision system
(Varian Inc., Palo Alto, CA). It consists of a matrix of 256  256 liquid-filled ionization
chambers located in a sensitive area of 32  32 cm2. The matrix with supporting electronics
is mounted on a (computerized) retractable arm. The focus-detector distance can be varied
between 105 and 180 cm. Successively, rows of 256 chambers are read out by applying a high
voltage on the ionization chambers to measure the ionization currents with 256 electrometers.
In the normal, non-smoothed sampling mode (standard acquisition mode) the sampling time
for one row is 20 ms and the image scan time is 5.6 s [43]. Due to this (relatively long) read
out time, this device can only measure dose rate. To derive absolute doses a conversion of the
measured dose rate image is necessary, which requires a continuous read out of the monitor
chamber signal of the accelerator during image acquisition and the number of MU given during
the irradiation fraction [9].
The dosimetric characteristics of this EPID have been investigated by several groups [9,
11, 43, 44, 111, 173, 176]. The main results are: (i) the reproducibility of EPID signals is 1%
(1 SD) [44, 176], (ii) the doserate-response of the EPID can be described accurately by an
equation with a term proportional to the square root of the doserate and another term linear to
the doserate [44] or a power law [9], (iii) images have to be corrected for the side scatter in
the EPID (which is lacking in the cylindrical mini phantom used to calibrate the system) using
a deconvolution filter [44] and (iv) images have to be corrected for the differences in relative
sensitivity of each individual ionization chamber - electrometer combination [44]. Boellaard et
al. investigated the buildup required to obtain electronic equilibrium in the detector [11]. The
standard buildup layer in front of the liquid has a water equivalent thickness of 8 mm. They
found that for a 25 MV beam an additional buildup of 28 mm polystyrene was required. This
adds a weight of 4.5 kg to the detector. Due to the extra layer the image quality deteriorates.
Whether the images can still be used for patient setup verification has not yet been described
in the literature.
So far no results have been published for dosimetric application of the liquid filled EPID
in intensity modulated beams produced with DMLC. Maximum leaf speeds during DMLC on
various treatment machines are between 1 and 3 cm s−1 at isocenter. In the fastest acquisition
mode the read-out time of the matrix is 1.6 s (at full resolution) [158]. This seams too low
to acquire enough snap shots of the beam to accurately reconstruct arbitrary intensity profiles
produced with DMLC. Intensity modulated beams can also be produced with the ‘step-and-
shoot’ technique by superpositioning a number of partially overlapping, static, irregularly
shaped fields produced with the MLC [16]. The liquid filled EPID may be suited for controlling
the delivery of a sequence of these static fields.
9.2.2 The fluoroscopic SRI-100 EPID
The SRI-100 was developed in a collaboration between the former Philips Radiotherapy
Systems, the former Laboratory for Space Research in Leiden and the Daniel den Hoed Cancer
Center (DDHCC) [164]. This EPID was used in our studies. The SRI-100 basically consists of
a fluorescent screen, two mirrors and a CCD camera. The EPID has a fixed focus to fluorescent
screen distance of 160 cm. The fluorescent screen is a 1.65 mm thick stainless steel plate
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coated with a layer of gadolinium oxysulfide. X-ray photons which hit the detector screen
generates visible light in the fluorescent layer, which is viewed by a CCD camera using two
45o tilted mirrors. A limitation of fluoroscopic systems is the light collecting efficiency of the
optical chain. Because the light is highly scattered within the phosphor screen, the light is
emitted from the rear of the screen in all directions. Only those light photons that are emitted
within a small cone subtended by the lens of the camera can generate a signal on the CCD
chip. Much of the effort in the development of fluoroscopic EPIDs has been to improve the
light collection in the optical chain, by increasing the light output of the fluorescent screen, a
lens that collects more light or camera’s with a higher light-quantum efficiency [munro95]. An
advantage of CCD camera based systems over scanning systems is the high data acquisition
rate and capability to measure simultaneously in all points of the treatment field, which makes
it an ideal tool for verification of DMLC [5, 96, 112–114, 116].
We have investigated the dosimetric characteristics of this EPID in a 6 MV and a 25 MV
photon beam [61, 116]. To reduce the detection of high energy electrons generated in the patient,
we mounted an additional 1 mm thick stainless steel slab on top of the standard fluorescent
screen. The added slab hardly affects the image quality [85]. The acquired images may be
used both for patient setup verification and for in vivo dosimetry [84]. We found that: (i) the
day-to-day variation of the EPID response per unit of delivered dose is only 0.4% (1 SD), (ii)
the EPID response is non-uniform (related to the 45o tilted mirror), (iii) the EPID response
as function of the transmitted dose measured with an ionization chamber is not linear, due to
non-linear electronics and a difference in spectral sensitivity of the EPID and the ionization
chamber and (iv) visible photons produced by the x-ray beam in a point of the fluorescent
screen do not only generate a signal in the corresponding pixel of the EPID image, but also
cause an increased signal at all other pixels due to light scatter from components of the EPID
structure onto the CCD chip (optical ‘cross talk’).
To convert measured EPID images into absolute dose distributions a three steps procedure
was developed. Acquired images are first corrected for the non-linear response of the
system [116, 125]. Then, the image is corrected for the optical ‘cross talk’ by deconvolving
it with a point spread function [61, 116]. Finally, the resulting array is divided by an array
that accounts for variations in local EPID sensitivity [116]. The accuracy of the method was
assessed by comparing PDIs measured with the EPID with PDIs measured with a scanning
ionization chamber in a mini phantom, located at the same position as the fluorescent screen.
For irradiations in open, wedged and intensity modulated 25 MV photon beams (produced with
DMLC) EPID and ionization chamber measurements agreed to within 1% (1 SD) [116].
9.2.3 Flat panel imager
Recently, prototypes of a new type of EPID have been developed by Antonuk et al. [3]: the
active matrix flat-panel imager (AMFPIs). It basically consist of a large area light sensor
which is placed in direct contact with a fluorescent screen. The high optical transfer efficiency
of these devices compared to that of camera based systems, leads to significantly improved
image quality, which is important for patient setup verification. They are also less bulky
than the present camera based systems. For transmission dosimetry these systems have the
potential advantage over CCD camera based systems that they do not suffer from optical ‘cross
talk’ [108]. Disadvantages of these systems are the high costs, the complex electronics that are
required and the sensitivity of the detector and the supporting electronics for radiation damage.
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A detailed study of the dosimetric properties of the first prototypes have not yet been reported.
A Monte Carlo model of the detector [77] may be useful to understand and to improve the
dosimetric properties of these new devices.
9.2.4 Conclusions
With respect to the PortalVision and the SRI-100 the following conclusions can be drawn. (i)
Both systems are very stable and allow reproducible, quantitative measurements in static beams.
(ii) For both systems methods have been developed for accurate derivation of portal doses from
measured images. (iii) The SRI-100 is operated fully independent of the linear accelerator.
Dosimetry with the PortalVision system is performed using a read out of the monitor chamber
system of the accelerator during image acquisition and the number of monitor units given during
the irradiation fraction [9]. (iv) The SRI-100 is an area detector, visualizing the whole radiation
field and allowing simultaneous absolute dose measurements in all points of the field, making it
suitable for use in intensity modulated beams produced with DMLC. The PortalVision system
is a scanning system making it less suitable for dose measurements in these fields.
9.3 Dosimetric applications of EPIDs
Several studies on dosimetric applications of EPIDs have been performed. Kirby et al. have
evaluated possibilities of the SRI-100 EPID for the routine, off-line check of the field profile
of a treatment unit [81]. In our institution, this EPID is in daily use for quality control of the
absolute output and field flatness of the 10 MV and 25 MV photon beams of a MM50 Racetrack
Microtron [39].
Evans et al. have studied the use of their EPID for determination of so-called pseudo-CT
slices for breast cancer patients for derivation of tissue compensators to obtain a homogeneous
dose distribution in the target [49–51]. Yin [174] and Roback [131] have studied the design of
missing tissue compensators, yielding a constant transmission dose distribution as measured
with their EPID. Low et al. have developed a system for verification of milled compensators,
prior to irradiation of the patient, using their EPID. They compared the fluence measured with
an EPID with corresponding fluences calculated using the intended filter shape [95]. We have
developed a method to determine the 2D thickness profile of a compensator, prior to clinical
application, with an accuracy of 0.5 mm (1 SD) [123, 124]. An error of 0.5 mm in thickness
corresponds to a change in transmitted dose of 1% for a 10 MV beam.
A number of groups has performed studies on anthropomorphic phantoms and/or clinical
pilot studies (maximum number of patients: 12) to evaluate the use of EPIDs for dosimetric
quality control of treatments (in vivo dosimetry) [43, 44, 59–61, 80, 81, 84, 85, 98, 99, 118, 144,
176] Recently, a larger study with 115 patients was completed in our institute (chapter 6).
Several approaches for in vivo dosimetry with an EPID have been proposed. Kirby et al.
have studied a method for estimation of the on-axis patient exit dose from measured SRI-
100-signals, using a set of calibration measurements for homogeneous, flat water-equivalent
absorbers [80, 81]. Heijmen et al. pointed at an inherently limited accuracy of this method,
when applied in the thorax region of patients or in case of the use of (strongly) intensity
modulated beams [61].
Van Dam and Fiorino have investigated the use of portal films to measure 2-dimensional
exit dose profiles [52, 155]. Huyskens et al. have described a method to determine midplane
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dose distributions from on-axis measured entrance and exit doses, using semiconductors [71],
and an exit dose profile derived from portal film. For twelve lung cancer patients, Essers et al.
have measured exit dose rate profiles with a PortalVision system that was positioned as close
as possible to the exit side of the patient (usually at a distance of 12 cm) [44]. They used diodes
to convert relative dose rate profiles into absolute dose profiles.
Leong and Wong have proposed to compare predicted portal dose images (PDIs) - i.e. dose
distributions behind patients in a plane perpendicular to the beam axis - with PDIs measured
during treatment [89, 172]. For a 60Co beam, Wong et al. have assessed the accuracy of the
Delta Volume method for prediction of PDIs in a plane close behind the patient [172]. In our
institution, a method has been developed for accurate prediction of PDIs, using the planning
CT-data of the patients [64, 115, 117, 126]. For each beam quality, the calculations are based
on a set of input functions - such as attenuation curves for primary radiation, and radial scatter
point spread functions describing the scatter from the patient onto the EPID - that have been
derived from a limited set of measured beam data.
Hansen et al. derived the primary fluence from a measured PDI and back projected
that fluence through the patient to yield the primary fluence distribution in the patient.
This distribution was then convoluted with dose deposition kernels to derive the dose
distribution in the patient [58, 60]. Results were presented for a humanoid phantom and
a pelvic patient. McNutt et al. developed an iterative convolution/superposition algorithm,
based on precalculated Monte Carlo data, to reconstruct dose distributions in patients from
exit dose measurements with an EPID and showed results for three phantoms [98]. The
method does not allow a fully independent verification of the patient dose description a
the convolution/superposition algorithm is both used for designing the treatment plan and
verification of the patient dose distribution. We have proposed to use predicted transmissions
T .x; y/ of the high energy photon beam through the patient to derive the two-dimensional beam
fluence profile entering the patient, from the measured EPID image. Transmissions T .x; y/
are calculated using the planning CT-data. The derived beam fluence profiles can be used
for a forward calculation of the patient dose distribution. All three methods require that the
patient geometry during treatment is known, i.e. that the planning CT-scan closely represents
the patient anatomy during treatment. In the method ofYing et al., a deviating patient anatomy
at the time of treatment is accounted for in an iterative procedure that modifies the planning
CT-data [175].
Boellaard et al. have developed a convolution model to convert measured PDIs into exit
dose distributions [12, 13]. Later the model was extended to derive the midplane dose in the
patient, which than can be compared with the dose calculated by the TPS [10]. The model
takes into account patient inhomogeneities using the radiological path length to the patient.
The radiological path length is derived from the transmission through the patient measured
with the EPID (which requires an extra measurement without the patient in the beam). The
planning CT data of the patient is not used. It is assumed that inhomogeneities are distributed
symmetrically around the midplane, which is not always correct. A clinical pilot study was
performed for 5 larynx cancer patients, 2 breast cancer patients, 5 lung cancer patients and 10
prostate cancer patients [14]. Generally, the calculated and backprojected dose agreed within
2.5% (1 SD), for a few of the prostate and long cancer patients larger local differences were
found due to differences between the actual patient anatomy and the planning CT-data; e.g. as
a result of variable rectum filling and anatomical changes in the lung.
In a pilot study with ten prostate cancer patients we encountered the problem of deviating
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patient anatomies due to internal organ motion [84, 85, 118]. Comparison of predicted
PDIs with PDIs measured during treatment with the EPID often revealed large differences
in transmitted doses in those parts of the PDI that, according to the planning CT-scan,
corresponded to raylines that should pass the rectum, the posterior part of the prostate, or
the seminal vesicles. The observed differences - that were attributed to variations in rectal
filling - pointed at shifts in anterior-posterior direction of the prostate and seminal vesicles.
Comparing a measured PDI with a predicted PDI cannot reveal an error in the MU
calculation, since the calculated number of MU is both used for treatment (and thus affects the
PDI measurement) and for PDI prediction. Therefore, we developed a method that enables
‘in vivo’ verification of the MU calculation of the treatment beams by comparing the intended
on-axis patient dose at 5 cm depth (D5), as determined from the relative dose distribution
calculated by the TPS and the prescribed isocenter dose (2 Gy), with D5 as derived from the
portal dose Dp measured with the EPID. The method was evaluated clinically for 115 prostate
cancer patients. It allowed accurate verification of the MU calculation. Deviations for the
lateral beams were 2.4% (1 SD) and for the anterior-posterior (AP) beam 3.4% (1 SD). The
standard deviations for the AP beam are larger since variations in radiological thickness have
relatively more effect on the transmitted dose and the central rayline in the AP beam passes
both the rectum and the bladder, whereas the central rayline in the lateral fields does not pass
through organs with variable filling.
Intensity modulated radiotherapy (IMRT), especially with DMLC, is a rapidly evolving field
and the first patient has already been treated [93]. DMLC is complex and requires extensive
quality assurance. CCD camera based EPIDs are an ideal tool for verification of DMLC due
to their high data acquisition rate and capability to measure simultaneously in all points of the
treatment field [5, 96, 112, 113, 116]. Balter et al. showed preliminary results of a method to
derive leaf positions in each camera frame acquired during treatment and to compare them with
a table of prescribed leaf positions [5]. Leaf positions could be determined with an accuracy
of 0.6 mm and a duty cycle of less than 1 s. A similar approach was implemented by Partridge
et al. [112]. Ma et al. calculated normalized reference images from MLC leaf sequencing
files and compared these with normalized images measured with a fluoroscopic beam imaging
system (BIS, Wellhöfer Dosimetrie, Schwarzenbruck, Germany) for a 6 MV photon beam [96].
They were able to detect uncertainties of less than 0.5 mm in leaf position during DMLC.
The above described methods to verify leaf motion cannot be used to check whether the
calculated leaf trajectories do indeed generate the absolute beam fluence profiles used in
treatment planning. Therefore we have developed an accurate method for a pretreatment
verification of the intensity modulated beams. For each beam, 2D dose distributions are
measured with the EPID and compared with predicted dose distributions [113]. The method
verifies: (i) the leaf trajectory calculation (including the models to incorporate collimator
scatter and leaf transmission), (ii) the correct transfer of the leaf sequencing file to the
treatment machine and (iii) the mechanical and dosimetrical performance of the treatment
unit. Predictions and EPID measurements for 10 and 25 MV photon beams agreed within 2%
(1 SD).
9.4 Future investigations
Treatment verification with an EPID (in vivo) is still in its infancy. Only one large clinical study
(N=115) and a few pilot studies have been performed with very small numbers of patients (2-
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12) and methods are still under development. New tumor sites need to be included in the
investigations and the developed methods must be tested, optimized and evaluated in large
clinical studies. For all sites guide lines for clinical application have to be established including
action levels.
Comparison of predicted PDIs with PDIs measured with an EPID can reveal internal organ
motion, i.e. the patient anatomy at the time of treatment differs from the anatomy as recorded
in the planning CT-scan [84]. To use of EPIDs for detection of internal motion needs to be
further investigated. Currently a study is performed based on multiple CT data [146]. For each
patient, changes in the anatomy as indicated by the planning CT-scans will be correlated with
changes in the calculated, i.e. simulated, PDIs that would have been measured with the EPID
during treatment.
Obviously, in vivo dosimetry with an EPID could also greatly contribute to the daily, quality
control of dynamic treatments. As described in this thesis methods have been developed for
fast and accurate pretreatment verification of beams produced with DMLC (Chapter 8 [113])
using an EPID. The developed method will be extended to enable verification of DMLC during
patient treatment. Acquisition of portal images suitable for dosimetric verification of DMLC
can be fully integrated into existing imaging routines for patient setup verification, without
introducing an increase in the overall treatment time [84].
9.5 Conclusions
This thesis describes the development and clinical implementation of models to use a
fluoroscopic, CCD camera based EPID for in vivo dosimetry. It has been shown that the
developed procedures for measurement and prediction of PDIs allow accurate dosimetric
quality control of the treatment of prostate cancer patients and that comparison of measured
PDIs with predicted PDIs can reveal internal organ motion. Furthermore, an accurate method
for verification of the MU calculation of an x-ray beam using EPID measurements has been
developed. The method allows to discriminate on errors that are due to changes in patient
anatomy and errors due to a deviating cGy/MU-value. With a CCD camera based EPID
dosimetric information is simultaneously obtained over the whole beam area and not only in
a single or a few points. Therefore, portal dosimetry with this EPID is a valuable tool for
verification of DMLC. Due to the necessarily small number of detectors, full verification of
treatments delivered with DMLC is not possible with conventional in vivo dosimetry using
diodes or Thermoluminescence Dosimetry (TLD). It can be concluded that in vivo dosimetry
with a fluoroscopic EPID is efficient tool for two-dimensional in vivo dosimetry.

Summary
Radiotherapy is with surgery and chemotherapy one of the three main modalities for treating
patients with cancer. The aim of curative radiation therapy is to deliver as high dose to diseased
tissue as needed or as possible without causing unacceptable side effects to the patient. The
treatment usually consists of irradiation of the patient from different directions with a high
energy photon or electron beam. Beam directions are chosen such that the radiation damage to
critical organs and healthy tissues is minimized. In conformal radiotherapy the beam shapes
and, increasingly also beam intensity patterns, are optimized to further improve conformity of
the high dose volume to the tumor volume.
All (complex) procedures involved in the planning and execution of (conformal)
radiotherapy treatments do contribute to the overall uncertainty in the delivered dose
distributions. As dose response curves for tumors and normal tissues may be steep, verification
of dose delivery is mandatory. Treatment verification while the patient is being irradiated
can be split into geometrical and dosimetrical verification. Portal imaging with film or with
an electronic portal imaging device (EPID) is applied to evaluate the patient setup during
treatment and thermoluminescence dosimetry (TLD) or diodes are used to measure the dose
at the entrance and/or at the exit side of the patient. A drawback of this approach is that
dosimetric information is only obtained in a single or a few points. Moreover, the use of
different equipment for geometrical and dosimetrical verification results in extra costs, extra
maintenance work and increased treatment times. The aim of this study was therefore to
develop techniques for integrated geometrical and dosimetric treatment verification using an
EPID.
In chapter 2 the dosimetric characteristics of the in this study applied fluoroscopic EPID
(SRI-100, Philips Medical Systems, Crawley, UK) are described. This EPID basically consists
of a fluorescent screen, mirrors and a CCD camera. Image acquisition for portal dose
measurement was performed with a special procedure, written in the command language
that comes with the system. For a 6 MV beam, the observed day-to-day variation in local
EPID responses, i.e. measured pixel value (EPID signal) per unit of delivered portal dose,
is 0.4% (1 SD); day-to-day variations in relative EPID responses (e.g. normalized to the
on-axis response) are within 0.2% (1 SD). Measured pixel values are linearly proportional to
transmitted portal doses with a proportionality constant which is independent of the thickness
of a flat, waterequivalent absorber in the beam, but which does significantly depend on the size
of the applied x-ray beam. It was shown that the observed increase in EPID response with
increasing field size is mainly due to contributions to the EPID signals from scattered light:
Visible photons produced by the x-ray beam in a point of the fluorescent screen do not only
generate a signal in the corresponding point of the EPID image, but do also lead (due to scatter
from components of the EPID structure onto the CCD chip) to an increased pixel value in all
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other points of the image. A point spread function, derived from measured data and describing
the increase in EPID response at the beam axis due to off-axis irradiation of the fluorescent
screen, was successfully applied to connect portal doses with pixel values measured with the
EPID.
In chapter 3 a method is presented to accurately measure portal dose images (PDIs) with the
SRI-100 EPID. The method accounts for (i) the optical ‘cross talk’ within the EPID structure
(see chapter 2), (ii) the spatially non-uniform EPID response and (iii) the observed non-linearity
of the EPID response (mainly due to non linear electronics). It is based on a deconvolution
algorithm. Measurement of the required input data is straightforward. The accuracy of the
method was assessed by comparing PDIs measured with the EPID with PDIs measured with a
scanning ionization chamber in a mini phantom, located at the same position as the fluorescent
screen. For irradiations in open, wedged and intensity modulated 25 MV photon beams
(produced with dynamic multileaf collimation) EPID and ionization chamber measurements
agreed to within 1% (1 SD).
A method for prediction of these PDIs in open (non wedged) beams is described in chapter 4.
The following equation for calculation of PDIs is used Dp.x; y/ D T .x; y/  Dp;0.x; y/,
with Dp.x; y/ the portal dose in point .x; y/ of the PDI, T .x; y/ a function describing the
transmission of the high energy photon beam through the patient and Dp;0.x; y/ the portal
dose that would have occurred in .x; y/ in the absence of the patient. For the calculation of
the dose distributions Dp;0.x; y/ in the detector plane of the EPID, we have slightly modified
an algorithm that was developed in our institute for dose calculations in water phantoms. The
transmission calculations are based on the planning CT-scan of the patient and on the irradiation
geometry as determined in the treatment planning process. For each beam quality, the required
input data for this algorithm are derived from a limited number of measured beam data. The
method was tested for a PDI-plane at 160 cm from the focus, in agreement with the fixed
focus-to-detector distance of our fluoroscopic EPIDs. For 6, 23 and 25 MV photon beams
good agreement (1%) was found between calculated and measured transmissions T .x; y/
through anthropomorphic phantoms.
Results of a first clinical evaluation of developed methods for dosimetrical treatment
verification are presented in chapter 5. For ten prostate cancer patients, the inter-fraction
variation within measured PDIs was assessed and measured PDIs were compared with
corresponding predicted PDIs, based on the planning CT scan of the patient. For the lateral
fields, the average standard deviation in the measured on-axis portal doses during the course
of a treatment was 0.9%; for the anterior-posterior (AP) fields this standard deviation was
2.2%. The difference between the average on-axis measured portal dose and the predicted
portal dose was 0.3  2.1% (1 SD) for the lateral fields and 0.7  3.4% (1 SD) for the AP
fields. Off-axis differences between measured and predicted portal doses for the lateral fields
were regularly much larger (up to 15%) and were caused by frequently occurring gas pockets
inside the rectum of the patients during treatment or during acquisition of the planning CT
scan. The detected gas pockets did sometimes extend into the gross tumor volume (GTV) area
as outlined in the planning CT scans, implying a shift of the anterior rectum wall and prostate
in anterior direction (internal organ motion). This clinical study has shown that the developed
procedures for measurement and prediction of PDIs allow accurate dosimetric quality control
of the treatment of prostate cancer patients and that comparing measured PDIs with predicted
PDIs can reveal internal organ motion.
However, comparisons of PDIs can not reveal errors in the MU calculation of a beam, since
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the calculated number of MU is both used for treatment (and thus affects the PDI measurement)
and for PDI prediction. In chapter 6 a method is presented that enables in vivo verification of
the MU calculation of the treatment beams. The method is based on comparison of the intended
on-axis patient dose at 5 cm depth, D5, with D5 as derived from the portal dose Dp measured
with an EPID. The developed method was evaluated clinically for a group of 115 prostate cancer
patients. The on-axis patient dose D5 was derived from the measured portal dose using (i) the
predicted beam transmission calculated with the planning CT data of the patient (see chapter 4)
and (ii) an empirical relation between portal doses Dp and patient doses D5. Derived patient
doses D5 were compared with intended doses D5 which were determined from the relative
dose distribution calculated by the treatment planning system and the prescribed isocenter
dose (2 Gy). For interpretation of observed differences, the corresponding on-axis measured
portal doses Dp were also compared with predicted portal doses. For the three open beams,
in total 7828 images were analyzed. The mean difference between the predicted patient dose
and the patient dose derived from the average measured portal dose was: 0:4  3:4% (1 SD)
for the AP beam and −1:5  2:4% (1 SD) for the lateral beams. For 7 patients the difference
between the predicted portal dose and the average measured portal dose for the AP beam and
the corresponding difference in patient dose D5 were both greater than 5%. All these patients
had relatively large gas pockets (3-3.5 cm in AP direction) in the rectum during acquisition of
the planning CT, which were not present during (most) treatments. The developed methods
allow to discriminate on errors that are due to changes in patient anatomy and errors due to a
deviating cGy/MU-value.
Dose distributions can often be significantly improved by modulating the two-dimensional
intensity profile of the individual x-ray beams. At the Daniel den Hoed Cancer Center
two techniques are used for generating these intensity modulated beams; compensators and
dynamic multileaf collimation (DMLC). The EPID is suitable for fast and accurate pretreatment
verification of intensity modulated beams generated with these techniques as shown in the next
two chapters.
In chapter 7 a method is presented for verification of compensator thicknesses. The method
is based on the measured transmission T .x; y/ through the compensator, defined by the ratio of
the portal dose with the compensator in the beam and the portal dose without the compensator
in the beam. The compensator transmission is determined with the EPID by dividing two
images, acquired with and without compensator inserted, which are only corrected for the
non-linear response of the SRI-100 system (see chapter 3). The transmission has a primary
and a scatter component. The primary component is derived from the measured transmission
by subtracting the predicted scatter component. The primary component for each point is only
related to the thickness of the compensator along the ray line between the focus and that point.
Compensator thicknesses are derived from the primary components taking into account off-
axis variations in beam quality. The developed method was tested for various compensators
made of a granulate of stainless steel. The compensator thicknesses could be determined with
an accuracy of 0.5 mm (1 SD), corresponding to a change in the transmitted dose of about 1%
for a 10 MV beam. The method is fast, accurate and insensitive to long-term output and beam
profile fluctuations of the linac.
In chapter 8 a method is presented for a pretreatment dosimetric verification of intensity
modulated beams generated with DMLC. In the absence of the patient EPID images are
acquired for all beams produced with DMLC. These images are then converted into 2D dose
distributions and compared with predicted dose distributions. The predictions are performed
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with the same pencil beam algorithm as implemented in our commercially available treatment
planning system, using the same absolute beam fluence profiles as used for calculation of the
patient dose distribution. The method verifies: (i) the leaf trajectory calculation (including
the models to incorporate collimator scatter and leaf transmission), (ii) the correct transfer
of the leaf sequencing file to the treatment machine and (iii) the mechanical and dosimetrical
performance of the treatment unit. The method was tested for intensity modulated 10 and 25 MV
photon beams; both model cases and real clinical cases were studied. Dose profiles measured
with the EPID were also compared with ionization chamber measurements. In all cases both
predictions and EPID measurements and EPID and ionization chamber measurements agreed
within 2% (1 SD). The study has demonstrated that the proposed method allows fast and
accurate pretreatment verification of DMLC.
In the final chapter the developed methods for dosimetric treatment verification with
an EPID are evaluated and compared with other methods. Furthermore, the dosimetric
characteristics of the fluoroscopic EPID are compared with those of an EPID system consisting
of a matrix of liquid filled ionization chambers. The overall result of this study is that the
developed techniques allow accurate dosimetric quality control of the treatment of prostate
cancer patients and that comparison of measured PDIs with predicted PDIs can reveal internal
organ motion.
Samenvatting
Radiotherapie is met chirurgie en chemotherapie een van de drie belangrijkste modaliteiten
voor het behandelen van patiënten met kanker. Het doel van curatieve radiotherapie is het
afgeven van een zo hoog mogelijke dosis als nodig of mogelijk aan aangetast weefsel zonder
onacceptabele neveneffecten te veroorzaken bij de patiënt. De behandeling bestaat gewoonlijk
uit bestraling van de patiënt uit verschillende richtingen met een hoog energetische fotonen of
electronen bundel. De bundelrichtingen worden zo gekozen dat de stralingsschade aan gezond
weefsel wordt geminimaliseerd. In conformatie radiotherapie worden de bundel vorm en, in
toenemende mate ook het bundel intensiteitsprofiel, geoptimaliseerd om het hoge dosis volume
verder te conformeren rond het tumor volume.
Alle (complexe) procedures die gebruikt worden tijdens de planning en uitvoering van een
(conformatie) radiotherapie behandeling dragen bij aan de totale onzekerheid in de afgegeven
dosisverdeling. Omdat dosis respons curven voor zowel tumor als gezond weefsel steil kunnen
zijn is verificatie van de dosisverdeling noodzakelijk. Verificatie van behandelingen terwijl
de patiënt wordt bestraald kan worden gesplitst in geometrische en dosimetrische verificatie.
Megavolt afbeeldingen van de patiënt in de bundel kunnen worden gemaakt met film of een
electronisch Megavolt Afbeelding (MVA) systeem en worden gebruikt om de positionering
van de patiënt in de bundel te verifiëren. Thermoluminescentie dosimetrie chips (TLDs) of
diodes kunnen worden gebruikt om de dosis aan het in- of uittree vlak van de patiënt te meten.
Een nadeel van deze benadering is dat dosimetrische informatie alleen wordt verkregen in een
enkel of een paar punten. Ook leidt het gebruik van verschillende apparatuur voor positie en
dosimetrische verificatie tot hogere kosten, extra onderhoudswerk en extra behandeltijd. Het
doel van de in dit proefschrift beschreven studie was het ontwikkelen van technieken voor
geïntegreerde geometrische en dosimetrische verificatie met behulp van een MVA systeem.
In hoofdstuk 2 worden de dosimetrische eigenschappen van het in deze studie gebruikte
fluorescopisch MVA systeem (Philips SRI-100, Philips Medical Systems, Crawley, UK)
beschreven. Dit systeem bestaat uit een fluorescerend scherm, twee 45o spiegels en een
CCD camera. Het opnemen van beelden voor transmissiedosis metingen werd gedaan met een
speciale procedure, geschreven in de macro taal die bij het systeem geleverd wordt. Opgenomen
beelden kunnen zowel voor geometrische als voor dosimetrische verificatie worden gebruikt.
Voor een 6 MV fotonen bundel is de dag-tot-dag variatie in lokale MVA respons, m.a.w. de
gemeten pixel waarde (MVA signaal) per eenheid van afgeleverde dosis, 0.4% (1 SD); de dag-
tot-dag variatie in relatieve MVA respons (genormeerd op de respons op de bundelas) is kleiner
dan 0.2%. Gemeten pixel waardes hangen lineair af van de transmissiedosis met een constante
die onafhankelijk is van de dikte van een vlak waterequivalent fantoom in de bundel, maar die
significant afhangt van de grootte van de gehanteerde fotonenbundel. Het is aangetoond dat de
geobserveerde toename in MVA respons met toenemende veldgrootte voornamelijk komt door
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bijdragen aan het MVA signaal van gereflecteerd licht: licht fotonen geproduceerd door de
megavolt fotonen in een punt van het fluorescentie scherm genereren niet alleen een signaal in
het overeenkomstige punt van het MVA beeld, maar ook (door licht reflecties van componenten
van de MVA systeem op de CCD chip) tot een toename van de pixel waarde in alle andere
punten van het MVA beeld. Een punt spreid functie, afgeleid uit gemeten data die de MVA
respons toename op de bundelas beschrijft door een bestraling van het fluorescentie scherm
elders, is met succes gebruikt om de relatie te beschrijven tussen transmissiedosis en pixel
waardes gemeten met het MVA systeem.
In hoofdstuk 3 wordt een methode gepresenteerd om nauwkeurig transmissiedosis-
verdelingen met het SRI-100 MVA systeem te meten. De methode verrekent de (i) optische
‘overspraak’binnen de EPID structuur (zie hoofdstuk 2), (ii) de ruimtelijke niet uniforme MVA
gevoeligheid en (iii) de gevonden niet lineaire MVA respons (voornamelijk door niet lineaire
electronica). De methode is gebaseerd op een deconvolutie algoritme. Er is een beperkte
gemeten dataset nodig. De nauwkeurigheid van de methode is bepaald door het vergelijken
van transmissiedosisverdelingen gemeten met het MVA systeem met dosisverdelingen gemeten
met een scannende ionisatie kamer in een mini meetfantoom in hetzelfde vlak als het
fluorescerend scherm. Voor bestralingen in open, wig en intensiteits gemoduleerde 25 MV
bundels (geproduceerd met dynamische multileaf collimatie) komen MVA en ionisatie kamer
metingen overeen binnen 1% (1 SD).
Een methode voor voorspelling van deze transmissiedosisverdelingen in open (zonder
wig) velden wordt beschreven in hoofdstuk 4. De formule die wordt gebruikt voor het
berekenen van de transmissiedosisverdeling is Dp.x; y/ D T .x; y/Dp;0.x; y/, met Dp.x; y/
de transmissiedosis in punt .x; y/ van het detectorvlak, T .x; y/ de transmissie van de
bundel door de patiënt en Dp;0.x; y/ de transmissiedosis die zou zijn opgetreden in .x; y/
zonder patiënt in de bundel. Voor de berekening van Dp;0.x; y/ in het detectorvlak van het
MVA systeem, hebben we een algoritme aangepast dat in ons instituut is ontwikkeld voor
berekeningen in waterfantomen. De berekening van de transmissie is gebaseerd op de planning
CT scan van de patiënt en de bestralingsgeometrie zoals bepaald tijdens de planning. Voor
iedere bundelenergie wordt de vereiste invoerdata voor dit algoritme afgeleid uit een beperkte
set meetdata. De methode is getest voor een transmissiedosis vlak op 160 cm van het focus, in
overeenstemming met de vaste focus detector afstand van onze fluorescopische MVA systemen.
Voor 6, 23 en 25 MV fotonen bundels is er goede overeenstemming (binnen 1%) gevonden
tussen gemeten en berekende transmissies.
Resultaten van een eerste klinische evaluatie van de ontwikkelde methodes voor
dosimetrische behandel verificatie worden gepresenteerd in hoofdstuk 5. Voor tien
prostaatkanker patiënten is de variatie in gemeten transmissiedosisverdelingen tussen
behandel fracties vastgesteld en zijn gemeten transmissiedosisverdelingen vergeleken met
transmissiedosisverdelingen berekend met behulp van de planning CT van de patiënt. Voor de
laterale velden was de gemiddelde standaard deviatie (SD) 0.9%, voor de anterior-posterior
(AP) bundel was deze standaard deviatie 2.2%. De verschillen tussen de gemiddelde op
de bundelas gemeten transmissie dosis en de voorspelde transmissiedosis was 0:3  2:1%
(1 SD) voor de laterale velden en 0.73.4% (1 SD) voor de anterior posterior velden.
Naast de bundelas zijn verschillen tussen gemeten en voorspelde transmissiedosis voor de
laterale velden veel groter (tot 15%). Deze verschillen werden veroorzaakt door regelmatig
optredende gasbellen in de endeldarm van de patiënt. De gedetecteerde gasbellen liepen
soms door tot in het in de planning CT scan ingetekende tumorvolume (gross target volume;
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GTV), hetgeen een verschuiving van de anterior wand van de endeldarm en de prostaat in
anterior richting impliceert (interne orgaan beweging). Deze studie heeft aangetoond dat de
ontwikkelde procedure voor het meten en voorspellen van transmissiedosisverdelingen geschikt
is voor nauwkeurige dosimetrische kwaliteitsbewaking van de behandeling van prostaatkanker
patiënten en dat met het vergelijken van gemeten en voorspelde transmissiedosisverdelingen
interne orgaanbeweging kan worden aangetoond.
Het vergelijken van transmissiedosisverdelingen kan echter geen fouten in de Monitor
Eenheden (ME) berekening van een bundel aantonen, omdat het berekende aantal ME zowel
voor de behandeling (en dus de meting) als voor de voorspelling wordt gebruikt. In hoofdstuk 6
wordt een methode gepresenteerd die in vivo verificatie van de ME berekening van de
verschillende bundels mogelijk maakt. De methode is gebaseerd op het vergelijken van de
geplande dosis in de patiënt op de bundelas op 5 cm diepte, D5, met D5 afgeleid van de
transmissiedosis Dp gemeten met een MVA systeem. De ontwikkelde methode is klinisch
getest voor 115 prostaatkanker patiënten. De patiëntdosis op de bundelas D5 wordt afgeleid
van de gemeten transmissiedosis gebruik makend van (i) de bundel transmissie berekend aan
de hand van de planning CT data van de patiënt (zie hoofdstuk 4) en (ii) een empirische relatie
tussen transmissiedosis Dp en patiëntdosis D5. De afgeleide patiëntdosis D5 is vergeleken met
de geplande dosis D5 welke bepaald werd aan de hand van de relatieve dosisverdeling berekend
door het planning systeem en de voorgeschreven isocentrum dosis van 2 Gray (Gy). Voor
interpretatie van de geobserveerde verschillen is de gemeten transmissiedosis op de bundelas
ook vergeleken met de voorspelde transmissiedosis. Voor de drie open bundels zijn in totaal
7828 beelden geanalyseerd. Het gemiddelde verschil tussen de voorspelde patiënt dosis en
de patiëntdosis afgeleid uit de gemiddelde gemeten transmissiedosis was 0.43.4% (1 SD)
voor de AP bundel en -1.52.4% (1 SD) voor de laterale bundels. Voor 7 patiënten was het
verschil tussen de voorspelde en de gemiddelde gemeten transmissiedosis voor de AP bundel
en het corresponderende verschil in patiëntdosis D5 groter dan 5%. Al deze patiënten hadden
relatief grote gasbellen in de endeldarm tijdens het maken van de planning CT, hetgeen tijdens
de meeste behandelingen niet het geval was. De ontwikkelde methode maakt onderscheid
mogelijk tussen fouten door veranderingen in de patiënt anatomie en verschillen door een
afwijkende cGy/ME waarde.
Dosisverdelingen kunnen vaak aanzienlijk verbeterd worden door het moduleren van het
twee-dimensionale intensiteitprofiel van de individuele fotonenbundels. In de Daniel den Hoed
Kliniek worden twee technieken gebruikt voor het genereren van deze intensiteits gemoduleerde
bundels; compensatoren en dynamische multileaf collimatie (DMLC). Het MVA systeem is
geschikt voor snelle en nauwkeurige verificatie van bundels gegenereerd met deze technieken
zoals aangetoond wordt in de volgende twee hoofdstukken.
In hoofdstuk 7 wordt een methode gepresenteerd voor verificatie van compensator diktes.
De methode is gebaseerd op de gemeten transmissie T .x; y/ door de compensator, gedefinieerd
als de ratio van de transmissie dosisverdeling met de compensator in de bundel en de
dosisverdeling zonder compensator in de bundel. De compensator transmissie wordt bepaald
met het MVA systeem door het delen van twee beelden, opgenomen met en zonder compensator
in de bundel, die uitsluitend gecorrigeerd worden voor de niet lineaire respons van de SRI-
100 (zie hoofdstuk 3). De transmissie heeft een primaire en een scatter component. De
primaire component wordt afgeleid van de gemeten transmissie door het aftrekken van een
voorspelde scatter component. De primaire component voor elk punt is alleen afhankelijk van
de dikte van de compensator langs de rayline van het focus naar dat punt. Compensator dikte
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wordt afgeleid van de primaire component waarbij rekening wordt gehouden met het verloop
in bundel hardheid als functie van de afstand tot de bundelas. De ontwikkelde methode is
getest voor verschillende compensatoren gemaakt van roestvrijstalen korrels. De compensator
diktes konden worden afgeleid met een nauwkeurigheid van 0.5 mm (1 SD), hetgeen voor een
10 MV bundel overeenkomt met verandering in transmissie dosis van 1%. De methode is snel,
nauwkeurig en ongevoelig voor lange termijn output en bundel fluctuaties van de versneller.
In hoofdstuk 8 wordt een methode gepresenteerd voor dosimetrische verificatie van
intensiteits gemoduleerde bundels gegenereerd met DMLC. Zonder de patiënt in de
bundel worden MVA beelden opgenomen voor alle bundels gegenereerd met DMLC.
Deze beelden worden dan geconverteerd naar twee-dimensionale dosisverdelingen en
vergeleken met voorspelde dosisverdelingen. De voorspellingen worden gedaan met hetzelfde
algoritme als geïmplementeerd in een commercieel verkrijgbaar planningssysteem, gebruik
makend van de absolute bundelprofielen die ook gebruikt worden voor berekening van
de patiëntdosisverdeling. De methode verifieert: (i) de berekening van de leaf beweging
(inclusief de modellen voor het verrekenen van collimator scatter en leaf transmissie), (ii) de
correcte overdracht van de leaf beweging file naar de behandel machine en (iii) de correcte
mechanische en dosimetrische werking van het toestel. De methode is getest voor intensiteits
gemoduleerde 10 en 25 MV fotonen bundel; zowel test gevallen als klinische bundels zijn
gebruikt. Dosisprofielen gemeten met het MVA systeem zijn vergeleken met ionisatiekamer
metingen. In alle gevallen klopten zowel voorspellingen en MVA metingen als MVA metingen
en vat metingen binnen 2% (1 SD). Deze studie heeft aangetoond dat de voorgestelde methodes
snelle en nauwkeurige verificatie van DMLC voor de patiënt behandeling mogelijk maken.
In het laatste hoofdstuk worden de ontwikkelde methodes voor dosimetrische behandel
verificatie met een MVA systeem geëvalueerd en vergeleken met andere methodes. Verder
worden de dosimetrische karakteristieken van het fluorescopische MVA systeem vergeleken
met die van een MVA systeem bestaand uit een matrix van vloeistof gevulde ionisatiekamers.
Het uiteindelijke resultaat van deze studie is dat met de ontwikkelde technieken nauwkeurige
dosimetrische verificatie van bestralingen van prostaatkankerpatiënten mogelijk is en dat met
het vergelijken van gemeten en berekende transmissiedosisverdelingen interne orgaanbeweging
kan worden aangetoond.
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nalezen van verschillende onderdelen. Leven is meer dan werken alleen, daarom ook dank aan
mijn zweefvliegcollega’s. Met een kleine groep een paar honderd kilometer overlandvliegen,
soms op euforische hoogtes dan weer knokkend met de elementen, om vervolgens (op de
goede dagen) met 250 km/u op boomtop hoogte weer terug te komen op Malden; een betere
ontspanning kan ik me niet voorstellen.
Tot slot het thuisfront: Tjip en Stefan, bij deze voeg ik een millimeter of 8 toe aan de
“familie-boekenkast”.
Curriculum vitae
De auteur van dit proefschrift werd geboren op 5 oktober 1968 te Nijmegen. Daar behaalde hij
in 1988 het diploma Atheneum  aan het Dukenburg College. In datzelfde jaar begon hij zijn
studie Natuurkunde aan de Katholieke Universiteit Nijmegen. Het afstudeeronderzoek vond
plaats bij de afdeling Medische en Biofysica. In 1994 studeerde hij af in de informatische
fysica en trad in dienst als onderzoeker in opleiding bij de Erasmus Universiteit Rotterdam.
Hij werd gedetacheerd bij de afdeling Klinische Fysica van de Daniel den Hoed Kliniek. Daar
heeft hij onderzoek verricht naar toepassingen van een megavolt afbeeldingssysteem voor in
vivo dosimetrie en dosimetrische verificatie van intensiteits gemoduleerde bundels in het kader
van een door de Nederlandse Kankerbestrijding (NKB) gefinancierd project. De resultaten
van dit onderzoek zijn beschreven in dit proefschrift. Sinds augustus 1998 is hij als postdoc
werkzaam op dezelfde afdeling op een door het NKB gefinancierd vervolgproject. Tevens is
hij in opleiding voor klinische fysicus radiotherapie. Naast zijn werk is de auteur een actief
zweefvlieger, hij heeft 360 vlieguren en een veertigtal overlandvluchten gemaakt.
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